As	O	ADP	O
demonstrated	O	VERB	O
by	O	ADP	O
in	O	X	B
vitro	O	X	I
studies	O	NOUN	I
,	O	PUNCT	O
cisplatin	B-I	NOUN	B
(	I-I	PUNCT	O
CDDP	I-I	NOUN	B
)	I-I	PUNCT	O
is	O	AUX	O
able	O	ADJ	O
to	O	PART	O
down-regulate	O	VERB	B
the	O	DET	O
AGAT	O	NOUN	B
activity	O	NOUN	B
,	O	PUNCT	O
suggesting	O	VERB	O
that	O	SCONJ	O
CDDP	B-I	NOUN	B
could	O	AUX	O
enhance	O	VERB	B
the	O	DET	O
antitumor	B-OUT	NOUN	B
activity	I-OUT	NOUN	I
of	I-OUT	ADP	O
TMZ	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Patient	B-P	NOUN	B
and	I-P	CCONJ	O
tumor	I-P	NOUN	B
characteristics	I-P	NOUN	B
were	O	AUX	O
well	O	ADV	O
balanced	O	ADJ	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
arms	O	NOUN	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
with	I-P	ADP	O
cerebral	I-P	ADJ	B
metastases	I-P	NOUN	I
were	I-P	AUX	O
included	I-P	VERB	O
.	I-P	PUNCT	O


There	O	PRON	O
was	O	AUX	O
significantly	O	ADV	O
more	O	ADJ	O
grade	B-OUT	NOUN	B
3	I-OUT	NUM	I
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
emesis	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
No	B-OUT	DET	B
clear	I-OUT	ADJ	I
benefit	I-OUT	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
response	B-OUT	NOUN	B
rates	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
median	I-OUT	ADJ	O
TTP	I-OUT	NOUN	B
or	O	CCONJ	O
OS	O	NOUN	B
was	O	AUX	O
shown	O	VERB	O
with	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
TMZ	B-I	NOUN	B
+	I-I	CCONJ	O
CDDP	I-I	NOUN	B
.	I-I	PUNCT	O


Additionally	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
combination	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
higher	O	ADJ	O
incidence	O	NOUN	B
of	O	ADP	O
grade	B-OUT	NOUN	B
3	I-OUT	NUM	I
and	I-OUT	CCONJ	O
4	I-OUT	NUM	O
emesis	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
control	O	NOUN	B
toothpaste	O	NOUN	I
was	O	AUX	O
a	O	DET	O
conventional	B-I	ADJ	B
,	I-I	PUNCT	O
moderately	I-I	ADV	B
abrasive	I-I	ADJ	B
paste	I-I	NOUN	I
containing	I-I	VERB	O
0.8	I-I	NUM	O
%	I-I	NOUN	O
sodium	I-I	NOUN	B
monofluorophosphate	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
children	B-P	NOUN	B
were	O	AUX	O
examined	O	VERB	O
clinically	O	ADV	B
and	O	CCONJ	O
radiologically	O	ADV	B
each	O	DET	O
year	O	NOUN	B
.	O	PUNCT	O


Caries	B-OUT	NOUN	B
increments	I-OUT	NOUN	B
after	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
DMF	O	NOUN	B
teeth	O	NOUN	B
and	O	CCONJ	O
DMF	O	NOUN	B
surfaces	O	NOUN	B
,	O	PUNCT	O
showed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	B-P	DET	O
MFP	I-I	PROPN	B
test	I-I	NOUN	I
group	I-P	NOUN	I
(	I-P	PUNCT	O
444	I-P	NUM	O
children	I-P	NOUN	B
)	I-P	PUNCT	O
and	I-P	CCONJ	O
the	I-P	DET	O
MFP	I-I	PROPN	B
control	I-I	NOUN	I
group	I-P	NOUN	I
(	I-P	PUNCT	O
450	I-P	NUM	O
children	I-P	NOUN	B
)	I-P	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
TMP	B-I	PROPN	B
test	I-P	NOUN	O
group	I-P	NOUN	O
(	I-P	PUNCT	O
425	I-P	NUM	O
children	I-P	NOUN	B
)	I-P	PUNCT	O
had	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
caries	B-OUT	NOUN	B
increments	I-OUT	NOUN	B
than	O	ADP	O
the	O	DET	O
MFP	B-I	PROPN	B
control	I-I	NOUN	I
group	O	NOUN	I
.	O	PUNCT	O


Therapeutic	O	ADJ	B
recommendations	B-OUT	NOUN	B
in	O	ADP	O
polycythemia	O	NOUN	B
vera	O	NOUN	B
based	O	VERB	O
on	O	ADP	O
Polycythemia	O	NOUN	B
Vera	O	PROPN	B
Study	O	PROPN	I
Group	O	PROPN	B
protocols	O	NOUN	O
.	O	PUNCT	O


With	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
final	O	ADJ	O
question	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
optimal	O	ADJ	B
treatment	O	NOUN	B
for	O	ADP	O
polycythemia	O	NOUN	B
vera	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
is	O	AUX	O
apparent	O	ADJ	B
that	O	SCONJ	O
the	O	DET	O
expectation	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	B-I	ADJ	O
optimal	I-I	ADJ	B
therapy	I-I	NOUN	B
that	O	PRON	O
would	O	AUX	O
apply	O	VERB	O
to	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
at	O	ADP	O
all	O	DET	O
ages	O	NOUN	B
and	O	CCONJ	O
stages	O	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
was	O	AUX	O
naive	O	ADJ	B
.	O	PUNCT	O


Moreover	O	ADV	O
,	O	PUNCT	O
the	O	DET	O
group	O	NOUN	B
has	O	AUX	O
defined	O	VERB	O
more	O	ADV	O
precisely	O	ADV	O
than	O	ADP	O
ever	O	ADV	O
before	O	ADP	O
the	O	DET	O
nature	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
complications	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
disease	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
the	O	DET	O
risks	B-OUT	NOUN	B
of	I-OUT	ADP	O
specific	I-OUT	ADJ	O
complications	I-OUT	NOUN	B
with	O	ADP	O
specific	O	ADJ	O
forms	O	NOUN	O
of	O	ADP	O
therapy	O	NOUN	B
.	O	PUNCT	O


Environmental	B-I	ADJ	B
enrichment	I-I	NOUN	B
as	O	ADP	O
a	O	DET	O
therapy	O	NOUN	B
for	O	ADP	O
autism	B-P	NOUN	B
:	I-P	PUNCT	O
A	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
replication	O	NOUN	B
and	O	CCONJ	O
extension	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
an	O	DET	O
initial	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
,	O	PUNCT	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
who	I-P	PRON	O
received	I-P	VERB	O
sensorimotor	I-I	NOUN	B
enrichment	I-I	NOUN	O
at	I-I	ADP	O
home	I-I	NOUN	B
for	I-P	ADP	O
6	I-P	NUM	O
months	I-P	NOUN	B
had	I-P	AUX	O
significant	I-P	ADJ	O
improvements	I-P	NOUN	B
in	I-P	ADP	O
both	I-P	CCONJ	O
their	I-P	PRON	O
cognitive	I-P	ADJ	B
ability	I-P	NOUN	I
and	I-P	CCONJ	O
the	I-P	DET	O
severity	I-P	NOUN	B
of	I-P	ADP	O
their	I-P	PRON	O
autism	I-P	NOUN	B
symptoms	I-P	NOUN	B
(	O	PUNCT	O
Woo	O	PROPN	O
&	O	CCONJ	O
Leon	O	PROPN	O
,	O	PUNCT	O
2013	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
the	O	DET	O
outcomes	O	NOUN	B
of	O	ADP	O
a	O	DET	O
similar	O	ADJ	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
in	O	ADP	O
which	O	DET	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
,	I-P	PUNCT	O
3	I-P	NUM	O
to	I-P	PART	O
6	I-P	NUM	O
years	I-P	NOUN	B
old	I-P	ADJ	O
,	I-P	PUNCT	O
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	ADP	O
groups	B-I	NOUN	B
that	I-I	PRON	O
received	I-I	VERB	O
either	I-I	CCONJ	O
daily	I-I	ADJ	B
sensorimotor	I-I	NOUN	B
enrichment	I-I	NOUN	O
,	I-I	PUNCT	O
administered	I-I	VERB	B
by	I-I	ADP	O
their	I-I	PRON	O
parents	I-I	NOUN	B
,	I-I	PUNCT	O
along	I-I	ADP	O
with	I-I	ADP	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
,	I-I	PUNCT	O
or	I-I	CCONJ	O
they	I-I	PRON	O
received	I-I	VERB	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
alone	I-I	ADV	O
.	I-I	PUNCT	O


After	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
enriched	O	ADJ	O
children	O	NOUN	B
showed	O	VERB	O
statistically	O	ADV	B
significant	O	ADJ	I
gains	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
IQ	B-OUT	NOUN	B
scores	I-OUT	NOUN	B
,	O	PUNCT	O
a	O	DET	O
decline	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
atypical	B-OUT	ADJ	B
sensory	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
an	O	DET	O
improvement	O	NOUN	B
in	O	ADP	O
their	O	PRON	O
receptive	B-OUT	ADJ	B
language	I-OUT	NOUN	B
performance	I-OUT	NOUN	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
controls	O	NOUN	B
.	O	PUNCT	O


RESULT	O	NOUN	B
(	O	PUNCT	O
S	O	NOUN	B
)	O	PUNCT	O
No	O	INTJ	O
statistically	O	ADV	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
detected	O	VERB	B
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
survival	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
percentage	O	NOUN	B
of	O	ADP	O
detectable	B-OUT	ADJ	B
spindle	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
group	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	O
completely	O	ADV	O
denuded	O	VERB	B
oocytes	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
either	O	CCONJ	O
immediately	O	ADV	O
after	O	ADP	O
warming	O	NOUN	B
or	O	CCONJ	O
3	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
incubation	O	NOUN	B
.	O	PUNCT	O


Racemic	B-I	ADJ	B
epinephrine	I-I	NOUN	B
has	O	AUX	O
been	O	AUX	O
advocated	O	VERB	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
croup	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
controlled	O	VERB	B
studies	O	NOUN	I
have	O	AUX	O
not	O	PART	O
proved	O	VERB	O
it	O	PRON	O
more	O	ADV	O
effective	O	ADJ	B
than	O	ADP	O
saline	O	NOUN	B
.	O	PUNCT	O


Twenty	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
aged	I-P	ADJ	B
4	I-P	NUM	O
months	I-P	NOUN	B
to	I-P	PART	O
5	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
hospitalized	I-P	VERB	B
with	I-P	ADP	O
acute	I-P	ADJ	B
croup	I-P	NOUN	I
and	I-P	CCONJ	O
persistent	I-P	ADJ	B
inspiratory	I-P	ADJ	B
stridor	I-P	NOUN	I
at	I-P	ADP	O
rest	I-P	NOUN	O
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
two	O	NUM	O
treatment	O	NOUN	B
groups	O	NOUN	I
:	O	PUNCT	O
saline	B-I	NOUN	B
or	I-I	CCONJ	O
racemic	I-I	ADJ	B
epinephrine	I-I	NOUN	B
,	O	PUNCT	O
both	O	CCONJ	O
nebulized	O	VERB	B
and	O	CCONJ	O
delivered	O	VERB	O
by	O	ADP	O
intermittent	O	ADJ	B
positive	O	ADJ	I
pressure	O	NOUN	I
breathing	O	NOUN	I
.	O	PUNCT	O


Racemic	B-I	ADJ	B
epinephrine	I-I	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
more	O	ADV	O
effective	B-OUT	ADJ	B
than	O	ADP	O
saline	O	NOUN	B
at	O	ADP	O
10	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.01	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
30	O	NUM	O
minutes	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
.05	O	NUM	O
)	O	PUNCT	O
but	O	CCONJ	O
not	O	PART	O
at	O	ADP	O
120	O	NUM	O
minutes	O	NOUN	B
after	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
double-blind	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
clomipramine	B-I	NOUN	B
,	I-I	PUNCT	O
desipramine	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autistic	B-P	ADJ	B
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
Following	O	VERB	O
a	O	DET	O
2-week	O	ADJ	B
,	O	PUNCT	O
single-blind	O	ADJ	B
placebo	B-I	NOUN	B
washout	O	NOUN	B
phase	O	NOUN	I
,	O	PUNCT	O
12	B-P	NUM	O
autistic	I-P	ADJ	B
subjects	I-P	NOUN	I
completed	O	VERB	O
a	O	DET	O
10-week	O	NOUN	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
crossover	O	NOUN	B
comparison	O	NOUN	I
of	O	ADP	O
clomipramine	B-I	NOUN	B
and	I-I	CCONJ	O
placebo	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
12	B-P	NUM	O
different	I-P	ADJ	O
subjects	I-P	NOUN	B
completed	O	VERB	O
a	O	DET	O
similar	O	ADJ	O
comparison	O	NOUN	B
of	O	ADP	O
clomipramine	B-I	NOUN	B
and	O	CCONJ	O
desipramine	B-I	NOUN	B
.	I-I	PUNCT	O


PATIENTS	O	VERB	B
A	B-P	DET	O
referral	I-P	NOUN	B
sample	I-P	NOUN	O
of	I-P	ADP	O
30	I-P	NUM	O
male	I-P	NOUN	B
and	I-P	CCONJ	O
female	I-P	ADJ	B
autistic	I-P	ADJ	B
patients	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
,	I-P	PUNCT	O
and	I-P	CCONJ	O
24	I-P	NUM	O
completed	I-P	VERB	B
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


CONCLUSION	O	NOUN	O
Biological	O	ADJ	B
links	O	NOUN	O
between	O	ADP	O
compulsions	O	NOUN	B
and	O	CCONJ	O
stereotyped	O	ADJ	B
,	O	PUNCT	O
repetitive	O	ADJ	B
behaviors	O	NOUN	I
in	O	ADP	O
autistic	B-P	ADJ	B
disorder	I-P	NOUN	I
should	O	AUX	O
be	O	AUX	O
explored	O	VERB	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
pill	B-I	NOUN	B
containing	I-I	VERB	O
drospirenone	I-I	NOUN	B
with	I-I	ADP	O
those	I-I	DET	O
of	I-I	ADP	O
a	I-I	DET	O
combined	I-I	ADJ	B
contraceptive	I-I	ADJ	B
vaginal	I-I	ADJ	I
ring	I-I	NOUN	I
on	I-I	ADP	O
the	O	DET	O
lipid	O	NOUN	B
and	O	CCONJ	O
carbohydrate	O	NOUN	B
metabolism	O	NOUN	I
and	O	CCONJ	O
on	O	ADP	O
the	O	DET	O
surrogate	O	NOUN	B
markers	O	NOUN	B
of	O	ADP	O
arterial	O	ADJ	B
function	O	NOUN	I
.	O	PUNCT	O


SETTING	O	NOUN	B
Bologna	B-P	PROPN	I
University	I-P	PROPN	I
School	I-P	PROPN	I
of	I-P	ADP	I
Medicine	I-P	PROPN	I
.	I-P	PUNCT	O


The	O	DET	O
6-month	O	ADJ	B
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
vaginal	O	ADJ	B
ring	O	NOUN	I
significantly	O	ADV	O
improved	O	VERB	O
the	O	DET	O
area	B-OUT	NOUN	B
under	I-OUT	ADP	I
the	I-OUT	DET	I
curve	I-OUT	NOUN	I
for	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
insulin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
C-peptide	I-OUT	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
drospirenone+ethinylestradiol	O	NOUN	B
pill	O	NOUN	I
induced	O	VERB	B
an	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
the	O	DET	O
insulinogenic	B-OUT	ADJ	B
index	I-OUT	NOUN	I
and	O	CCONJ	O
homeostatic	B-OUT	ADJ	B
model	I-OUT	NOUN	I
assessment	I-OUT	NOUN	I
estimate	I-OUT	NOUN	O
for	I-OUT	ADP	O
insulin	I-OUT	NOUN	B
resistance	I-OUT	NOUN	I
values	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
who	I-OUT	PRON	O
needed	I-OUT	VERB	O
a	I-OUT	DET	O
second	I-OUT	ADJ	O
blood	I-OUT	NOUN	B
patch	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
6	O	NUM	O
(	O	PUNCT	O
10.0	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
prophylactic	B-I	ADJ	B
epidural	I-I	ADJ	O
blood	I-I	NOUN	O
patch	I-I	NOUN	O
and	O	CCONJ	O
4	O	NUM	O
(	O	PUNCT	O
11.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
for	O	ADP	O
therapeutic	B-I	ADJ	B
epidural	I-I	ADJ	O
blood	I-I	NOUN	O
patch	I-I	NOUN	O
.	I-I	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
acebutolol	B-I	NOUN	B
on	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
performance	O	NOUN	I
was	O	AUX	O
examined	O	VERB	O
by	O	ADP	O
various	O	ADJ	O
noninvasive	O	ADJ	B
means	O	NOUN	O
in	O	ADP	O
three	O	NUM	O
studies	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
13	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
stable	I-P	ADJ	B
angina	I-P	ADJ	I
pectoris	I-P	NOUN	I
,	O	PUNCT	O
single-pass	O	ADJ	B
studies	O	NOUN	I
of	O	ADP	O
left	O	ADJ	B
ventricular	O	ADJ	I
function	O	NOUN	I
with	O	ADP	O
indium	O	NOUN	B
113	O	NUM	O
under	O	ADP	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	O	ADJ	B
conditions	O	NOUN	O
similarly	O	ADV	O
showed	O	VERB	O
acebutolol	B-I	NOUN	B
to	O	PART	O
have	O	AUX	O
no	O	DET	O
clinically	O	ADV	B
significant	O	ADJ	I
negative	O	ADJ	B
inotropic	O	ADJ	B
effects	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Effects	O	NOUN	B
of	O	ADP	I
electroacupuncture	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
behavior	I-I	NOUN	B
therapy	I-I	NOUN	I
on	O	ADP	O
intelligence	O	NOUN	B
and	O	CCONJ	O
behavior	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
of	I-P	ADP	O
autism	I-P	NOUN	B
]	I-P	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Sixty	B-P	NUM	O
children	I-P	NOUN	B
of	I-P	ADP	O
autism	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
divided	O	VERB	O
into	O	ADP	O
an	O	DET	O
electroacupuncture	B-I	NOUN	B
(	I-I	PUNCT	O
EA	I-I	NOUN	B
)	I-I	PUNCT	O
plus	I-I	CCONJ	O
behavior	I-I	NOUN	B
therapy	I-I	NOUN	I
group	I-I	NOUN	B
and	I-I	CCONJ	O
a	I-I	DET	O
behavior	I-I	NOUN	B
therapy	I-I	NOUN	I
group	I-I	NOUN	B
,	O	PUNCT	O
30	O	NUM	O
cases	O	NOUN	B
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
routine	B-I	ADJ	B
behavior	I-I	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
EA	B-I	NOUN	B
at	O	ADP	O
Baihui	O	PROPN	B
(	O	PUNCT	O
GV	O	NOUN	O
20	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Sishencong	O	PROPN	B
(	O	PUNCT	O
EX-HN	O	NOUN	O
1	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Shenting	O	PROPN	B
(	O	PUNCT	O
GV	O	PROPN	O
24	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Benshen	O	PROPN	B
(	O	PUNCT	O
GB	O	PROPN	O
13	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Yintang	O	PROPN	B
(	O	PUNCT	O
EX-HN	O	NOUN	O
3	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Naohu	O	PROPN	B
(	O	PUNCT	O
GV	O	NOUN	B
17	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Naokong	O	PROPN	B
(	O	PUNCT	O
GB	O	PROPN	O
19	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
Neiguan	O	PROPN	B
(	O	PUNCT	O
PC	O	NOUN	B
6	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
scalp	B-I	ADJ	B
acupuncture	I-I	NOUN	I
at	O	ADP	O
Speech	O	PROPN	B
Areas	O	PROPN	I
I	O	PROPN	I
,	O	PUNCT	O
II	O	PROPN	B
,	O	PUNCT	O
III	O	NUM	O
added	O	VERB	O
for	O	ADP	O
the	O	DET	O
EA	B-I	NOUN	B
plus	I-I	CCONJ	O
behavior	I-I	NOUN	B
therapy	I-I	NOUN	I
group	O	NOUN	B
.	O	PUNCT	O


Their	O	PRON	O
therapeutic	O	ADJ	B
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
picture	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
vocabulary	I-OUT	ADJ	B
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
PPVT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	O	CCONJ	O
behavior	B-OUT	NOUN	B
ability	I-OUT	NOUN	I
were	O	AUX	O
detected	O	VERB	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
EA	B-I	NOUN	B
combined	I-I	VERB	O
with	I-I	ADP	O
behavior	I-I	NOUN	B
therapy	I-I	NOUN	I
can	O	AUX	O
significantly	O	ADV	O
improve	O	VERB	O
clinical	O	ADJ	B
symptoms	O	NOUN	I
of	O	ADP	O
autism	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
does	O	AUX	O
not	O	PART	O
improve	O	VERB	O
intelligence	O	NOUN	B
.	O	PUNCT	O


Clinical	B-I	ADJ	B
hypnosis	I-I	NOUN	I
versus	I-I	CCONJ	O
cognitive	I-I	ADJ	B
behavioral	I-I	ADJ	O
training	I-I	NOUN	O
for	O	ADP	O
pain	B-OUT	NOUN	B
management	I-OUT	NOUN	I
with	O	ADP	O
pediatric	B-P	ADJ	B
cancer	I-P	NOUN	I
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
bone	I-P	NOUN	B
marrow	I-P	NOUN	I
aspirations	I-P	NOUN	I
.	I-P	PUNCT	O


Patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
one	O	NUM	O
of	O	ADP	O
three	O	NUM	O
groups	O	NOUN	B
:	O	PUNCT	O
hypnosis	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
package	I-I	NOUN	B
of	I-I	ADP	O
CB	I-I	NOUN	B
coping	I-I	NOUN	O
skills	I-I	NOUN	O
,	I-I	PUNCT	O
and	I-I	CCONJ	O
no	I-I	DET	O
intervention	I-I	NOUN	B
.	I-I	PUNCT	O


Forty-seven	B-P	NUM	O
children	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	PART	O
treatment	I-P	NOUN	B
and	I-P	CCONJ	O
wait-list	I-P	ADJ	O
control	I-P	NOUN	B
groups	I-P	NOUN	I
.	I-P	PUNCT	O


Treatment	O	NOUN	B
group	O	NOUN	I
children	O	NOUN	B
received	O	VERB	O
the	O	DET	O
parent-delivered	B-I	ADJ	B
program	I-I	NOUN	I
for	I-I	ADP	O
4	I-I	NUM	O
mo	I-I	NOUN	O
.	I-I	PUNCT	O


Trained	O	ADJ	B
therapists	O	NOUN	B
provided	O	VERB	O
parent	B-I	NOUN	B
training	I-I	NOUN	B
and	I-I	CCONJ	O
support	I-I	NOUN	O
.	I-I	PUNCT	O


Results	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
parent-delivered	O	ADJ	B
program	O	NOUN	I
was	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
improving	O	VERB	B
measures	O	NOUN	B
of	O	ADP	O
autism	O	NOUN	B
(	O	PUNCT	O
medium	O	NOUN	B
effect	O	NOUN	O
size	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
sensory	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
self-regulatory	I-OUT	ADJ	B
responses	I-OUT	NOUN	I
(	O	PUNCT	O
large	O	ADJ	O
effect	O	NOUN	B
size	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


At	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
86	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CHOP	B-I	NOUN	B
arm	O	NOUN	O
had	O	AUX	O
responded	O	VERB	O
with	O	ADP	O
58	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
CR	O	NOUN	B
.	O	PUNCT	O


Treatment	O	NOUN	B
studies	O	NOUN	I
document	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
precessation	O	NOUN	B
NRT	B-I	PROPN	B
and	O	CCONJ	O
support	O	VERB	O
important	O	ADJ	O
roles	O	NOUN	O
for	O	ADP	O
level	O	NOUN	B
of	O	ADP	O
nicotine	O	NOUN	B
dependence	O	NOUN	B
and	O	CCONJ	O
precessation	O	NOUN	B
smoking	O	NOUN	B
reduction	O	NOUN	B
in	O	ADP	O
successful	O	ADJ	O
quitting	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
now	O	ADV	O
report	O	VERB	O
influences	O	NOUN	B
of	O	ADP	O
v1.0	B-OUT	NOUN	B
quit-success	I-OUT	ADJ	O
genotype	I-OUT	NOUN	O
score	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
dependence	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
precessation	I-OUT	NOUN	B
smoking	I-OUT	NOUN	B
reduction	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
smoking	O	NOUN	B
cessation	O	NOUN	I
trial	O	NOUN	I
that	O	PRON	O
examined	O	VERB	O
effects	O	NOUN	B
of	O	ADP	I
21	O	NUM	O
versus	O	CCONJ	O
42	O	NUM	O
mg/24	O	NOUN	O
h	O	NOUN	O
precessation	O	NOUN	B
NRT	B-I	NOUN	B
.	I-I	PUNCT	O


Four	B-P	NUM	O
hundred	I-P	NUM	O
seventy-nine	I-P	NUM	B
smokers	I-P	NOUN	I
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
21	O	NUM	O
or	O	CCONJ	O
42	O	NUM	O
mg	O	NOUN	O
NRT	B-I	NOUN	B
,	O	PUNCT	O
initiated	O	VERB	O
2	O	NUM	O
wks	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
target	O	VERB	B
quit	O	NOUN	O
dates	O	NOUN	B
.	O	PUNCT	O


Genotyping	B-P	NOUN	B
used	I-P	VERB	O
Affymetrix	I-OUT	PROPN	B
arrays	I-OUT	NOUN	I
(	I-P	PUNCT	O
Santa	I-P	PROPN	B
Clara	I-P	PROPN	I
,	I-P	PUNCT	O
CA	I-P	PROPN	B
,	I-P	PUNCT	O
USA	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
10-wk	B-OUT	ADJ	O
continuous	I-OUT	ADJ	B
smoking	I-OUT	NOUN	B
abstinence	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


NRT	B-OUT	NOUN	B
dose	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
level	I-OUT	NOUN	B
of	I-OUT	ADP	O
nicotine	I-OUT	NOUN	B
dependence	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
genotype	I-OUT	NOUN	B
scores	I-OUT	NOUN	O
displayed	O	VERB	O
significant	B-OUT	ADJ	O
interactive	I-OUT	ADJ	B
effects	I-OUT	NOUN	B
on	O	ADP	O
successful	O	ADJ	O
quitting	O	NOUN	B
.	O	PUNCT	O


Successful	B-OUT	ADJ	O
abstinence	I-OUT	NOUN	B
also	O	ADV	O
was	O	AUX	O
predicted	O	VERB	O
by	O	ADP	O
CO	B-OUT	NOUN	B
reductions	I-OUT	NOUN	B
during	O	ADP	O
precessation	O	NOUN	B
NRT	B-I	PROPN	B
.	I-I	PUNCT	O


Eleven	B-P	NUM	O
healthy	I-P	ADJ	B
tobacco	I-P	NOUN	B
smoking	I-P	VERB	I
adult	I-P	ADJ	B
male	I-P	NOUN	B
volunteers	I-P	NOUN	B
of	I-P	ADP	O
mixed	I-P	ADJ	B
race	I-P	NOUN	I
were	O	AUX	O
tobacco	B-I	NOUN	B
abstinent	I-I	VERB	I
overnight	O	ADV	O
for	O	ADP	O
this	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


Nicotine	B-I	NOUN	B
caused	O	VERB	O
a	O	DET	O
small	O	ADJ	B
overall	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
global	B-OUT	ADJ	B
cerebral	I-OUT	ADJ	I
metabolism	I-OUT	NOUN	I
of	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
but	O	CCONJ	O
,	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
data	O	NOUN	B
were	O	AUX	O
normalized	O	VERB	B
,	O	PUNCT	O
several	O	ADJ	O
brain	O	NOUN	B
regions	O	NOUN	I
showed	O	VERB	O
relative	O	ADJ	O
increases	B-OUT	NOUN	B
in	I-OUT	ADP	O
activity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Structures	O	NOUN	B
with	O	ADP	O
a	O	DET	O
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
regional	I-OUT	ADJ	B
cerebral	I-OUT	ADJ	B
metabolism	I-OUT	NOUN	I
of	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
pepper	I-OUT	NOUN	B
minus	O	CCONJ	O
nicotine	B-OUT	NOUN	B
)	I-OUT	PUNCT	O
were	O	AUX	O
the	O	DET	O
left	O	ADJ	B
insula	O	NOUN	I
and	O	CCONJ	O
right	O	ADV	B
inferior	O	ADJ	I
occipital	O	ADJ	I
gyrus	O	NOUN	I
,	O	PUNCT	O
with	O	ADP	O
Z	O	NOUN	B
scores	O	NOUN	I
>	O	VERB	O
3.5	O	NUM	O
.	O	PUNCT	O


Study	O	NOUN	B
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	ADP	O
the	O	DET	O
two	O	NUM	O
treatment	O	NOUN	B
arms	O	NOUN	I
,	O	PUNCT	O
Er	B-I	INTJ	B
:	I-I	PUNCT	O
YAG	I-I	NOUN	B
(	O	PUNCT	O
3.8	O	NUM	O
J/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
pattern	B-I	NOUN	B
overlap	I-I	NOUN	I
,	O	PUNCT	O
0	O	NUM	O
%	O	NOUN	O
interpulse	B-I	ADJ	B
overlap	I-I	NOUN	B
,	O	PUNCT	O
15	O	NUM	O
microm	O	NOUN	O
per	O	ADP	O
pass	O	NOUN	O
with	O	ADP	O
no	O	DET	O
coagulation	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
IPL	B-I	NOUN	B
(	O	PUNCT	O
560-nm	O	NOUN	O
filter	O	NOUN	O
,	O	PUNCT	O
30	O	NUM	O
J/cm	O	NOUN	O
(	O	PUNCT	O
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
2.4/4.0-ms	O	NUM	O
pulse	O	NOUN	B
with	O	ADP	O
10-ms	O	ADJ	O
delay	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
each	O	DET	O
receiving	O	VERB	O
three	O	NUM	O
sequential	O	ADJ	B
treatments	O	NOUN	B
spaced	O	VERB	O
1	O	NUM	O
month	O	NOUN	B
apart	O	ADV	O
.	O	PUNCT	O


Baseline	O	NOUN	B
subjective	O	ADJ	B
and	O	CCONJ	O
blinded	B-OUT	ADJ	B
physician	I-OUT	NOUN	B
dyschromia	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
rhytid	I-OUT	NOUN	B
scores	I-OUT	NOUN	I
revealed	O	VERB	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
between	O	ADP	O
the	O	DET	O
IPL	O	NOUN	B
and	O	CCONJ	O
Er	O	PROPN	B
:	O	PUNCT	O
YAG	O	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
sides	O	NOUN	O
.	O	PUNCT	O


Subjective	B-OUT	ADJ	O
global	I-OUT	ADJ	O
facial	I-OUT	ADJ	O
appearance	I-OUT	NOUN	B
scores	I-OUT	NOUN	B
worsened	O	VERB	B
by	O	ADP	O
5	O	NUM	O
%	O	NOUN	O
while	O	SCONJ	O
blinded	O	VERB	B
physician	O	NOUN	B
scores	O	NOUN	B
improved	O	VERB	B
by	O	ADP	O
16	O	NUM	O
%	O	NOUN	O
3	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
Er	O	INTJ	B
:	O	PUNCT	O
YAG	O	NOUN	B
treatments	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
by	O	ADP	O
28	O	NUM	O
and	O	CCONJ	O
20	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
IPL	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
overall	B-OUT	ADJ	O
incidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
adverse	I-OUT	ADJ	B
events	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
subsequent	I-OUT	ADJ	O
downtime	I-OUT	NOUN	B
was	O	AUX	O
increased	O	VERB	B
for	O	ADP	O
Er	O	INTJ	B
:	O	PUNCT	O
YAG	O	NOUN	B
(	O	PUNCT	O
1/10	O	NUM	O
patients	O	NOUN	B
experienced	O	VERB	O
hyperpigmentation	B-OUT	NOUN	B
,	O	PUNCT	O
3/10	O	NUM	O
exfoliation	B-OUT	NOUN	B
,	O	PUNCT	O
1/10	O	NUM	O
blistering	B-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
5/10	O	NUM	O
discomfort	B-OUT	NOUN	B
)	I-OUT	PUNCT	O
compared	O	VERB	O
to	O	PART	O
IPL	O	NOUN	B
(	O	PUNCT	O
1/10	O	NUM	O
exfoliation	O	NOUN	B
and	O	CCONJ	O
1/10	O	NUM	O
discomfort	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
although	O	SCONJ	O
no	O	DET	O
permanent	O	ADJ	B
side	O	NOUN	B
effects	O	NOUN	I
were	O	AUX	O
observed	O	VERB	B
with	O	ADP	O
either	O	CCONJ	O
treatment	O	NOUN	B
arm	O	NOUN	I
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
tested	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
a	O	DET	O
parent-mediated	B-I	ADJ	B
intervention	I-I	NOUN	I
on	I-I	ADP	O
parental	I-I	ADJ	B
responsiveness	I-I	NOUN	I
with	O	ADP	O
their	O	PRON	O
toddlers	B-P	NOUN	B
at	I-P	ADP	O
high	I-P	ADJ	B
risk	I-P	NOUN	I
for	I-P	ADP	O
an	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
treatment	O	NOUN	B
effects	O	NOUN	O
on	O	ADP	O
child	B-OUT	NOUN	B
outcomes	I-OUT	NOUN	B
of	O	ADP	O
joint	B-OUT	ADJ	B
attention	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Children	O	NOUN	B
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
made	O	VERB	O
significant	O	ADJ	B
developmental	O	ADJ	B
gains	O	NOUN	B
in	O	ADP	O
cognition	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
language	I-OUT	NOUN	B
skills	I-OUT	NOUN	B
over	O	ADP	O
one	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


These	O	DET	O
results	O	NOUN	B
support	O	VERB	O
parental	B-I	ADJ	B
responsiveness	I-I	NOUN	B
as	O	ADP	O
an	O	DET	O
important	O	ADJ	O
intervention	O	NOUN	B
target	O	NOUN	B
given	O	VERB	O
its	O	PRON	O
general	O	ADJ	O
association	O	NOUN	B
with	O	ADP	I
child	O	NOUN	B
outcomes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
extant	O	ADJ	O
literature	O	NOUN	B
;	O	PUNCT	O
however	O	ADV	O
,	O	PUNCT	O
additional	O	ADJ	O
supports	O	NOUN	O
are	O	AUX	O
likely	O	ADV	O
needed	O	VERB	O
to	O	PART	O
fully	O	ADV	O
maintain	O	VERB	O
the	O	DET	O
treatment	O	NOUN	B
effect	O	NOUN	I
and	O	CCONJ	O
to	O	PART	O
affect	O	VERB	O
child	O	NOUN	B
outcomes	O	NOUN	B
.	O	PUNCT	O


Pharmacologic	O	ADJ	B
treatment	O	NOUN	I
is	O	AUX	O
usually	O	ADV	O
begun	O	VERB	O
with	O	ADP	O
nonopioid	O	ADJ	B
analgesics	O	NOUN	I
,	O	PUNCT	O
most	O	ADV	O
frequently	O	ADV	O
acetaminophen	B-I	NOUN	B
.	I-I	PUNCT	O


If	O	SCONJ	O
pain	B-OUT	NOUN	B
relief	I-OUT	NOUN	I
is	O	AUX	O
not	O	PART	O
achieved	O	VERB	O
,	O	PUNCT	O
the	O	DET	O
so-called	O	ADJ	O
"	O	PUNCT	O
weak	O	ADJ	B
"	O	PUNCT	O
opioids	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
codeine	B-I	NOUN	B
and	I-I	CCONJ	O
hydrocodone	I-I	NOUN	B
,	O	PUNCT	O
may	O	AUX	O
be	O	AUX	O
used	O	VERB	O
in	B-I	ADP	O
combination	I-I	NOUN	B
with	I-I	ADP	O
acetaminophen	I-I	NOUN	B
.	I-I	PUNCT	O


OBJECTIVE	O	VERB	O
The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
analgesic	B-OUT	NOUN	B
efficacy	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
of	O	ADP	O
codeine	B-I	NOUN	B
phosphate	I-I	NOUN	I
versus	I-I	CCONJ	O
hydrocodone	I-I	NOUN	B
bitartrate	I-I	NOUN	I
in	O	ADP	O
combination	O	NOUN	B
with	O	ADP	O
acetaminophen	B-I	NOUN	B
in	O	ADP	O
the	O	DET	O
relief	O	NOUN	B
of	O	ADP	O
cancer-related	O	ADJ	B
pain	O	NOUN	I
.	O	PUNCT	O


Outpatients	B-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
were	I-P	AUX	O
eligible	I-P	ADJ	B
for	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
if	I-P	SCONJ	O
they	I-P	PRON	O
were	I-P	AUX	O
aged	I-P	ADJ	B
>	I-P	NOUN	O
-18	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
had	I-P	AUX	O
chronic	I-P	ADJ	B
(	I-P	PUNCT	O
duration	I-P	NOUN	B
,	I-P	PUNCT	O
>	I-P	X	O
/=	I-P	NOUN	O
3	I-P	NUM	O
months	I-P	NOUN	B
)	I-P	PUNCT	O
moderate	I-P	ADJ	B
to	I-P	PART	O
severe	I-P	ADJ	B
cancer-related	I-P	ADJ	B
pain	I-P	NOUN	I
(	I-P	PUNCT	O
score	I-P	NOUN	B
on	I-P	ADP	O
10-cm	I-P	ADJ	O
visual	I-P	ADJ	B
analog	I-P	NOUN	I
scale	I-P	NOUN	I
[	I-P	PUNCT	I
VAS	I-P	NOUN	B
]	I-P	PUNCT	O
,	I-P	PUNCT	O
>	I-P	X	O
3	I-P	NUM	O
cm	I-P	NOUN	O
[	I-P	PUNCT	O
moderate	I-P	ADJ	B
]	I-P	PUNCT	O
;	I-P	PUNCT	O
score	I-P	VERB	B
on	I-P	ADP	O
a	I-P	DET	O
4-point	I-P	ADJ	O
verbal	I-P	ADJ	B
pain-intensity	I-P	ADJ	I
scale	I-P	NOUN	I
,	I-P	PUNCT	O
>	I-P	X	O
1	I-P	NUM	O
[	I-P	PUNCT	O
moderate	I-P	ADJ	B
]	I-P	PUNCT	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Eligible	O	ADJ	O
patients	O	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
receive	O	VERB	O
1	O	NUM	O
tablet	O	NOUN	B
of	B-I	ADP	O
codeine/acetaminophen	I-I	NOUN	B
(	I-I	PUNCT	O
C/A	I-I	NOUN	B
)	I-I	PUNCT	O
30/500	O	NUM	O
mg	O	NOUN	O
or	B-I	CCONJ	O
hydrocodone/acetaminophen	I-I	NOUN	B
(	I-I	PUNCT	O
H/A	I-I	NOUN	B
)	I-I	PUNCT	O
5/500	O	NOUN	O
mg	O	NOUN	O
PO	O	NOUN	B
q4h	O	NOUN	O
(	O	PUNCT	O
total	O	ADJ	O
daily	O	ADJ	O
doses	O	NOUN	B
,	O	PUNCT	O
150/2500	O	NUM	O
and	O	CCONJ	O
25/2500	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
for	O	ADP	O
23	O	NUM	O
days	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	O
end	O	NOUN	O
point	O	NOUN	O
was	O	AUX	O
the	B-OUT	DET	O
proportion	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
who	I-OUT	PRON	O
achieved	I-OUT	VERB	O
pain	I-OUT	NOUN	B
relief	I-OUT	NOUN	I
(	O	PUNCT	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
score	O	NOUN	B
of	O	ADP	O
>	O	X	O
1	O	NUM	O
on	O	ADP	O
a	O	DET	O
5-point	O	ADJ	O
verbal	O	ADJ	O
rating	O	NOUN	O
scale	O	NOUN	O
[	O	PUNCT	O
VRS	O	PROPN	B
]	O	PUNCT	O
(	O	PUNCT	O
0	O	NUM	O
=	O	ADJ	O
none	O	NOUN	O
;	O	PUNCT	O
1	O	NUM	O
=	O	ADJ	O
a	O	DET	O
little	O	ADJ	O
;	O	PUNCT	O
2	O	NUM	O
=	O	ADJ	O
some	O	DET	O
;	O	PUNCT	O
3	O	NUM	O
=	O	ADJ	O
a	O	DET	O
lot	O	NOUN	O
;	O	PUNCT	O
and	O	CCONJ	O
4	O	NUM	O
=	O	ADJ	O
complete	O	ADJ	B
)	O	PUNCT	O
on	O	ADP	O
study	O	NOUN	B
days	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
2	O	NUM	O
and	O	CCONJ	O
weeks	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
2	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
3	O	NUM	O
.	O	PUNCT	O


The	O	DET	O
secondary	O	ADJ	B
end	O	NOUN	I
point	O	NOUN	I
was	O	AUX	O
the	B-OUT	DET	O
proportion	I-OUT	NOUN	B
of	I-OUT	ADP	O
patients	I-OUT	NOUN	B
in	I-OUT	ADP	O
whom	I-OUT	PRON	O
pain	I-OUT	NOUN	B
was	I-OUT	AUX	O
decreased	I-OUT	VERB	B
(	O	PUNCT	O
VAS	O	NOUN	B
score	O	NOUN	I
,	O	PUNCT	O
<	O	X	O
-	O	PUNCT	O
3	O	NUM	O
cm	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Of	B-P	ADP	O
the	I-OUT	DET	O
total	I-OUT	ADJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
cases	I-OUT	NOUN	B
,	I-P	PUNCT	O
59	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
aged	I-P	ADJ	B
60	I-P	NUM	O
to	I-P	PART	O
89	I-P	NUM	O
years	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
55	I-P	NUM	O
%	I-P	NOUN	O
were	I-P	AUX	O
men	I-P	NOUN	B
.	O	PUNCT	O


The	O	DET	O
most	O	ADV	O
common	O	ADJ	O
AEs	O	NOUN	B
in	O	ADP	O
the	B-I	DET	O
C/A	I-I	NOUN	B
and	I-I	CCONJ	O
H/A	I-I	NOUN	B
groups	O	NOUN	I
were	B-OUT	AUX	O
constipation	I-OUT	NOUN	B
(	O	PUNCT	O
36	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
29	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
,	O	PUNCT	O
dizziness	B-OUT	ADJ	B
(	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
19	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
vomiting	B-OUT	NOUN	B
(	O	PUNCT	O
24	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
16	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
dry	I-OUT	ADJ	B
mouth	I-OUT	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


MF101	B-I	NOUN	B
,	I-I	PUNCT	O
a	I-I	DET	O
selective	I-I	ADJ	O
estrogen	I-I	NOUN	B
receptor	I-I	NOUN	I
beta	O	NOUN	I
modulator	O	NOUN	I
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
menopausal	O	ADJ	B
hot	O	ADJ	I
flushes	O	NOUN	I
:	O	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
mean	B-OUT	ADJ	O
percent	I-OUT	NOUN	O
decrease	I-OUT	NOUN	B
in	I-OUT	ADP	O
frequency	I-OUT	NOUN	B
of	I-OUT	ADP	O
hot	I-OUT	ADJ	B
flushes	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
10	O	NUM	O
g/day	O	NOUN	O
group	O	NOUN	B
was	O	AUX	O
12.9	O	NUM	O
%	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	B-I	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.15	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
median	O	ADJ	B
percent	O	NOUN	O
decrease	O	NOUN	B
was	O	AUX	O
11.7	O	NUM	O
%	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
proportion	B-OUT	NOUN	B
of	I-OUT	ADP	O
women	I-OUT	NOUN	B
with	I-OUT	ADP	O
at	I-OUT	ADP	O
least	I-OUT	ADJ	O
a	I-OUT	DET	O
50	I-OUT	NUM	O
%	I-OUT	NOUN	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
hot	I-OUT	ADJ	B
flushes	I-OUT	NOUN	I
was	O	AUX	O
16.2	O	NUM	O
%	O	NOUN	O
greater	O	ADJ	O
than	O	ADP	O
that	O	DET	O
in	O	ADP	O
the	O	DET	O
placebo	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	B
Treatment	O	NOUN	B
with	O	ADP	O
10	O	NUM	O
g/day	O	NOUN	O
of	O	ADP	O
MF101	B-I	NOUN	B
reduces	O	VERB	B
the	O	DET	O
frequency	O	NOUN	B
of	O	ADP	O
hot	O	ADJ	B
flushes	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
a	O	DET	O
combined	O	ADJ	O
intervention	O	NOUN	B
including	O	VERB	O
MP	O	NOUN	B
plus	O	CCONJ	O
a	O	DET	O
nursing	B-I	NOUN	B
telephone	I-I	NOUN	I
intervention	I-I	NOUN	I
(	I-I	PUNCT	O
NTI	I-I	NOUN	B
)	I-I	PUNCT	O
was	O	AUX	O
also	O	ADV	O
assessed	O	VERB	B
.	O	PUNCT	O


Median	B-OUT	ADJ	B
FACIT-F	I-OUT	PROPN	B
fatigue	I-OUT	NOUN	O
scores	I-OUT	NOUN	O
improved	O	VERB	B
from	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
day	O	NOUN	B
15	O	NUM	O
in	O	ADP	O
all	O	DET	O
groups	O	NOUN	B
:	O	PUNCT	O
MP+NTI	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
score	O	NOUN	I
,	O	PUNCT	O
4.5	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.005	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
PL+NTI	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
score	O	NOUN	I
,	O	PUNCT	O
8.0	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
MP+CTI	O	ADJ	B
(	O	PUNCT	O
median	O	ADJ	B
score	O	NOUN	I
,	O	PUNCT	O
7.0	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.004	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
PL+CTI	O	NOUN	B
(	O	PUNCT	O
median	O	ADJ	B
score	O	NOUN	I
,	O	PUNCT	O
5.0	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.03	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
there	O	PRON	O
were	O	AUX	O
no	O	DET	O
significant	O	ADJ	O
differences	O	NOUN	O
in	O	ADP	O
the	O	DET	O
median	O	ADJ	B
improvement	O	NOUN	B
in	B-OUT	ADP	O
FACIT-F	I-OUT	ADJ	B
fatigue	I-OUT	NOUN	B
between	O	ADP	O
the	O	DET	O
MP	O	NOUN	B
and	O	CCONJ	O
PL	O	NOUN	B
groups	O	NOUN	B
(	O	PUNCT	O
5.5	O	NUM	O
v	O	DET	O
6.0	O	NUM	O
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.69	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
among	O	ADP	O
all	O	DET	O
four	O	NUM	O
groups	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.16	B-OUT	NUM	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Fatigue	B-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
nausea	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.01	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
depression	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.02	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
anxiety	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.01	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
drowsiness	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
appetite	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.009	B-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
sleep	I-OUT	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	B-OUT	CCONJ	O
feeling	I-OUT	NOUN	B
of	I-OUT	ADP	I
well-being	I-OUT	ADJ	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
as	O	ADP	O
measured	O	VERB	B
by	O	ADP	O
the	O	DET	O
ESAS	O	NOUN	B
,	O	PUNCT	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
received	O	VERB	O
NTI	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


CONCLUSION	O	NOUN	O
MP	O	NOUN	B
and	O	CCONJ	O
NTI	O	NOUN	B
alone	O	ADV	O
or	O	CCONJ	O
combined	O	VERB	B
were	O	AUX	O
not	O	PART	O
superior	B-I	ADJ	O
to	I-I	PART	O
placebo	I-I	NOUN	B
in	O	ADP	O
improving	B-OUT	VERB	B
CRF	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
the	O	DET	O
video	B-I	NOUN	B
game	I-I	NOUN	O
Mindlight	I-I	PROPN	B
on	O	ADP	O
anxiety	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
Autism	I-P	PROPN	B
Spectrum	I-P	PROPN	I
Disorder	I-P	PROPN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
setting	O	NOUN	I
,	O	PUNCT	O
a	O	DET	O
large	O	ADJ	O
proportion	O	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
an	I-P	DET	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	VERB	B
)	I-P	PUNCT	O
experience	I-P	NOUN	O
anxiety	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


This	O	DET	O
approach	O	NOUN	O
is	O	AUX	O
based	O	VERB	O
on	O	ADP	O
recent	O	ADJ	O
research	O	NOUN	B
suggesting	O	VERB	O
that	O	SCONJ	O
video	B-I	NOUN	B
games	I-I	NOUN	B
might	O	AUX	O
be	O	AUX	O
suitable	O	ADJ	O
as	O	ADP	O
an	O	DET	O
intervention	O	NOUN	B
vehicle	O	NOUN	I
to	O	PART	O
enhance	O	VERB	B
mental	O	ADJ	B
health	O	NOUN	I
in	O	ADP	O
children	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
expected	O	VERB	O
that	O	SCONJ	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
condition	O	NOUN	I
will	O	AUX	O
show	O	VERB	O
lower	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
anxiety	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
at	O	ADP	O
3-months	O	X	B
follow-up	O	X	B
,	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
children	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
condition	O	NOUN	I
.	O	PUNCT	O


[	B-OUT	PUNCT	O
Acute	I-OUT	ADJ	B
cardiovascular	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
metabolic	I-OUT	ADJ	B
changes	I-OUT	NOUN	B
in	O	ADP	O
interval	O	NOUN	B
and	O	CCONJ	O
endurance	B-I	NOUN	B
training	I-I	NOUN	I
in	O	ADP	O
selected	B-P	VERB	O
patients	I-P	NOUN	B
following	I-P	VERB	O
aortocoronary	I-P	ADJ	B
bypass	I-P	NOUN	I
operation	I-P	NOUN	I
]	I-P	PUNCT	O
.	O	PUNCT	O


UNLABELLED	O	VERB	B
This	O	DET	O
study	O	NOUN	B
compared	O	VERB	O
the	O	DET	O
acute	B-OUT	ADJ	B
changes	I-OUT	NOUN	B
of	I-OUT	ADP	O
cardiovascular	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
metabolic	I-OUT	ADJ	B
reactions	I-OUT	NOUN	I
during	O	ADP	O
interval	B-I	NOUN	B
and	I-I	CCONJ	O
continuous	I-I	ADJ	B
training	I-I	NOUN	O
after	O	ADP	O
coronary	O	ADJ	B
bypass	O	NOUN	I
surgery	O	NOUN	I
.	O	PUNCT	O


)	B-P	PUNCT	O
each	I-I	DET	O
trained	I-I	VERB	B
on	I-I	ADP	O
bicycle	I-I	NOUN	B
ergometer	I-I	NOUN	I
start	I-I	NOUN	O
on	I-I	ADP	O
post-operative	I-I	ADJ	B
days	I-I	NOUN	B
24	I-I	NUM	O
and	I-I	CCONJ	O
26	I-I	NUM	O
,	I-I	PUNCT	O
resp	I-I	NOUN	B
.	I-I	PUNCT	O


In	B-I	ADP	O
the	I-I	DET	O
last	I-I	ADJ	O
week	I-I	NOUN	B
of	I-I	ADP	O
training	I-I	VERB	B
the	I-I	DET	O
exercise	I-I	NOUN	B
intensity	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
group	I-I	NOUN	B
of	I-I	ADP	O
patients	I-I	NOUN	B
who	I-I	PRON	O
were	I-I	AUX	O
trained	I-I	VERB	B
by	I-I	ADP	O
the	I-I	DET	O
continuous	I-I	ADJ	B
method	I-I	NOUN	I
was	I-I	AUX	O
at	I-I	ADP	O
83	I-I	NUM	O
watts	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
at	I-I	ADP	O
20:121	I-I	ADJ	O
watts	I-I	NOUN	B
in	I-I	ADP	O
the	I-I	DET	O
group	I-I	NOUN	B
of	I-I	ADP	O
patients	I-I	NOUN	B
who	I-I	PRON	O
were	I-I	AUX	O
trained	I-I	VERB	B
by	I-I	ADP	O
interval	I-I	NOUN	B
method	I-I	NOUN	I
(	I-I	PUNCT	O
rest	I-I	NOUN	B
:	I-I	PUNCT	O
work	I-I	VERB	O
each	I-I	DET	O
1:1	I-I	NUM	O
min	I-I	NOUN	O
)	I-I	PUNCT	O
.	I-I	PUNCT	O


RESULTS	O	NOUN	B
In	O	ADP	O
both	O	DET	O
methods	O	NOUN	B
there	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
significant	I-OUT	ADJ	O
differences	I-OUT	NOUN	O
in	I-OUT	ADP	O
systolic	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
diastolic	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
rate-pressure	I-OUT	ADJ	B
product	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
in	I-OUT	ADP	O
glucose	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
catecholamine	I-OUT	NOUN	B
levels	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Moderate-intensity	B-I	ADJ	B
exercise	I-I	NOUN	O
training	I-I	NOUN	O
with	O	ADP	O
elements	O	NOUN	O
of	O	ADP	O
step	O	NOUN	O
aerobics	O	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
a	O	DET	O
specific	O	ADJ	O
program	O	NOUN	B
of	O	ADP	O
moderate-intensity	B-I	ADJ	B
step	I-I	NOUN	O
aerobics	I-I	NOUN	B
training	I-I	NOUN	B
may	O	AUX	O
be	O	AUX	O
sufficient	O	ADJ	O
to	O	PART	O
improve	O	VERB	B
the	O	DET	O
exercise	O	NOUN	B
tolerance	O	NOUN	I
of	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
chronic	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
control	O	ADJ	B
group	O	NOUN	I
did	O	AUX	O
not	O	PART	O
perform	B-I	VERB	O
a	I-I	DET	O
training	I-I	NOUN	B
program	I-I	NOUN	I
.	I-I	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	X	B
MEASURES	O	X	O
Peak	B-OUT	ADJ	B
oxygen	I-OUT	NOUN	I
uptake	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
peak	I-OUT	NOUN	B
workload	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
percent	I-OUT	NOUN	O
of	I-OUT	ADP	O
predicted	I-OUT	VERB	B
power	I-OUT	NOUN	O
ability	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
peak	B-OUT	NOUN	B
oxygen	I-OUT	NOUN	I
uptake	I-OUT	NOUN	I
(	O	PUNCT	O
15	O	NUM	O
+/-	O	CCONJ	O
3.4	O	NUM	O
to	O	PART	O
18.5	O	NUM	O
+/-	O	CCONJ	O
2.9mL/kg/min	O	ADJ	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
peak	B-OUT	NOUN	B
workload	I-OUT	NOUN	I
(	O	PUNCT	O
77	O	NUM	O
+/-	O	CCONJ	O
26	O	NUM	O
to	O	PART	O
99	O	NUM	O
+/-	O	CCONJ	O
31	O	NUM	O
watts	O	NOUN	B
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.000	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
percent	B-OUT	NOUN	O
of	I-OUT	ADP	O
predicted	I-OUT	VERB	O
power	I-OUT	NOUN	O
ability	I-OUT	NOUN	O
(	O	PUNCT	O
43	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
10	O	NUM	O
%	O	NOUN	O
to	O	PART	O
56	O	NUM	O
%	O	NOUN	O
+/-	O	CCONJ	O
13	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.000	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
the	O	DET	O
exercise	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
critical	O	ADJ	O
changes	O	NOUN	B
in	O	ADP	O
heart	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
blood	I-OUT	NOUN	B
pressure	I-OUT	NOUN	I
in	O	ADP	O
either	O	DET	O
group	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
priming	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
automatic	O	ADJ	B
imitation	O	NOUN	B
paradigm	O	NOUN	B
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
acquire	O	VERB	O
an	O	DET	O
index	B-OUT	NOUN	O
of	I-OUT	ADP	O
imitation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Whereas	O	SCONJ	O
imitation	B-OUT	NOUN	B
levels	I-OUT	NOUN	O
were	O	AUX	O
higher	O	ADJ	O
for	O	ADP	O
pro-socially	O	ADV	B
primed	O	VERB	B
relative	O	ADJ	O
to	O	PART	O
non-socially	O	ADV	B
primed	O	ADJ	O
control	B-P	NOUN	O
participants	I-P	NOUN	O
,	O	PUNCT	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
difference	O	NOUN	O
between	O	ADP	O
pro-	O	NOUN	B
and	O	CCONJ	O
non-	O	ADJ	O
socially	O	ADV	B
primed	O	VERB	O
individuals	B-P	NOUN	B
with	I-P	ADP	O
ASC	I-P	NOUN	B
.	I-P	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
high-functioning	B-P	ADJ	B
adults	I-P	NOUN	B
with	I-P	ADP	O
ASC	I-P	NOUN	B
demonstrate	O	VERB	O
atypical	B-OUT	ADJ	B
social	I-OUT	ADJ	B
modulation	I-OUT	NOUN	I
of	I-OUT	ADP	O
imitation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
limited	O	ADJ	O
sampling	O	NOUN	O
model	O	NOUN	O
has	O	AUX	O
been	O	AUX	O
developed	O	VERB	O
for	O	ADP	O
flunarizine	O	NOUN	B
following	O	VERB	O
a	O	DET	O
30	O	NUM	O
mg	O	NOUN	O
oral	O	ADJ	B
dose	O	NOUN	I
in	O	ADP	O
epileptic	B-P	ADJ	B
patients	I-P	NOUN	I
who	I-P	PRON	O
were	I-I	AUX	O
receiving	I-I	VERB	O
phenytoin	I-I	NOUN	B
or	I-I	CCONJ	O
carbamazepine	I-I	NOUN	B
or	I-I	CCONJ	O
both	I-I	DET	O
,	I-I	PUNCT	O
to	I-I	PART	O
estimate	I-OUT	VERB	B
the	I-OUT	DET	O
area	I-OUT	NOUN	B
under	I-OUT	ADP	I
the	I-OUT	DET	I
curve	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
AUC	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
maximum	I-OUT	ADJ	B
plasma	I-OUT	NOUN	B
concentration	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
Cmax	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
model	O	NOUN	B
was	O	AUX	O
developed	O	VERB	O
using	O	VERB	O
training	O	NOUN	B
data	O	NOUN	I
sets	O	VERB	I
from	O	ADP	O
30	B-P	NUM	O
,	I-P	PUNCT	O
20	I-P	NUM	O
,	I-P	PUNCT	O
15	I-P	NUM	O
,	I-P	PUNCT	O
or	I-P	CCONJ	O
10	I-P	NUM	O
patients	I-P	NOUN	B
at	I-P	ADP	O
one	I-P	NUM	O
or	I-P	CCONJ	O
two	I-P	NUM	O
time	I-P	NOUN	B
points	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
model	O	NOUN	B
provided	O	VERB	O
reasonably	O	ADV	O
good	O	ADJ	O
estimates	B-OUT	NOUN	B
for	I-OUT	ADP	O
both	I-OUT	CCONJ	O
AUC	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
Cmax	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


The	O	DET	O
bias	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
prediction	I-OUT	NOUN	B
was	O	AUX	O
2	O	NUM	O
%	O	NOUN	O
and	O	CCONJ	O
precision	O	NOUN	B
was	O	AUX	O
28	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


The	O	DET	O
mean	O	NOUN	O
predicted	B-OUT	VERB	O
Cmax	I-OUT	NOUN	B
of	I-OUT	ADP	O
flunarizine	I-OUT	NOUN	B
was	O	AUX	O
86	O	NUM	O
+/-	O	CCONJ	O
32	O	NUM	O
ng	O	NOUN	O
mL-1	O	NOUN	O
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
an	O	DET	O
observed	B-OUT	VERB	O
mean	I-OUT	ADJ	O
Cmax	I-OUT	NOUN	B
of	O	ADP	O
90	O	NUM	O
+/-	O	CCONJ	O
42	O	NUM	O
ng	O	NOUN	O
mL-1	O	NOUN	B
.	O	PUNCT	O


Naltrexone	B-I	NOUN	B
in	O	ADP	O
young	B-P	ADJ	B
autistic	I-P	ADJ	B
children	I-P	NOUN	B
:	I-P	PUNCT	O
a	O	DET	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
crossover	O	NOUN	B
study	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
evaluated	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
naltrexone	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
opiate	O	ADJ	B
blocker	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
autism	B-P	NOUN	B
.	I-P	PUNCT	O


Dependent	B-I	ADJ	B
measures	I-I	NOUN	B
included	I-I	VERB	O
parent	I-I	NOUN	B
and	I-I	CCONJ	O
teacher	I-I	NOUN	B
Clinical	I-OUT	PROPN	B
Global	I-OUT	PROPN	I
Impressions	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
CGI	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
Conners	I-OUT	PROPN	B
Rating	I-OUT	PROPN	I
Scales	I-OUT	PROPN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
Naltrexone	I-OUT	NOUN	B
Side-Effects	I-OUT	PROPN	O
(	I-OUT	PUNCT	O
SE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
Rating	I-OUT	NOUN	O
Scale	I-OUT	NOUN	O
;	I-OUT	PUNCT	O
laboratory	I-OUT	ADJ	B
CGI	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
movement	I-OUT	NOUN	B
actometer	I-OUT	NOUN	B
readings	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
a	I-OUT	DET	O
10-second	I-OUT	ADJ	B
interval	I-OUT	NOUN	I
recording	I-OUT	NOUN	I
system	I-OUT	NOUN	I
analysis	I-OUT	NOUN	I
of	I-OUT	ADP	O
on-task	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
communication	I-OUT	NOUN	B
initiations	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
disruptive	I-OUT	ADJ	B
behavior	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
self-stimulation	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Adverse	B-OUT	ADJ	B
side	I-OUT	NOUN	I
effects	I-OUT	NOUN	I
were	O	AUX	O
behavioral	O	ADJ	B
,	O	PUNCT	O
mild	O	ADJ	B
,	O	PUNCT	O
and	O	CCONJ	O
transient	O	ADJ	B
.	O	PUNCT	O


Frequent	O	ADJ	B
treatment-emergent	O	ADJ	O
grade	O	NOUN	O
3/4	O	NUM	O
hematologic	B-OUT	ADJ	B
abnormalities	I-OUT	NOUN	I
were	O	AUX	O
lymphopenia	B-OUT	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
%	O	NOUN	O
v	O	ADP	O
11	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
anemia	B-OUT	NOUN	B
(	O	PUNCT	O
9	O	NUM	O
%	O	NOUN	O
v	O	CCONJ	O
8	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
neutropenia	B-OUT	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
%	O	NOUN	O
v	O	NOUN	O
<	O	X	O
1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
all-E-Zeaxanthin	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
increased	O	VERB	B
from	O	ADP	O
0.048	O	NUM	O
+/-	O	CCONJ	O
0.026	O	NUM	O
micro	O	ADJ	B
mol/L	O	NOUN	I
at	O	ADP	O
baseline	O	NOUN	B
to	O	PART	O
0.20	O	NUM	O
+/-	O	CCONJ	O
0.07	O	NUM	O
and	O	CCONJ	O
0.92	O	NUM	O
+/-	O	CCONJ	O
0.28	O	NUM	O
micro	O	ADJ	B
mol/L	O	NOUN	I
with	O	ADP	O
1	O	NUM	O
and	O	CCONJ	O
10	O	NUM	O
mg	O	NOUN	O
zeaxanthin	B-I	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
.	O	PUNCT	O


The	O	DET	O
dose-normalized	B-OUT	ADJ	B
bioavailability	I-OUT	NOUN	B
of	I-OUT	ADP	O
all-E-zeaxanthin	I-OUT	NOUN	B
after	O	ADP	O
the10-mg	O	NOUN	B
dose	O	NOUN	I
was	O	AUX	O
40	O	NUM	O
%	O	NOUN	O
lower	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
than	O	ADP	O
after	O	ADP	O
the	O	DET	O
1-mg	O	ADJ	O
dose	O	NOUN	B
.	O	PUNCT	O


Other	O	ADJ	O
kinetic	B-OUT	ADJ	B
parameters	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
differ	O	VERB	O
significantly	O	ADV	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
time	B-OUT	NOUN	B
course	I-OUT	NOUN	I
of	I-OUT	ADP	O
plasma	I-OUT	NOUN	B
all-E-3-'dehydro-lutein	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	I
resembled	O	VERB	O
that	O	DET	O
of	O	ADP	O
all-E-zeaxanthin	B-I	NOUN	B
.	I-I	PUNCT	O


Concentrations	B-OUT	NOUN	B
of	I-OUT	ADP	O
other	I-OUT	ADJ	O
carotenoids	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
affected	O	VERB	B
.	O	PUNCT	O


AIMS	O	NOUN	B
We	O	PRON	O
therefore	O	ADV	O
used	O	VERB	O
functional	B-I	ADJ	B
magnetic	I-I	ADJ	B
resonance	I-I	NOUN	I
imaging	I-I	NOUN	I
(	O	PUNCT	O
fMRI	O	NOUN	B
)	O	PUNCT	O
to	O	PART	O
investigate	O	VERB	B
the	O	DET	O
so	O	ADV	O
far	O	ADV	O
unknown	O	ADJ	O
shared	O	VERB	O
and	O	CCONJ	O
disorder-specific	O	ADJ	B
inhibitory	B-OUT	ADJ	I
brain	I-OUT	NOUN	O
dysfunctions	I-OUT	NOUN	O
in	O	ADP	O
these	O	DET	O
two	O	NUM	O
disorders	O	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
a	O	DET	O
single	O	ADJ	B
dose	O	NOUN	I
of	O	ADP	O
the	O	DET	O
selective	O	ADJ	O
serotonin	O	NOUN	B
reuptake	O	NOUN	I
inhibitor	O	NOUN	I
fluoxetine	O	NOUN	B
.	O	PUNCT	O


Repeated	O	VERB	B
measures	O	NOUN	O
analyses	O	NOUN	O
within	O	ADP	O
patients	O	NOUN	B
assessed	O	VERB	B
drug	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
findings	O	NOUN	B
show	O	VERB	O
that	O	SCONJ	O
fluoxetine	O	NOUN	B
normalises	O	VERB	B
frontal	B-OUT	ADJ	B
lobe	I-OUT	ADJ	I
dysfunctions	I-OUT	NOUN	I
in	O	ADP	O
both	O	DET	O
disorders	O	NOUN	B
via	O	ADP	O
inverse	O	ADJ	B
effects	O	NOUN	I
,	O	PUNCT	O
downregulating	O	VERB	B
abnormally	O	ADV	B
increased	O	VERB	B
frontal	B-OUT	ADJ	B
activation	I-OUT	NOUN	I
in	O	ADP	O
ASD	O	PROPN	B
and	O	CCONJ	O
upregulating	O	NOUN	B
abnormally	O	ADV	B
decreased	O	VERB	B
frontal	B-OUT	ADJ	B
activation	I-OUT	NOUN	I
in	O	ADP	O
ADHD	O	NOUN	B
,	O	PUNCT	O
potentially	O	ADV	O
reflecting	O	VERB	O
inverse	O	ADJ	B
baseline	O	NOUN	B
serotonin	O	NOUN	B
levels	O	NOUN	B
in	O	ADP	O
both	O	DET	O
disorders	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
immunotherapy	B-I	NOUN	B
for	O	ADP	O
persistent	B-P	ADJ	B
genital	I-P	ADJ	B
warts	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	NOUN	O
Of	B-P	ADP	O
33	I-P	NUM	O
protocol	I-P	NOUN	B
compliant	I-P	ADJ	O
Brisbane	I-P	PROPN	B
recipients	I-P	NOUN	I
of	I-P	ADP	O
placebo	I-P	ADJ	B
immunotherapy	I-P	NOUN	I
,	O	PUNCT	O
11	O	NUM	O
were	O	AUX	O
disease	O	NOUN	B
free	O	ADJ	I
at	O	ADP	O
two	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
a	O	DET	O
further	O	ADV	O
9	O	NUM	O
demonstrated	O	VERB	O
reduction	O	NOUN	B
of	O	ADP	O
>	O	SYM	O
50	O	NUM	O
%	O	NOUN	O
in	B-OUT	ADP	O
total	I-OUT	ADJ	B
wart	I-OUT	ADJ	I
area	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Wart	B-OUT	PROPN	B
area	I-OUT	NOUN	I
reduction	I-OUT	NOUN	B
following	O	VERB	O
destructive	O	ADJ	B
treatment	O	NOUN	B
correlated	O	VERB	B
with	O	ADP	O
prior	O	ADJ	O
duration	O	NOUN	B
of	O	ADP	I
disease	O	NOUN	I
.	O	PUNCT	O


Prior	B-OUT	ADJ	O
disease	I-OUT	NOUN	B
duration	O	NOUN	I
was	O	AUX	O
much	O	ADV	O
shorter	O	ADJ	B
in	O	ADP	O
Wenzhou	O	PROPN	B
subject	O	NOUN	I
(	O	PUNCT	O
8.1	O	NUM	O
	O	NOUN	O
1.1	O	NUM	O
mo	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
in	O	ADP	O
Brisbane	O	PROPN	B
subjects	O	NOUN	I
(	O	PUNCT	O
53.7	O	NUM	O
	O	NOUN	O
5.5	O	NUM	O
mo	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
mean	I-OUT	ADJ	B
wart	O	ADJ	I
area	O	NOUN	O
was	O	AUX	O
observed	B-P	VERB	O
for	I-P	ADP	O
the	I-P	DET	O
168	I-P	NUM	O
Wenzhou	I-P	PROPN	B
protocol	I-P	NOUN	I
compliant	I-P	ADJ	O
subjects	I-P	NOUN	B
who	I-P	PRON	O
also	I-P	ADV	O
received	I-P	VERB	O
VLP	I-P	NOUN	B
immunotherapy	I-P	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
confirms	O	VERB	O
the	O	DET	O
findings	O	NOUN	B
in	O	ADP	O
a	O	DET	O
previous	O	ADJ	O
open	O	ADJ	O
label	O	NOUN	O
trial	O	NOUN	O
that	O	SCONJ	O
administration	O	NOUN	B
of	O	ADP	O
VLP	O	NOUN	B
immunotherapy	O	NOUN	B
may	O	AUX	O
assist	O	VERB	O
in	O	ADP	O
clearance	O	NOUN	B
of	B-OUT	ADP	O
recurrent	I-OUT	ADJ	B
genital	I-OUT	ADJ	O
warts	I-P	NOUN	O
in	I-P	ADP	O
patients	I-P	NOUN	B
for	I-P	ADP	O
whom	I-P	PRON	O
destructive	I-P	ADJ	B
therapy	I-P	NOUN	I
is	I-P	AUX	O
unsuccessful	I-P	ADJ	O
and	O	CCONJ	O
that	O	SCONJ	O
unsuccessful	O	ADJ	O
destructive	O	ADJ	B
therapy	O	NOUN	I
is	O	AUX	O
more	O	ADV	O
common	O	ADJ	O
with	O	ADP	O
increasing	O	VERB	B
prior	O	ADJ	O
disease	O	NOUN	B
duration	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
extracorporeal	B-I	ADJ	B
shock	I-I	NOUN	I
wave	I-I	NOUN	I
therapy	I-I	NOUN	I
(	O	PUNCT	O
ESWT	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
chronically	B-P	ADV	B
painful	I-P	ADJ	I
proximal	I-P	ADJ	B
plantar	I-P	NOUN	B
fasciitis	I-P	NOUN	I
with	O	ADP	O
a	O	DET	O
further	O	ADV	O
conventional	O	ADJ	O
conservative	O	ADJ	B
treatment	O	NOUN	I
.	O	PUNCT	O


Forty-seven	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
49	I-P	NUM	O
feet	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
previously	I-P	ADV	O
unsuccessful	I-P	ADJ	O
nonsurgical	I-P	ADJ	B
treatment	I-P	NOUN	I
of	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
6	I-P	NUM	O
months	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
to	I-P	ADP	O
two	I-P	NUM	O
groups	I-P	NOUN	B
.	I-P	PUNCT	O


Heel	B-I	ADJ	B
cups	I-I	NOUN	I
had	O	AUX	O
to	O	PART	O
be	O	AUX	O
worn	O	VERB	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


At	O	ADP	O
12	O	NUM	O
weeks	O	NOUN	B
after	O	ADP	O
ESWT	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
pain	B-OUT	NOUN	B
estimation	I-OUT	NOUN	B
on	I-OUT	ADP	O
the	I-OUT	DET	O
visual	I-OUT	ADJ	B
analogue	I-OUT	NOUN	I
scale	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VAS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
for	I-OUT	ADP	O
activities	I-OUT	NOUN	B
of	I-OUT	ADP	O
daily	I-OUT	ADV	B
living	I-OUT	NOUN	O
diminished	O	VERB	O
significantly	O	ADV	O
by	O	ADP	O
62.9	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
by	O	ADP	O
63.0	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
group	O	NOUN	B
2	O	NUM	I
.	O	PUNCT	O


The	O	DET	O
comfortable	B-OUT	ADJ	B
walking	I-OUT	NOUN	I
time	I-OUT	NOUN	O
had	O	AUX	O
increased	O	VERB	B
significantly	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
pilot	O	NOUN	B
study	O	NOUN	I
on	O	ADP	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
melodic	B-I	ADJ	B
based	I-I	VERB	O
communication	I-I	NOUN	B
therapy	I-I	NOUN	I
for	O	ADP	O
eliciting	B-OUT	VERB	O
speech	I-OUT	NOUN	B
in	O	ADP	O
nonverbal	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
purpose	O	NOUN	O
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
compare	O	VERB	B
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
melodic	B-I	ADJ	B
based	I-I	VERB	O
communication	I-I	NOUN	B
therapy	I-I	NOUN	I
(	I-I	PUNCT	O
MBCT	I-I	NOUN	B
)	I-I	PUNCT	O
to	I-I	ADP	O
traditional	I-I	ADJ	B
speech	I-I	NOUN	B
and	I-I	CCONJ	O
language	I-I	NOUN	B
therapy	I-I	NOUN	I
for	O	ADP	O
eliciting	B-OUT	VERB	O
speech	I-OUT	NOUN	B
in	O	ADP	O
nonverbal	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
MBCT	O	NOUN	B
group	O	NOUN	B
progressed	O	VERB	O
significantly	O	ADV	O
in	O	ADP	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
verbal	I-OUT	ADJ	B
attempts	I-OUT	NOUN	I
after	O	ADP	O
weeks	O	NOUN	B
1	O	NUM	O
through	O	ADP	O
4	O	NUM	O
and	O	CCONJ	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
correct	I-OUT	ADJ	B
words	I-OUT	NOUN	B
after	O	ADP	O
weeks	O	NOUN	B
1	O	NUM	O
and	O	CCONJ	O
3	O	NUM	O
,	O	PUNCT	O
while	O	SCONJ	O
the	O	DET	O
traditional	O	ADJ	B
group	O	NOUN	B
progressed	O	VERB	O
significantly	O	ADV	O
after	O	ADP	O
weeks	O	NOUN	B
4	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
in	O	ADP	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
verbal	I-OUT	ADJ	B
attempts	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
correct	I-OUT	ADJ	B
words	I-OUT	NOUN	B
were	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
groups	O	NOUN	B
following	O	VERB	O
treatment	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
repeat	B-OUT	NOUN	O
pregnancy	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
was	O	AUX	O
12	O	NUM	O
%	O	NOUN	O
after	O	ADP	O
18	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
28	O	NUM	O
%	O	NOUN	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
.	O	PUNCT	O


After	O	ADP	O
12	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
infants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
experimental	O	ADJ	B
group	O	NOUN	I
were	O	AUX	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
be	O	AUX	O
fully	B-OUT	ADV	O
immunized	I-OUT	VERB	B
(	O	PUNCT	O
33	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
than	O	ADP	O
the	O	DET	O
infants	O	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
(	O	PUNCT	O
18	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Outcome	B-OUT	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
centrally	I-P	ADV	O
reviewed	I-P	VERB	B
low-grade	I-P	ADJ	B
gliomas	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
chemotherapy	I-I	NOUN	B
with	I-I	ADP	O
or	I-I	CCONJ	O
without	I-I	ADP	O
radiotherapy	I-I	NOUN	B
on	O	ADP	O
Children	O	PROPN	B
's	O	PART	I
Cancer	O	PROPN	I
Group	O	PROPN	B
high-grade	O	ADJ	O
glioma	O	NOUN	O
study	O	NOUN	O
CCG-945	O	NOUN	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
objectives	O	NOUN	O
of	O	ADP	O
the	O	DET	O
current	O	ADJ	O
study	O	NOUN	B
were	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
outcome	B-OUT	NOUN	B
of	O	ADP	O
children	B-P	NOUN	B
who	I-P	PRON	O
were	I-P	AUX	O
treated	I-P	VERB	B
with	I-P	ADP	I
chemotherapy	I-I	NOUN	B
and	I-I	CCONJ	O
radiotherapy	I-I	NOUN	B
on	I-P	ADP	O
the	I-P	DET	O
Children	I-P	PROPN	B
's	I-P	PART	I
Cancer	I-P	PROPN	I
Group	I-P	PROPN	I
(	I-P	PUNCT	O
CCG	I-P	NOUN	B
)	I-P	PUNCT	O
high-grade	I-P	ADJ	B
glioma	I-P	NOUN	O
protocol	I-P	NOUN	O
(	I-P	PUNCT	O
CCG-945	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
diagnosed	I-P	VERB	B
with	I-P	ADP	O
low-grade	I-P	ADJ	B
gliomas	I-P	NOUN	B
on	I-P	ADP	O
post	I-P	NOUN	B
hoc	I-P	NOUN	I
central	I-P	ADJ	I
pathologic	I-P	ADJ	I
review	I-P	NOUN	I
and	O	CCONJ	O
to	O	PART	O
identify	O	VERB	O
clinical	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
biologic	I-OUT	ADJ	B
features	I-OUT	NOUN	B
associated	O	VERB	B
with	O	ADP	I
prognosis	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
Between	B-P	ADP	O
1985	I-P	NUM	O
and	I-P	CCONJ	O
1991	I-P	NUM	O
,	I-P	PUNCT	O
250	I-P	NUM	O
children	I-P	NOUN	B
with	I-P	ADP	O
institutionally	I-P	ADV	B
classified	I-P	VERB	O
high-grade	I-P	ADJ	B
gliomas	I-P	NOUN	B
were	I-P	AUX	O
enrolled	I-P	VERB	O
on	I-P	ADP	O
CCG-945	I-P	PROPN	B
.	I-P	PUNCT	O


Central	O	ADJ	B
independent	O	ADJ	O
review	O	NOUN	O
by	O	ADP	O
5	O	NUM	O
neuropathologists	O	NOUN	B
led	O	VERB	O
to	O	PART	O
a	O	DET	O
reclassification	O	NOUN	B
of	O	ADP	O
low-grade	B-P	ADJ	B
glioma	I-P	NOUN	B
in	I-P	ADP	O
70	I-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
the	I-P	DET	O
focus	I-P	NOUN	O
of	I-P	ADP	O
the	I-P	DET	O
current	I-P	ADJ	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
involved	O	VERB	O
42	B-P	NUM	O
males	I-P	NOUN	B
and	I-P	CCONJ	O
28	I-P	NUM	O
females	I-P	NOUN	B
(	I-P	PUNCT	O
median	I-P	ADJ	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
7.7	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
with	I-P	ADP	O
a	I-P	DET	O
median	I-P	ADJ	B
follow-up	I-P	NOUN	B
of	I-P	ADP	O
10.4	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


CONCLUSIONS	O	NOUN	O
The	O	DET	O
current	O	ADJ	O
report	O	NOUN	O
calls	O	VERB	O
attention	O	NOUN	O
to	O	ADP	O
the	O	DET	O
importance	O	NOUN	O
of	O	ADP	O
central	O	ADJ	B
pathologic	O	ADJ	I
review	O	NOUN	I
in	O	ADP	O
large	O	ADJ	O
multiinstitutional	O	ADJ	B
trials	O	NOUN	I
of	O	ADP	O
children	O	NOUN	B
with	O	ADP	O
gliomas	O	NOUN	B
and	O	CCONJ	O
suggests	O	VERB	O
that	O	SCONJ	O
aggressive	O	ADJ	B
front-line	O	ADJ	B
combined	O	ADJ	O
chemoradiotherapy	O	NOUN	B
does	O	AUX	O
not	O	PART	O
confer	O	VERB	O
a	O	DET	O
survival	B-OUT	NOUN	B
advantage	I-OUT	NOUN	O
in	O	ADP	O
this	O	DET	O
highly	O	ADV	O
selected	O	VERB	O
population	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
.	O	PUNCT	O


Dalteparin	B-I	NOUN	B
low	O	ADJ	O
molecular	O	ADJ	O
weight	O	NOUN	O
heparin	B-I	NOUN	O
(	O	PUNCT	O
LMWH	O	NOUN	B
)	O	PUNCT	O
in	O	ADP	O
ovarian	B-P	ADJ	B
cancer	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
phase	O	NOUN	B
II	O	NUM	I
randomized	O	ADJ	I
study	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
multicentre	O	NOUN	B
phase	O	NOUN	I
II	O	NUM	I
randomized	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
done	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
antineoplastic	O	ADJ	B
potential	O	NOUN	I
of	O	ADP	O
dalteparin	B-I	NOUN	B
in	O	ADP	O
ovarian	O	ADJ	B
cancer	O	NOUN	I
(	O	PUNCT	O
OC	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	PROPN	O
Women	B-P	NOUN	B
with	I-P	ADP	O
newly-diagnosed	I-P	ADJ	B
epithelial	I-P	ADJ	O
OC	I-P	NOUN	O
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
standard	B-I	ADJ	B
chemotherapy	I-I	NOUN	I
(	I-I	PUNCT	O
CT	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
of	O	ADP	O
3	O	NUM	O
doses	O	NOUN	B
of	O	ADP	O
dalteparin	B-I	NOUN	B
(	O	PUNCT	O
50	O	NUM	O
IU/kg	O	NOUN	O
,	O	PUNCT	O
100	O	NUM	O
IU/kg	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
150	O	NUM	O
IU/kg	O	NOUN	O
)	O	PUNCT	O
subcutaneously	O	ADV	B
once	O	ADV	O
daily	O	ADV	O
during	O	ADP	O
the	O	DET	O
first	O	ADJ	O
3	O	NUM	O
of	O	ADP	O
6	O	NUM	O
cycles	O	NOUN	B
of	O	ADP	O
3-weekly	O	ADJ	O
CT	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
was	O	AUX	O
tumor	B-OUT	NOUN	B
response	I-OUT	NOUN	I
defined	I-OUT	VERB	O
by	I-OUT	ADP	O
	I-OUT	NOUN	O
50	I-OUT	NUM	O
%	I-OUT	NOUN	O
reduction	I-OUT	NOUN	B
in	I-OUT	ADP	O
serum	I-OUT	NOUN	B
CA125	I-OUT	NOUN	B
from	I-OUT	ADP	O
baseline	I-OUT	NOUN	B
sustained	I-OUT	ADJ	B
for	I-OUT	ADP	O
at	I-OUT	ADP	O
least	I-OUT	ADV	O
28	I-OUT	NUM	O
days	I-OUT	NOUN	B
.	O	PUNCT	O


A	O	DET	O
50	O	NUM	O
%	O	NOUN	O
drop	O	NOUN	B
in	B-OUT	ADP	O
CA125	I-OUT	NOUN	B
at	O	ADP	O
the	O	DET	O
end	O	NOUN	O
of	O	ADP	O
cycle	O	NOUN	O
3	O	NUM	O
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
50	O	NUM	O
IU/kg	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
92	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
100	O	NUM	O
IU/kg	O	NOUN	O
group	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
85	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
the	O	DET	O
150	O	NUM	O
IU/kg	O	NOUN	O
group	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	B-OUT	DET	O
symptomatic	I-OUT	ADJ	B
VTE	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
major	I-OUT	ADJ	O
bleeding	I-OUT	NOUN	B
events	I-OUT	NOUN	O
while	O	SCONJ	O
on	O	ADP	O
dalteparin	O	NOUN	B
.	O	PUNCT	O


Women	O	NOUN	B
on	O	ADP	O
dalteparin	O	NOUN	B
had	O	AUX	O
lower	O	ADJ	O
levels	O	NOUN	O
of	B-OUT	ADP	O
D-dimer	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
thrombin-antithrombin	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
higher	I-OUT	ADJ	O
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
tissue	I-OUT	NOUN	B
factor	I-OUT	NOUN	I
pathway	I-OUT	NOUN	I
inhibitor	I-OUT	NOUN	B
,	O	PUNCT	O
relative	O	ADJ	O
to	O	PART	O
baseline	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	B-I	NOUN	O
Dalteparin	I-I	PROPN	B
is	I-OUT	AUX	O
safe	I-OUT	ADJ	O
and	O	CCONJ	O
well	B-OUT	ADV	O
tolerated	I-OUT	VERB	B
in	I-P	ADP	O
women	I-P	NOUN	B
receiving	I-P	VERB	O
CT	I-P	NOUN	B
for	I-P	ADP	O
newly-diagnosed	I-P	ADJ	B
epithelial	I-P	ADJ	O
OC	I-P	PROPN	O
.	O	PUNCT	O


Interferential	B-I	ADJ	B
therapy	I-I	NOUN	I
electrode	I-I	NOUN	O
placement	I-I	NOUN	O
technique	I-I	NOUN	O
in	O	ADP	O
acute	B-P	ADJ	B
low	I-P	ADJ	I
back	I-P	ADJ	I
pain	I-P	NOUN	I
:	I-P	PUNCT	O
a	O	DET	O
preliminary	O	ADJ	B
investigation	O	NOUN	B
.	O	PUNCT	O


PATIENTS	O	VERB	B
A	O	DET	O
random	O	ADJ	B
sample	O	NOUN	B
of	O	ADP	O
60	B-P	NUM	O
eligible	I-P	ADJ	O
patients	I-P	NOUN	B
with	I-P	ADP	O
back	I-P	ADJ	B
pain	I-P	NOUN	I
(	I-P	PUNCT	O
28	I-P	NUM	O
men	I-P	NOUN	B
,	I-P	PUNCT	O
32	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
were	I-P	AUX	O
recruited	I-P	VERB	O
by	I-P	ADP	O
general	I-P	ADJ	B
practitioners	I-P	NOUN	I
and	I-P	CCONJ	O
self-referral	I-P	ADJ	B
for	O	ADP	O
physiotherapy	O	NOUN	B
treatment	O	NOUN	I
and	O	CCONJ	O
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
1	O	NUM	O
of	O	ADP	O
3	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


INTERVENTIONS	O	NOUN	B
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
"	B-I	PUNCT	O
IFT	I-I	NOUN	B
painful	I-I	ADJ	I
area	I-I	NOUN	B
"	I-I	PUNCT	O
and	I-I	CCONJ	O
The	I-I	DET	O
Back	I-I	PROPN	B
Book	I-I	PROPN	I
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
"	B-I	PUNCT	O
IFT	I-I	NOUN	B
spinal	I-I	ADJ	B
nerve	I-I	NOUN	I
"	I-I	PUNCT	O
and	I-I	CCONJ	O
The	I-I	DET	O
Back	I-I	PROPN	B
Book	I-I	PROPN	I
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
"	B-I	PUNCT	O
Control	I-I	PROPN	B
,	I-I	PUNCT	O
"	I-I	PUNCT	O
The	I-I	DET	O
Back	I-I	PROPN	B
Book	I-I	PROPN	I
only	O	ADV	O
.	O	PUNCT	O


Standardized	O	ADJ	B
IFT	B-I	NOUN	B
stimulation	O	NOUN	O
parameters	O	NOUN	B
were	O	AUX	O
used	O	VERB	O
:	O	PUNCT	O
carrier	O	NOUN	B
frequency	O	NOUN	I
3.85	O	NUM	O
kHz	O	NOUN	O
;	O	PUNCT	O
140	O	NUM	O
Hz	O	NOUN	O
constant	O	NOUN	B
;	O	PUNCT	O
pulse	O	NOUN	B
duration	O	NOUN	I
130	O	NUM	O
micros	O	NOUN	O
;	O	PUNCT	O
30	O	NUM	O
minutes	O	NOUN	O
'	O	PART	O
duration	O	NOUN	B
.	O	PUNCT	O


Subjects	O	NOUN	B
managed	O	VERB	O
by	O	ADP	O
IFT	O	NOUN	B
spinal	O	ADJ	B
nerve	O	NOUN	I
and	O	CCONJ	O
The	O	DET	O
Back	O	PROPN	B
Book	O	PROPN	I
displayed	O	VERB	O
both	O	CCONJ	O
a	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
.030	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
clinically	O	ADV	B
meaningful	O	ADJ	O
reduction	B-OUT	NOUN	B
in	I-OUT	ADP	O
functional	I-OUT	ADJ	B
disability	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
RMDQ	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
compared	O	VERB	B
with	O	ADP	O
management	O	NOUN	B
via	O	ADP	O
IFT	O	NOUN	B
painful	O	ADJ	I
area	O	NOUN	B
and	O	CCONJ	O
The	O	DET	O
Back	O	PROPN	B
Book	O	PROPN	I
combined	O	VERB	O
or	O	CCONJ	O
The	O	DET	O
Back	O	PROPN	B
Book	O	PROPN	I
alone	O	ADV	O
.	O	PUNCT	O


Men	B-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
,	I-P	PUNCT	O
22-36	I-P	NUM	O
years	I-P	NOUN	O
old	I-P	ADJ	O
,	O	PUNCT	O
performed	O	VERB	O
a	O	DET	O
synchronization-continuation	B-I	ADJ	B
task	I-I	NOUN	O
with	I-I	ADP	O
intertap	I-I	NOUN	B
intervals	I-I	NOUN	I
(	I-I	PUNCT	O
ITI	I-I	NOUN	B
)	I-I	PUNCT	O
from	O	ADP	O
0.4	O	NUM	O
s	O	NOUN	O
to	O	PART	O
2.2	O	NUM	O
s.	O	NOUN	O
ISIP	O	NOUN	B
variability	O	NOUN	B
was	O	AUX	O
partitioned	O	VERB	O
into	O	ADP	O
components	O	NOUN	B
attributable	O	ADJ	O
to	O	PART	O
drift	O	VERB	B
and	O	CCONJ	O
1st-order	O	NUM	O
serial	O	ADJ	O
correlation	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
results	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
drift	O	NOUN	B
contributes	O	VERB	O
substantially	O	ADV	O
to	O	ADP	O
the	O	DET	O
dispersion	O	NOUN	B
for	O	ADP	O
longer	O	ADJ	B
ITIs	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
drift	O	NOUN	B
and	O	CCONJ	O
1st-order	O	NUM	O
correlation	O	NOUN	B
are	O	AUX	O
different	O	ADJ	O
functions	O	NOUN	B
of	O	ADP	O
the	O	DET	O
ITI	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
c	O	X	O
)	O	PUNCT	O
drift	O	NOUN	O
exhibits	O	VERB	O
break	O	NOUN	O
close	O	ADV	O
to	O	PART	O
1.0	O	NUM	O
s	O	NOUN	O
and	O	CCONJ	O
1.4	O	NUM	O
s	O	NOUN	O
ITI	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
study	O	NOUN	I
on	O	ADP	O
the	O	DET	O
influence	O	NOUN	B
of	O	ADP	O
acetaminophen	B-I	NOUN	B
,	I-I	PUNCT	O
diclofenac	I-I	NOUN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
naproxen	I-I	NOUN	B
on	I-I	ADP	O
aspirin-induced	I-I	ADJ	B
inhibition	O	NOUN	B
of	O	ADP	O
platelet	B-OUT	NOUN	B
aggregation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Nonsteroidal	B-I	ADJ	B
anti-inflammatory	I-I	ADJ	I
drugs	I-I	NOUN	I
(	I-I	PUNCT	O
NSAID	I-I	NOUN	B
)	I-I	PUNCT	O
may	O	AUX	O
interfere	O	VERB	B
with	O	ADP	I
aspirin	B-I	NOUN	B
(	I-I	PUNCT	O
acetylsalicylic	I-I	ADJ	B
acid	I-I	NOUN	I
)	I-I	PUNCT	O
and	O	CCONJ	O
increase	O	VERB	B
the	O	DET	O
risk	O	NOUN	B
for	O	ADP	O
cardiovascular	B-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Acetaminophen	B-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
compared	O	VERB	B
with	O	ADP	O
placebo	B-I	NOUN	B
.	I-I	PUNCT	O


We	O	PRON	O
conclude	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
co-administration	O	NOUN	B
of	O	ADP	O
NSAID	B-I	NOUN	B
and	O	CCONJ	O
aspirin	B-I	NOUN	B
may	O	AUX	O
interfere	O	VERB	B
with	O	ADP	I
platelet	B-OUT	NOUN	B
inhibition	I-OUT	NOUN	I
at	O	ADP	O
the	O	DET	O
beginning	O	NOUN	O
of	O	ADP	O
a	O	DET	O
treatment	O	NOUN	B
with	O	ADP	O
an	O	DET	O
increase	O	NOUN	B
of	O	ADP	O
naproxen	B-I	NOUN	B
and	O	CCONJ	O
a	O	DET	O
decrease	O	NOUN	B
of	O	ADP	O
diclofenac	B-I	NOUN	B
.	I-I	PUNCT	O


Piperacillin/tazobactam	B-I	NOUN	B
plus	I-I	CCONJ	O
tobramycin	I-I	NOUN	B
versus	I-I	CCONJ	O
ceftazidime	I-I	NOUN	B
plus	I-I	CCONJ	O
tobramycin	I-I	NOUN	B
as	O	ADP	O
empiric	O	ADJ	B
therapy	O	NOUN	I
for	O	ADP	O
fever	B-OUT	NOUN	B
in	O	ADP	O
severely	B-P	ADV	O
neutropenic	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
trial	O	NOUN	B
was	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
potential	O	ADJ	B
advantages	O	NOUN	O
of	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
of	O	ADP	O
piperacillin	B-I	NOUN	B
and	I-I	CCONJ	O
tazobactam	I-I	NOUN	B
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
of	O	ADP	O
fever	B-OUT	NOUN	B
in	I-P	ADP	O
neutropenic	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
this	O	DET	O
single-center	O	ADJ	B
study	O	NOUN	I
,	O	PUNCT	O
patients	B-P	NOUN	B
who	I-P	PRON	O
experienced	I-P	VERB	O
a	I-P	DET	O
total	I-P	NOUN	O
of	I-P	ADP	O
247	I-P	NUM	O
febrile	I-P	ADJ	B
episodes	I-P	NOUN	B
were	O	AUX	O
prospectively	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
either	O	CCONJ	O
our	O	PRON	O
standard	O	ADJ	B
regimen	O	NOUN	I
,	O	PUNCT	O
ceftazidime	B-I	NOUN	B
3	O	NUM	O
g/day	O	NOUN	O
(	O	PUNCT	O
1	O	NUM	O
g	O	NOUN	O
t.i.d	O	X	B
.	O	PUNCT	O


)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
piperacillin	B-I	NOUN	B
12	O	NUM	O
g/day	O	NOUN	O
plus	O	CCONJ	O
tazobactam	B-I	NOUN	B
1.5	O	NUM	O
g/day	O	NOUN	O
(	O	PUNCT	O
4	O	NUM	O
g+0.5	O	NOUN	O
g	O	NOUN	O
t.i.d	O	X	B
.	O	PUNCT	O


All	B-P	DET	O
247	I-P	NUM	O
episodes	I-P	NOUN	B
were	I-P	AUX	O
evaluable	I-P	ADJ	O
by	O	ADP	O
"	O	PUNCT	O
intent-to-treat	O	ADJ	B
"	O	PUNCT	O
analysis	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
trial	O	NOUN	B
confirmed	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
piperacillin/tazobactam	B-I	NOUN	B
combination	O	NOUN	B
for	O	ADP	O
empirical	O	ADJ	B
treatment	O	NOUN	I
of	O	ADP	O
febrile	B-P	ADJ	B
neutropenic	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Qualitative	O	ADJ	B
studies	O	NOUN	I
suggest	O	VERB	O
that	O	SCONJ	O
participation	O	NOUN	B
in	O	ADP	O
visual	O	ADJ	B
arts	O	NOUN	B
creative	O	ADJ	O
engagement	O	NOUN	O
interventions	O	NOUN	O
(	O	PUNCT	O
CEIs	O	NOUN	B
)	O	PUNCT	O
during	O	ADP	O
rehabilitation	O	NOUN	B
after	O	ADP	O
stroke	O	NOUN	B
may	O	AUX	O
improve	O	VERB	B
mood	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
self-esteem	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
hope	I-OUT	NOUN	O
and	O	CCONJ	O
some	O	DET	O
aspects	O	NOUN	O
of	O	ADP	O
physical	O	ADJ	B
recovery	O	NOUN	I
.	O	PUNCT	O


Artists	B-I	NOUN	B
will	I-I	AUX	O
follow	I-I	VERB	O
an	I-I	DET	O
intervention	I-I	NOUN	B
protocol	I-I	NOUN	I
with	I-I	ADP	O
specific	I-I	ADJ	O
components	I-I	NOUN	B
that	I-I	PRON	O
enable	I-I	VERB	O
participants	I-I	NOUN	B
to	I-I	PART	O
set	I-I	VERB	O
,	I-I	PUNCT	O
achieve	I-I	VERB	O
and	I-I	CCONJ	O
review	I-I	VERB	B
artistic	I-I	ADJ	B
goals	I-I	NOUN	B
.	I-I	PUNCT	O


Participants	B-I	NOUN	B
will	I-I	AUX	O
receive	I-I	VERB	O
up	I-I	ADV	O
to	I-I	PART	O
eight	I-I	NUM	O
intervention	I-I	NOUN	B
sessions	I-I	NOUN	B
,	I-I	PUNCT	O
four	I-I	NUM	O
within	I-I	ADP	O
a	I-I	DET	O
group	I-I	NOUN	B
and	I-I	CCONJ	O
four	I-I	NUM	O
one-to-one	I-I	NOUN	O
with	I-I	ADP	O
the	I-I	DET	O
artist	I-I	NOUN	B
.	I-I	PUNCT	O


Stroke-related	B-OUT	ADJ	B
health	I-OUT	NOUN	I
status	I-OUT	NOUN	I
is	O	AUX	O
the	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
;	O	PUNCT	O
mood	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
self-esteem	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
self-efficacy	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
perceived	I-OUT	VERB	B
recovery	I-OUT	NOUN	B
control	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
hope	I-OUT	NOUN	O
are	I-OUT	AUX	O
secondary	I-OUT	ADJ	B
outcomes	O	NOUN	I
.	O	PUNCT	O


Semi-structured	O	ADJ	B
interviews	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
conducted	O	VERB	O
with	O	ADP	O
purposively	O	ADV	B
selected	O	VERB	O
patients	O	NOUN	B
,	O	PUNCT	O
artists	O	NOUN	B
and	O	CCONJ	O
healthcare	O	NOUN	B
staff	O	NOUN	I
to	O	PART	O
elicit	B-OUT	VERB	O
views	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
experiences	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
and	O	CCONJ	O
feasibility	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
acceptability	I-OUT	NOUN	B
of	O	ADP	O
trial	O	NOUN	B
processes	O	NOUN	I
.	O	PUNCT	O


Data	O	NOUN	B
will	O	AUX	O
indicate	O	VERB	O
,	O	PUNCT	O
with	O	ADP	O
confidence	O	NOUN	B
intervals	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
proportion	O	NOUN	B
of	O	ADP	O
patients	O	NOUN	B
choosing	O	VERB	O
or	O	CCONJ	O
refusing	O	VERB	B
participation	O	NOUN	B
in	O	ADP	O
the	O	DET	O
CEI	O	NOUN	B
and	O	CCONJ	O
will	O	AUX	O
allow	O	VERB	O
calculation	O	NOUN	B
of	O	ADP	O
recruitment	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
for	O	ADP	O
a	O	DET	O
future	O	ADJ	O
definitive	O	ADJ	O
trial	O	NOUN	B
.	O	PUNCT	O


Ambulation	B-I	NOUN	B
in	O	ADP	O
labour	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	I
labour	I-OUT	NOUN	I
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
,	O	PUNCT	O
the	O	DET	O
need	B-OUT	NOUN	O
for	I-OUT	ADP	O
analgesia	I-OUT	NOUN	B
significantly	O	ADV	B
less	O	ADV	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
incidence	B-OUT	NOUN	B
of	I-OUT	ADP	O
fetal	I-OUT	ADJ	B
heart	I-OUT	NOUN	I
abnormalities	I-OUT	NOUN	I
significantly	O	ADV	O
smaller	O	ADJ	O
in	O	ADP	O
the	O	DET	O
ambulant	O	ADJ	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
recumbent	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Apgar	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
at	O	ADP	O
one	O	NUM	O
and	O	CCONJ	O
five	O	NUM	O
minutes	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
significantly	O	ADV	O
greater	O	ADJ	O
in	O	ADP	O
the	O	DET	O
ambulant	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


More	O	ADJ	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
recumbent	O	ADJ	B
group	O	NOUN	I
required	O	VERB	O
augmentations	B-OUT	NOUN	B
with	I-OUT	ADP	O
oxytocic	I-OUT	ADJ	B
drugs	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Ambulation	B-I	NOUN	B
in	O	ADP	O
labour	O	NOUN	B
should	O	AUX	O
be	O	AUX	O
encouraged	O	VERB	O
:	O	PUNCT	O
it	O	PRON	O
may	O	AUX	O
bring	O	VERB	O
human	O	ADJ	B
benefits	O	NOUN	B
while	O	SCONJ	O
allowing	O	VERB	O
the	O	DET	O
advantages	O	NOUN	O
of	O	ADP	O
hospital	O	NOUN	B
supervision	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
amount	O	NOUN	B
of	O	ADP	O
PGE-M	O	NOUN	B
excreted	O	VERB	B
decreased	O	VERB	B
significantly	O	ADV	O
after	O	ADP	O
administration	O	NOUN	B
of	O	ADP	O
indomethacin	B-I	NOUN	B
or	O	CCONJ	O
acetyl	B-I	ADJ	B
salicylic	I-I	ADJ	I
acid	I-I	NOUN	I
in	O	ADP	O
therapeutic	O	ADJ	B
doses	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
concomitant	O	ADJ	B
reduction	O	NOUN	B
of	O	ADP	O
the	O	DET	O
urinary	O	ADJ	B
excretion	O	NOUN	B
of	O	ADP	O
PGE-M	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
to	O	PART	O
85	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
prostaglandin	O	NOUN	B
E	O	NOUN	I
(	O	PUNCT	O
73	O	NUM	O
to	O	PART	O
100	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
)	O	PUNCT	O
after	O	ADP	O
indomethacin	B-I	NOUN	B
treatment	O	NOUN	B
in	O	ADP	O
each	O	DET	O
case	O	NOUN	B
(	O	PUNCT	O
n=8	O	NOUN	O
)	O	PUNCT	O
is	O	AUX	O
evidence	O	NOUN	B
that	O	SCONJ	O
a	O	DET	O
diminished	O	VERB	B
urinary	O	ADJ	B
PGE-M	O	NOUN	B
output	O	NOUN	B
reflects	O	VERB	O
a	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
prostaglandin	O	NOUN	B
E	O	NOUN	I
biosynthesis	O	NOUN	I
.	O	PUNCT	O


Phase	O	NOUN	B
III	O	NUM	I
trial	O	NOUN	I
of	O	ADP	O
satraplatin	B-I	NOUN	B
,	O	PUNCT	O
an	O	DET	O
oral	O	ADJ	B
platinum	B-I	NOUN	B
plus	I-I	CCONJ	I
prednisone	I-I	NOUN	B
vs.	I-I	CCONJ	O
prednisone	I-I	NOUN	B
alone	I-I	ADV	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
hormone-refractory	I-P	ADJ	B
prostate	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
randomized	O	ADJ	B
multicenter	O	NOUN	I
phase	O	NOUN	I
III	O	NUM	I
trial	O	NOUN	I
with	O	ADP	O
a	O	DET	O
target	O	NOUN	B
sample	O	NOUN	B
size	O	NOUN	I
of	O	ADP	O
380	B-P	NUM	O
patients	I-P	NOUN	B
was	I-P	AUX	O
initiated	I-P	VERB	O
in	I-P	ADP	O
men	I-P	NOUN	B
with	I-P	ADP	O
HRPC	I-P	NOUN	B
.	I-P	PUNCT	O


Median	B-OUT	ADJ	B
overall	I-OUT	ADJ	O
survival	I-OUT	NOUN	B
was	O	AUX	O
14.9	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
13.7-28.4	O	X	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
satraplatin	B-I	NOUN	B
plus	O	CCONJ	O
prednisone	B-I	NOUN	B
arm	O	NOUN	B
and	O	CCONJ	O
11.9	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
8.4-23.1	O	NUM	O
)	O	PUNCT	O
on	O	ADP	O
prednisone	B-I	NOUN	B
alone	O	ADV	O
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
,	O	PUNCT	O
HR	O	NOUN	B
=	O	ADJ	O
0.84	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
:	O	PUNCT	O
0.46-1.55	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
>	O	NOUN	O
50	O	NUM	O
%	O	NOUN	O
decrease	O	NOUN	B
in	O	ADP	O
prostrate	B-OUT	NOUN	B
specific	I-OUT	ADJ	I
antigen	I-OUT	NOUN	I
(	O	PUNCT	O
PSA	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
seen	O	VERB	O
in	O	ADP	O
9/27	O	NUM	O
(	O	PUNCT	O
33.3	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
satraplatin	B-I	NOUN	B
plus	I-I	CCONJ	O
prednisone	I-I	NOUN	B
arm	O	NOUN	O
vs.	O	CCONJ	O
2/23	O	NUM	O
(	O	PUNCT	O
8.7	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
prednisone	B-I	NOUN	B
alone	O	ADV	O
arm	O	NOUN	B
.	O	PUNCT	O


It	O	PRON	O
is	O	AUX	O
unknown	O	ADJ	O
whether	O	SCONJ	O
ST	B-I	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
or	O	CCONJ	O
without	O	ADP	O
concurrent	O	ADJ	B
endurance	O	NOUN	B
training	O	NOUN	O
,	O	PUNCT	O
would	O	AUX	O
have	O	AUX	O
a	O	DET	O
similar	O	ADJ	O
effect	O	NOUN	B
in	O	ADP	O
older	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
reduced	I-P	VERB	B
baseline	I-P	NOUN	B
arterial	I-OUT	ADJ	B
compliance	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Randomized	O	ADJ	B
,	O	PUNCT	O
controlled	O	VERB	B
intervention	O	NOUN	I
study	O	NOUN	I
in	O	ADP	O
which	O	DET	O
37	B-P	NUM	O
healthy	I-P	ADJ	B
,	I-P	PUNCT	O
sedentary	I-P	ADJ	B
men	I-P	NOUN	B
and	I-P	CCONJ	O
women	I-P	NOUN	B
(	I-P	PUNCT	O
52+/-2	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
performed	I-P	VERB	O
13	I-P	NUM	O
weeks	I-P	NOUN	B
of	I-P	ADP	O
ST	I-P	NOUN	B
(	I-P	PUNCT	O
n=13	I-P	NOUN	O
)	I-P	PUNCT	O
,	I-P	PUNCT	O
ST+aerobic	I-I	ADJ	B
exercise	I-I	NOUN	B
(	I-P	PUNCT	O
n=12	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
stretching	I-I	VERB	B
exercises	I-I	NOUN	I
as	I-I	ADP	O
a	I-I	DET	O
control	I-I	ADJ	B
group	I-I	NOUN	I
(	O	PUNCT	O
n=12	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
ST	O	ADJ	B
performed	O	VERB	O
alone	O	ADV	O
,	O	PUNCT	O
or	O	CCONJ	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
aerobic	B-I	ADJ	B
exercise	I-I	NOUN	I
,	O	PUNCT	O
improved	O	VERB	O
maximal	B-OUT	ADJ	B
muscle	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
increased	I-OUT	VERB	B
total	I-OUT	ADJ	B
lean	I-OUT	ADJ	I
body	I-OUT	NOUN	I
mass	I-OUT	NOUN	I
(	O	PUNCT	O
both	O	DET	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
changes	O	NOUN	B
were	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
carotid	B-OUT	NOUN	B
artery	I-OUT	NOUN	I
compliance	I-OUT	NOUN	B
or	I-OUT	CCONJ	O
carotid-femoral	I-OUT	ADJ	B
pulse	I-OUT	NOUN	I
wave	I-OUT	NOUN	I
velocity	I-OUT	NOUN	I
following	I-OUT	VERB	O
ST	I-OUT	ADJ	B
or	I-OUT	CCONJ	O
ST+aerobic	I-OUT	ADJ	B
exercise	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Observations	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
tests	I-OUT	NOUN	B
were	O	AUX	O
done	O	VERB	O
before	O	ADV	O
and	O	CCONJ	O
after	O	ADP	O
a	O	DET	O
period	O	NOUN	B
of	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
.	O	PUNCT	O


This	O	DET	O
is	O	AUX	O
the	O	DET	O
first	O	ADJ	O
phase	O	NOUN	B
III	O	NUM	I
randomised	O	ADJ	I
trial	O	NOUN	I
to	O	PART	O
evaluate	O	VERB	B
maintenance	O	NOUN	B
immunotherapy	O	NOUN	B
in	O	ADP	O
metastatic	B-P	ADJ	B
renal	I-P	ADJ	I
cell	I-P	NOUN	I
cancer	I-P	NOUN	I
(	O	PUNCT	O
mRCC	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Patients	B-P	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
to	O	PART	O
receive	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
a	O	DET	O
4-week	O	NOUN	O
cycle	O	NOUN	O
of	O	ADP	O
subcutaneous	B-I	ADJ	B
low	I-I	ADJ	O
doses	I-I	NOUN	O
IL-2	I-I	NOUN	B
+	I-I	CCONJ	O
IFN	I-I	NOUN	B
in	O	ADP	O
months	O	NOUN	B
1	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
and	O	CCONJ	O
5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
then	O	ADV	O
every	O	DET	O
3	O	NUM	O
months	O	NOUN	B
until	O	ADP	O
the	O	DET	O
first	O	ADJ	O
documented	O	VERB	B
disease	O	NOUN	B
progression	O	NOUN	I
(	O	PUNCT	O
arm	O	NOUN	B
A	O	NOUN	I
,	O	PUNCT	O
suspension	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
the	O	DET	O
same	O	ADJ	O
regimen	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
chronic	O	ADJ	B
maintenance	O	NOUN	B
of	O	ADP	O
immunotherapy	O	NOUN	B
,	O	PUNCT	O
regardless	O	ADV	O
of	O	ADP	O
tumour	O	NOUN	B
response	O	NOUN	I
,	O	PUNCT	O
until	O	ADP	O
death	O	NOUN	B
or	O	CCONJ	O
intolerable	O	ADJ	O
toxicity	O	NOUN	B
(	O	PUNCT	O
arm	O	NOUN	B
B	O	NOUN	I
,	O	PUNCT	O
maintenance	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
endpoint	O	NOUN	I
was	O	AUX	O
overall	B-OUT	ADJ	B
survival	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
OS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
;	I-OUT	PUNCT	O
secondary	O	ADJ	B
endpoints	O	NOUN	I
were	O	AUX	O
time	B-OUT	NOUN	O
from	I-OUT	ADP	O
first	I-OUT	ADJ	O
progression	I-OUT	NOUN	B
to	I-OUT	PART	O
death	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
TFPTD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
tolerability	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	O	ADP	O
a	O	DET	O
median	O	ADJ	B
follow-up	O	NOUN	B
of	O	ADP	O
53.9	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
response	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
median	I-OUT	ADJ	B
OS	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
median	I-OUT	ADJ	B
TFPTD	I-OUT	NOUN	B
were	O	AUX	O
14.7	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
6.3	O	NUM	O
%	O	NOUN	O
CR	O	NOUN	B
)	O	PUNCT	O
versus	O	CCONJ	O
11.3	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
5.5	O	NUM	O
%	O	NOUN	O
CR	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
14	O	NUM	O
versus	O	CCONJ	O
14	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
6	O	NUM	O
versus	O	CCONJ	O
5	O	NUM	O
months	O	NOUN	B
,	O	PUNCT	O
in	O	ADP	O
arms	O	NOUN	O
A	O	NOUN	O
and	O	CCONJ	O
B	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Cox	O	NOUN	B
regression	O	NOUN	I
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
chemotherapy	B-I	NOUN	B
after	O	ADP	O
first	O	ADJ	O
progression	O	NOUN	B
(	O	PUNCT	O
HR	O	NOUN	B
0.54	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.35-0.86	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.008	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
PS	O	NOUN	B
=	O	ADJ	O
0	O	NUM	O
(	O	PUNCT	O
HR	O	NOUN	B
0.53	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.35-0.81	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
female	O	ADJ	B
gender	O	NOUN	I
(	O	PUNCT	O
HR	O	NOUN	B
0.63	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.41-0.98	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.038	O	NUM	O
)	O	PUNCT	O
were	O	AUX	O
significantly	O	ADV	O
associated	O	VERB	B
with	O	ADP	I
a	O	DET	O
longer	O	ADV	O
TFPTD	B-OUT	NOUN	B
;	I-OUT	PUNCT	O
treatment	O	NOUN	B
arm	O	NOUN	I
was	O	AUX	O
not	O	PART	O
significant	O	ADJ	O
(	O	PUNCT	O
HR	O	NOUN	B
0.88	O	NUM	O
;	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.60-1.31	O	NUM	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.54	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Multi-institutional	O	ADJ	B
phase	O	NOUN	I
2	O	NUM	I
clinical	O	ADJ	B
and	O	CCONJ	O
pharmacogenomic	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
tipifarnib	B-I	NOUN	B
plus	I-I	CCONJ	O
etoposide	I-I	NOUN	B
for	O	ADP	O
elderly	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
newly	I-P	ADV	B
diagnosed	I-P	VERB	I
acute	I-P	ADJ	B
myelogenous	I-P	ADJ	I
leukemia	I-P	NOUN	I
.	I-P	PUNCT	O


Tipifarnib	O	NOUN	B
(	O	PUNCT	O
T	O	NOUN	B
)	O	PUNCT	O
exhibits	O	VERB	O
modest	O	ADJ	O
activity	O	NOUN	B
in	O	ADP	O
elderly	B-P	ADJ	B
adults	I-P	NOUN	I
with	I-P	ADP	O
newly	I-P	ADV	B
diagnosed	I-P	VERB	I
acute	I-P	ADJ	B
myelogenous	I-P	ADJ	I
leukemia	I-P	NOUN	I
(	I-P	PUNCT	O
AML	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Arm	O	NOUN	O
A	O	NOUN	O
(	O	PUNCT	O
T	O	NOUN	O
600	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
a	O	DET	O
day	O	NOUN	B
	O	NOUN	O
14	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
E	O	NOUN	B
100	O	NUM	O
mg	O	NOUN	O
days	O	NOUN	B
1-3	O	NUM	O
and	O	CCONJ	O
8-10	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
arm	O	NOUN	B
B	O	NOUN	I
(	O	PUNCT	I
T	O	NOUN	I
400	O	NUM	I
mg	O	NOUN	I
twice	O	ADV	O
a	O	DET	O
day	O	NOUN	B
	O	NOUN	O
14	O	NUM	O
days	O	NOUN	B
,	O	PUNCT	O
E	O	NOUN	B
200	O	NUM	O
mg	O	NOUN	O
days	O	NOUN	B
1-3	O	NUM	O
and	O	CCONJ	O
8-10	O	NUM	O
)	O	PUNCT	O
yielded	O	VERB	O
similar	O	ADJ	O
CR	O	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
arm	O	NOUN	B
B	O	NOUN	I
had	O	AUX	O
greater	O	ADJ	O
toxicity	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


A	O	DET	O
2-gene	O	ADJ	B
signature	O	NOUN	B
of	O	ADP	O
high	O	ADJ	O
RASGRP1	O	NOUN	B
and	O	CCONJ	O
low	O	ADJ	B
aprataxin	O	NOUN	B
(	O	PUNCT	O
APTX	O	NOUN	B
)	O	PUNCT	O
expression	O	NOUN	B
previously	O	ADV	O
predicted	O	VERB	B
for	O	ADP	O
T	O	NOUN	B
response	B-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
gastrointestinal	B-OUT	ADJ	B
cancer	I-OUT	NOUN	I
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
20	O	NUM	O
phase	O	NOUN	B
I	O	NUM	I
,	O	PUNCT	O
II	O	NUM	B
,	O	PUNCT	O
and	O	CCONJ	O
III	O	NUM	B
clinical	O	ADJ	I
trials	O	NOUN	I
from	B-P	ADP	O
1979	I-P	NUM	O
to	I-P	PART	O
1983	I-P	NUM	O
at	I-P	ADP	O
30	I-P	NUM	O
member	I-P	NOUN	O
institutions	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
Southeastern	I-P	PROPN	B
Cancer	I-P	PROPN	I
Study	I-P	PROPN	I
Group	I-P	PROPN	I
(	I-P	PUNCT	O
SECSG	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


These	O	DET	O
studies	O	NOUN	B
used	O	VERB	O
both	O	CCONJ	O
new	B-I	ADJ	O
and	I-I	CCONJ	O
commercially	I-I	ADV	O
available	I-I	ADJ	O
drugs	I-I	NOUN	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
surgery	B-I	NOUN	B
and/or	I-I	CCONJ	O
radiation	I-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
1,087	B-P	NUM	O
patients	I-P	NOUN	B
.	I-P	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
benefit	O	NOUN	B
was	O	AUX	O
seen	O	VERB	O
from	O	ADP	O
18	B-I	NUM	O
agents	I-I	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
one	O	NUM	O
agent	O	NOUN	B
is	O	AUX	O
still	O	ADV	O
under	O	ADP	O
evaluation	O	NOUN	B
.	O	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
RESULTS	O	VERB	O
A	O	DET	O
total	O	NOUN	O
of	O	ADP	O
979	B-P	NUM	O
ST-segment-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
patients	I-P	NOUN	B
enrolled	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
Harmonizing	I-P	PROPN	B
Outcomes	I-P	PROPN	I
with	I-P	ADP	O
Revascularization	I-P	PROPN	B
and	I-P	CCONJ	O
Stents	I-P	NOUN	B
in	I-P	ADP	O
Acute	I-P	ADJ	B
Myocardial	I-P	PROPN	I
Infarction	I-P	PROPN	I
(	I-P	PUNCT	O
HORIZONS-AMI	I-P	NOUN	B
)	I-P	PUNCT	O
trial	I-P	NOUN	O
had	O	AUX	O
BNP	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
measured	O	VERB	B
in	O	ADP	O
the	O	DET	O
emergency	O	NOUN	B
room	O	NOUN	I
prior	O	ADV	O
to	O	ADP	O
primary	O	ADJ	O
percutaneous	B-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
as	O	ADP	O
part	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
protocol	O	NOUN	I
.	O	PUNCT	O


CI-AKI	B-OUT	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
a	O	DET	O
relative	O	ADJ	O
increase	O	NOUN	B
in	O	ADP	O
serum	O	NOUN	B
creatinine	O	NOUN	I
of	O	ADP	O
25	O	NOUN	O
%	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
an	O	DET	O
absolute	O	ADJ	B
increase	O	NOUN	B
of	O	ADP	O
0.5	O	NUM	O
mg/dL	O	NOUN	O
,	O	PUNCT	O
occurring	O	VERB	O
within	O	ADP	O
48	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
contrast	O	NOUN	B
administration	B-OUT	NOUN	I
.	I-OUT	PUNCT	O


Logistic	B-OUT	ADJ	B
regression	I-OUT	NOUN	I
analysis	I-OUT	NOUN	I
was	O	AUX	O
used	O	VERB	O
to	O	PART	O
estimate	O	VERB	B
the	O	DET	O
association	O	NOUN	B
of	O	ADP	O
admission	O	NOUN	B
BNP	O	NOUN	B
with	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
CI-AKI	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	O	ADP	O
multivariable	O	ADJ	B
adjustment	O	NOUN	I
for	O	ADP	O
clinical	O	ADJ	B
,	O	PUNCT	O
laboratory	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
angiographic	O	ADJ	B
variables	B-OUT	NOUN	B
,	O	PUNCT	O
BNP	O	PROPN	B
remained	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
independent	O	ADJ	B
predictor	O	NOUN	B
of	O	ADP	O
CI-AKI	O	NOUN	B
(	O	PUNCT	O
1.29	O	NUM	O
[	O	PUNCT	O
1.10	O	NUM	O
,	O	PUNCT	O
1.51	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Measurement	B-OUT	NOUN	B
of	I-OUT	ADP	O
serum	I-OUT	NOUN	B
BNP	O	NOUN	B
at	O	ADP	O
hospital	O	NOUN	B
admission	O	NOUN	I
may	O	AUX	O
help	O	VERB	O
identify	B-P	VERB	O
patients	I-P	NOUN	B
who	I-P	PRON	O
are	I-P	AUX	O
at	I-P	ADP	O
risk	I-P	NOUN	B
for	I-P	ADP	O
developing	I-P	VERB	O
CI-AKI	I-P	NOUN	B
after	I-I	ADP	O
primary	I-I	ADJ	B
percutaneous	I-I	ADJ	B
coronary	I-I	ADJ	I
intervention	I-I	NOUN	I
in	I-P	ADP	O
ST-segment-elevation	I-P	ADJ	B
myocardial	I-P	ADJ	I
infarction	I-P	NOUN	I
.	O	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
vascularized	B-I	ADJ	B
bone	I-I	NOUN	O
grafts	I-I	NOUN	O
to	O	PART	O
reconstruct	O	VERB	O
extremity	O	NOUN	B
and	O	CCONJ	O
mandibular	O	ADJ	B
defects	O	NOUN	B
is	O	AUX	O
now	O	ADV	O
commonplace	O	ADJ	O
in	O	ADP	O
reconstructive	O	ADJ	B
surgery	O	NOUN	I
.	O	PUNCT	O


Five	B-P	NUM	O
pairs	I-P	NOUN	B
of	I-P	ADP	O
human	I-P	ADJ	B
radii	I-P	NOUN	B
were	I-P	AUX	O
used	I-P	VERB	O
for	I-P	ADP	O
the	I-P	DET	O
control	I-P	NOUN	B
in	I-P	ADP	O
the	I-P	DET	O
pilot	I-P	NOUN	B
study	I-P	NOUN	I
.	I-P	PUNCT	O


PURPOSE	O	PROPN	B
Cancer	B-OUT	NOUN	I
related	I-OUT	ADJ	I
fatigue	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CRF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
is	O	AUX	O
a	O	DET	O
common	O	ADJ	O
problem	O	NOUN	B
for	O	ADP	O
cancer	B-P	NOUN	B
patients	I-P	NOUN	B
across	I-P	ADP	O
diagnoses	I-P	NOUN	B
during	I-P	ADP	O
chemotherapy	I-I	NOUN	B
and	O	CCONJ	O
is	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
physical	O	ADJ	B
inactivity	O	NOUN	I
,	O	PUNCT	O
lower	O	ADJ	O
functional	O	ADJ	B
level	O	NOUN	O
and	O	CCONJ	O
lack	O	NOUN	B
of	O	ADP	O
energy	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
is	O	AUX	O
to	O	PART	O
evaluate	O	VERB	B
whether	O	SCONJ	O
a	O	DET	O
six-week	O	NOUN	B
supervised	B-I	ADJ	B
multimodal	I-I	ADJ	B
exercise	I-I	NOUN	I
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
adjunct	I-I	NOUN	B
to	I-I	PART	O
chemotherapy	I-I	NOUN	B
and	I-I	CCONJ	O
standard	I-I	ADJ	B
care	I-I	NOUN	I
,	O	PUNCT	O
can	O	AUX	O
reduce	O	VERB	O
the	O	DET	O
patient	O	NOUN	B
's	O	PART	I
CRF	B-OUT	NOUN	B
level	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


213	B-P	NUM	O
cancer	I-P	NOUN	B
patients	I-P	NOUN	B
with	I-P	ADP	O
different	I-P	ADJ	O
diagnoses	I-P	NOUN	B
were	O	AUX	O
randomised	O	VERB	B
into	B-P	ADP	O
an	O	DET	O
intervention	B-I	NOUN	B
group	I-I	NOUN	I
or	O	CCONJ	O
wait-list	B-I	ADJ	O
control	I-I	NOUN	B
group	I-I	NOUN	I
.	I-I	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
,	O	PUNCT	O
Fatigue	B-OUT	NOUN	B
score	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CRF	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	O	PUNCT	O
was	O	AUX	O
evaluated	O	VERB	B
by	O	ADP	O
the	O	DET	O
Functional	B-OUT	ADJ	B
Assessment	I-OUT	PROPN	I
of	I-OUT	ADP	I
Cancer	I-OUT	PROPN	I
Therapy-Anaemia	I-OUT	PROPN	I
Questionnaire	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
FACT-An-	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
FACT-G	I-OUT	NOUN	B
score	I-OUT	NOUN	I
&	I-OUT	CCONJ	O
FACT-An	I-OUT	PROPN	O
Anemia	I-OUT	NOUN	B
subscale	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
CRF	B-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
reduced	O	VERB	B
in	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
corresponding	O	VERB	O
to	O	ADP	O
a	O	DET	O
Fatigue	B-OUT	NOUN	B
score	I-OUT	NOUN	I
reduction	I-OUT	NOUN	B
of	O	ADP	O
3.04	O	NUM	O
(	O	PUNCT	O
effect	O	NOUN	B
size	O	NOUN	I
of	O	ADP	O
0.44	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
CI	O	NOUN	B
0.17-0.72	O	NUM	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
FACT-An	B-OUT	ADJ	B
score	I-OUT	NOUN	B
by	O	ADP	O
5.40	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.015	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
the	O	DET	O
FACT-An	B-OUT	ADJ	B
Toi	I-OUT	NOUN	I
score	O	NOUN	I
by	O	ADP	O
5.22	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.009	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
Anaemia-ANS	B-OUT	NOUN	B
by	O	ADP	O
3.76	O	NUM	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.002	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
In	O	ADP	O
summary	O	NOUN	O
,	O	PUNCT	O
this	O	DET	O
six-week	O	NOUN	B
supervised	B-I	ADJ	B
multimodal	I-I	ADJ	B
exercise	I-I	NOUN	I
intervention	I-I	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	PART	O
significant	O	ADJ	O
reduction	O	NOUN	B
in	O	ADP	O
self-reported	B-OUT	ADJ	B
CRF	I-OUT	NOUN	B
in	I-P	ADP	O
cancer	I-P	NOUN	B
patients	I-P	NOUN	B
undergoing	I-P	VERB	O
chemotherapy	I-P	NOUN	B
.	I-P	PUNCT	O


Histologic	B-OUT	ADJ	B
conversion	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
non-Hodgkin	B-P	ADJ	B
's	I-P	PART	I
lymphomas	I-P	NOUN	I
.	I-P	PUNCT	O


Among	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
achieved	B-OUT	VERB	O
a	I-OUT	DET	O
CR	I-OUT	NOUN	B
,	O	PUNCT	O
31	O	NUM	O
%	O	NOUN	O
later	O	ADV	O
relapsed	B-OUT	ADJ	B
.	I-OUT	PUNCT	O


The	O	DET	O
most	B-OUT	ADV	O
common	I-OUT	ADJ	O
type	O	NOUN	O
of	O	ADP	O
histologic	B-OUT	ADJ	B
conversion	I-OUT	NOUN	B
was	O	AUX	O
from	O	ADP	O
NLPD	O	NOUN	B
to	O	PART	O
diffuse	O	VERB	O
histiocytic	B-OUT	ADJ	B
lymphoma	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


However	O	ADV	O
,	O	PUNCT	O
those	O	DET	O
patients	O	NOUN	B
who	O	PRON	O
achieved	B-OUT	VERB	O
a	I-OUT	DET	O
CR	I-OUT	NOUN	B
after	O	ADP	O
conversion	B-OUT	NOUN	B
had	O	AUX	O
a	O	DET	O
more	O	ADV	O
favorable	B-OUT	ADJ	B
outcome	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
actuarial	I-OUT	ADJ	B
survival	I-OUT	NOUN	I
75	O	NUM	O
%	O	NOUN	O
at	O	ADP	O
5	O	NUM	O
yr	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
compare	B-OUT	VERB	B
elastic	I-I	ADJ	B
stable	I-I	ADJ	O
intramedullary	I-I	ADJ	B
nailing	I-I	NOUN	I
(	I-I	PUNCT	O
ESIN	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
nonoperative	B-I	ADJ	B
treatment	I-I	NOUN	I
of	O	ADP	O
fully	B-P	ADV	O
displaced	I-P	VERB	O
midshaft	I-P	NOUN	B
clavicular	I-P	NOUN	O
fractures	I-P	NOUN	O
in	I-P	ADP	O
adults	I-P	NOUN	B
.	I-P	PUNCT	O


PATIENTS	O	NOUN	B
AND	O	CCONJ	O
METHODS	O	NOUN	O
Sixty	B-P	NUM	O
patients	I-P	NOUN	B
between	I-P	ADP	O
18	I-P	NUM	O
and	I-P	CCONJ	O
65	I-P	NUM	O
years	I-P	NOUN	B
of	I-P	ADP	O
age	I-P	NOUN	B
participated	I-P	VERB	O
and	I-P	CCONJ	O
completed	I-P	VERB	B
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


INTERVENTION	O	PROPN	B
Thirty	O	NUM	O
patients	O	NOUN	B
were	O	AUX	O
treated	O	VERB	B
with	O	ADP	I
a	O	DET	O
simple	B-I	ADJ	O
shoulder	I-I	NOUN	B
sling	I-I	NOUN	I
and	O	CCONJ	O
30	O	NUM	O
patients	O	NOUN	B
with	O	ADP	O
ESIN	B-I	NOUN	B
within	O	ADP	O
3	O	NUM	O
days	O	NOUN	B
after	O	ADP	O
trauma	O	NOUN	B
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	VERB	O
MEASUREMENT	O	NUM	O
Complications	B-OUT	PROPN	B
after	O	ADP	O
operative	O	ADJ	B
and	O	CCONJ	O
nonoperative	O	ADJ	B
treatments	O	NOUN	I
,	O	PUNCT	O
Disabilities	B-OUT	PROPN	B
of	I-OUT	ADP	I
the	I-OUT	DET	I
Arm	I-OUT	NOUN	I
,	I-OUT	PUNCT	I
Shoulder	I-OUT	PROPN	I
and	I-OUT	CCONJ	I
Hand	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
DASH	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	O
and	O	CCONJ	O
Constant	B-OUT	ADJ	B
Shoulder	I-OUT	NOUN	I
Score	I-OUT	PROPN	I
for	O	ADP	O
outcome	B-OUT	NOUN	B
measurement	I-OUT	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
clavicular	B-OUT	NOUN	B
shortening	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	O
Fracture	B-OUT	PROPN	B
union	I-OUT	NOUN	I
was	O	AUX	O
achieved	O	VERB	O
in	O	ADP	O
all	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
operative	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
whereas	O	SCONJ	O
nonunion	B-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
3	O	NUM	O
of	O	ADP	O
30	O	NUM	O
patients	O	NOUN	B
of	O	ADP	O
the	O	DET	O
nonoperative	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Two	O	NUM	O
symptomatic	B-OUT	ADJ	B
malunions	I-OUT	NOUN	B
required	O	VERB	O
corrective	O	ADJ	B
osteotomy	O	NOUN	B
in	O	ADP	O
the	O	DET	O
nonoperative	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


Constant	B-OUT	ADJ	B
scores	I-OUT	NOUN	I
were	O	AUX	O
significantly	O	ADV	B
higher	O	ADJ	I
after	O	ADP	O
6	O	NUM	O
months	O	NOUN	B
and	O	CCONJ	O
2	O	NUM	O
years	O	NOUN	B
after	O	ADP	O
intramedullary	O	ADJ	B
stabilization	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
operative	O	ADJ	B
group	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
significant	O	ADJ	O
improvement	O	NOUN	B
of	O	ADP	O
posttraumatic	B-OUT	ADJ	B
clavicular	I-OUT	NOUN	I
shortening	I-OUT	NOUN	B
;	I-OUT	PUNCT	O
they	O	PRON	O
were	O	AUX	O
also	O	ADV	O
more	O	ADV	O
satisfied	B-OUT	ADJ	O
with	O	ADP	O
cosmetic	O	ADJ	B
appearance	O	NOUN	B
and	O	CCONJ	O
overall	B-OUT	ADJ	O
outcome	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Clavicular	B-OUT	NOUN	B
shortening	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
,	O	PUNCT	O
and	O	CCONJ	O
overall	B-OUT	ADJ	B
satisfaction	I-OUT	NOUN	I
was	O	AUX	O
higher	O	ADJ	B
in	O	ADP	O
the	O	DET	O
operative	O	ADJ	B
group	O	NOUN	I
.	O	PUNCT	O


A	O	DET	O
single	B-I	ADJ	B
nasal	I-I	ADJ	I
allergen	I-I	NOUN	I
challenge	I-I	NOUN	O
increases	O	VERB	B
induced	O	VERB	B
sputum	B-OUT	NOUN	B
inflammatory	I-OUT	ADJ	O
markers	I-OUT	NOUN	B
in	O	ADP	O
non-asthmatic	B-P	ADJ	B
subjects	I-P	NOUN	I
with	I-P	ADP	O
seasonal	I-P	ADJ	B
allergic	I-P	ADJ	I
rhinitis	I-P	NOUN	I
:	I-P	PUNCT	O
correlation	O	NOUN	B
with	O	ADP	O
plasma	O	NOUN	B
interleukin-5	O	NOUN	I
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
impact	O	NOUN	B
of	O	ADP	O
nasal	O	ADJ	B
allergy	O	NOUN	I
on	O	ADP	O
sputum	B-OUT	NOUN	B
inflammatory	I-OUT	ADJ	I
markers	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


After	B-I	ADP	O
a	I-I	DET	O
washout	I-I	ADJ	O
period	I-I	NOUN	B
of	I-I	ADP	O
at	I-I	ADP	O
least	I-I	ADV	O
4	I-I	NUM	O
weeks	I-I	NOUN	B
,	I-I	PUNCT	O
the	I-I	DET	O
procedure	I-I	NOUN	B
was	I-I	AUX	O
repeated	I-I	VERB	O
with	I-I	ADP	O
placebo	I-I	NOUN	B
challenge	I-I	NOUN	O
(	I-I	PUNCT	O
diluent	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


The	O	DET	O
absolute	O	ADJ	B
number	O	NOUN	O
of	O	ADP	O
blood	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
sputum	I-OUT	NOUN	B
eosinophils	I-OUT	NOUN	I
did	O	AUX	O
not	O	PART	O
change	O	VERB	O
significantly	O	ADV	O
after	O	ADP	O
allergen	O	NOUN	B
or	O	CCONJ	O
placebo	O	NOUN	B
challenge	O	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
>	O	X	O
0.07	O	NUM	O
,	O	PUNCT	O
both	O	DET	O
comparisons	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Plasma	B-OUT	NOUN	B
levels	I-OUT	NOUN	B
of	I-OUT	ADP	O
IL-5	I-OUT	NOUN	B
increased	O	VERB	B
after	O	ADP	O
allergen	O	NOUN	B
challenge	O	NOUN	B
(	O	PUNCT	O
8.7	O	NUM	O
+/-	O	CCONJ	O
2.9	O	NUM	O
to	O	PART	O
14.5	O	NUM	O
+/-	O	CCONJ	O
3.9	O	NUM	O
pg/mL	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
plasma	O	NOUN	B
IL-5	O	NOUN	B
was	O	AUX	O
positively	O	ADV	O
correlated	O	VERB	B
with	O	ADP	O
the	O	DET	O
rise	O	NOUN	O
in	O	ADP	O
sputum	B-OUT	NOUN	B
ECP	I-OUT	NOUN	B
in	O	ADP	O
a	O	DET	O
subgroup	O	NOUN	B
of	O	ADP	O
'responders	O	NOUN	B
'	O	PART	I
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
,	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.71	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.01	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
may	O	AUX	O
provide	O	VERB	O
additional	O	ADJ	O
explanatory	O	ADJ	B
data	O	NOUN	B
for	O	ADP	O
the	O	DET	O
high	O	ADJ	O
susceptibility	O	NOUN	B
of	O	ADP	O
SAR	B-P	NOUN	B
patients	I-P	NOUN	B
to	O	PART	O
incident	O	ADJ	B
asthma	O	NOUN	B
.	O	PUNCT	O


Once-daily	O	ADJ	B
MMX	B-I	NOUN	O
(	I-I	PUNCT	O
	I-I	NOUN	O
)	I-I	PUNCT	O
mesalamine	I-I	NOUN	B
for	O	ADP	O
endoscopic	O	ADJ	B
maintenance	O	NOUN	B
of	O	ADP	O
remission	O	NOUN	B
of	B-P	ADP	O
ulcerative	I-P	ADJ	B
colitis	I-P	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	O
Overall	B-P	ADV	O
,	I-P	PUNCT	O
826	I-P	NUM	O
patients	I-P	NOUN	B
were	I-P	AUX	O
randomized	I-P	VERB	B
and	I-P	CCONJ	O
dosed	I-P	VERB	B
.	O	PUNCT	O


At	O	ADP	O
month	O	NOUN	B
6	O	NUM	O
,	O	PUNCT	O
83.7	O	NUM	O
and	O	CCONJ	O
77.8	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
MMX	O	NOUN	B
mesalamine	O	NOUN	B
in	O	ADP	O
the	O	DET	O
PP	O	NOUN	B
and	O	CCONJ	O
intent-to-treat	O	ADJ	B
(	O	PUNCT	O
ITT	O	NOUN	B
)	O	PUNCT	O
populations	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
had	O	AUX	O
maintained	B-OUT	VERB	B
endoscopic	I-OUT	ADJ	B
remission	I-OUT	NOUN	I
compared	O	VERB	B
with	O	ADP	O
81.5	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
PP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
76.9	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
ITT	O	NOUN	B
)	O	PUNCT	O
of	O	ADP	O
patients	O	NOUN	B
receiving	O	VERB	O
delayed-release	O	ADJ	B
mesalamine	O	NOUN	I
(	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
for	O	ADP	O
difference	O	NOUN	O
:	O	PUNCT	O
-3.9	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
8.1	O	NUM	O
%	O	NOUN	O
(	O	PUNCT	O
PP	O	NOUN	B
)	O	PUNCT	O
;	O	PUNCT	O
-5.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
6.9	O	NUM	O
%	O	NOUN	O
(	B-OUT	PUNCT	O
ITT	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Comparison	O	NOUN	B
of	O	ADP	O
four	O	NUM	O
continuously	O	ADV	O
administered	O	VERB	B
progestogen	B-I	NOUN	B
plus	I-I	CCONJ	O
oestradiol	I-I	NOUN	B
combinations	O	NOUN	I
for	O	ADP	O
climacteric	B-OUT	ADJ	B
complaints	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Sixty	B-P	NUM	O
women	I-P	NOUN	B
with	I-P	ADP	O
climacteric	I-P	ADJ	B
complaints	I-P	NOUN	I
who	I-P	PRON	O
had	I-P	AUX	O
not	I-P	PART	O
menstruated	I-P	VERB	B
for	I-P	ADP	O
at	I-P	ADP	O
least	I-P	ADJ	O
1	I-P	NUM	O
year	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	PART	O
receive	O	VERB	O
one	O	NUM	O
of	O	ADP	O
four	O	NUM	O
hormonal	O	ADJ	B
replacement	O	NOUN	I
regimens	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
clinical	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
was	O	AUX	O
the	O	DET	O
same	O	ADJ	O
although	O	SCONJ	O
the	O	DET	O
alleviation	O	NOUN	B
of	O	ADP	O
vasomotor	B-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
was	O	AUX	O
somewhat	O	ADV	O
slower	O	ADJ	O
in	O	ADP	O
those	O	DET	O
women	O	NOUN	B
receiving	O	VERB	O
preparation	O	NOUN	B
A	O	NOUN	O
.	O	PUNCT	O


Irregular	B-OUT	ADJ	B
uterine	I-OUT	NOUN	O
bleeding	I-OUT	NOUN	O
was	O	AUX	O
almost	O	ADV	O
entirely	O	ADV	O
confined	O	VERB	O
to	O	PART	O
the	O	DET	O
earlier	O	ADJ	O
phase	O	NOUN	B
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
was	O	AUX	O
substantially	O	ADV	O
less	O	ADJ	O
with	O	ADP	O
the	O	DET	O
formulation	O	NOUN	B
containing	O	VERB	O
1	O	NUM	O
mg	O	NOUN	O
norethisterone	B-I	NOUN	B
acetate	I-I	NOUN	I
.	I-I	PUNCT	O


It	O	PRON	O
is	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
a	O	DET	O
continuous	O	ADJ	B
oestradiol-progestogen	B-I	ADJ	B
combination	I-I	NOUN	O
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
for	O	ADP	O
long-term	O	ADJ	B
treatment	O	NOUN	B
of	O	ADP	O
climacteric	B-OUT	ADJ	B
complaints	I-OUT	NOUN	I
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
and	O	CCONJ	O
that	O	SCONJ	O
after	O	ADP	O
4	O	NUM	O
months	O	NOUN	B
the	O	DET	O
clinical	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
is	O	AUX	O
the	O	DET	O
same	O	ADJ	O
irrespective	O	ADV	O
of	O	ADP	O
the	O	DET	O
type	O	NOUN	B
and	O	CCONJ	O
dose	O	NOUN	B
of	O	ADP	O
progestogen	B-I	NOUN	B
administered	O	VERB	B
.	O	PUNCT	O


Self-reported	B-OUT	ADJ	B
smoking	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
drinking	I-OUT	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
number	I-P	NOUN	O
of	I-P	ADP	O
substance	I-P	NOUN	B
using	I-P	VERB	O
friends	I-P	NOUN	B
were	I-P	AUX	O
assessed	I-P	VERB	B
5	I-P	NUM	O
times	I-P	NOUN	O
over	I-P	ADP	O
3	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
relationship	B-I	NOUN	B
between	I-I	ADP	O
peer	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
adolescent	I-OUT	ADJ	B
substance	I-OUT	NOUN	B
use	I-OUT	NOUN	I
were	I-I	AUX	O
assessed	I-I	VERB	B
in	I-I	ADP	O
parallel	I-I	NOUN	O
processes	I-I	NOUN	O
as	I-I	ADP	O
part	I-I	NOUN	O
of	I-I	ADP	O
an	I-I	DET	O
autoregressive	I-I	ADJ	B
latent	I-I	ADJ	O
trajectory	I-I	NOUN	O
model	I-I	NOUN	O
.	I-I	PUNCT	O


Bivariate	O	PROPN	B
,	O	PUNCT	O
lagged	O	VERB	B
autoregressive	O	ADJ	I
analyses	O	NOUN	I
of	O	ADP	O
the	O	DET	O
successive	O	ADJ	O
relationships	O	NOUN	B
from	O	ADP	O
one	O	NUM	O
assessment	O	NOUN	B
to	O	ADP	O
the	O	DET	O
next	O	ADJ	O
showed	O	VERB	O
consistent	O	ADJ	O
,	O	PUNCT	O
significant	O	ADJ	B
associations	O	NOUN	B
from	O	ADP	O
peer	B-OUT	NOUN	B
use	I-OUT	NOUN	O
to	I-OUT	PART	O
adolescent	I-OUT	ADJ	B
substance	I-OUT	NOUN	B
use	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
association	O	NOUN	B
from	O	ADP	O
adolescent	B-OUT	ADJ	B
to	I-OUT	ADP	O
peer	I-OUT	NOUN	B
use	I-OUT	NOUN	O
was	O	AUX	O
significant	O	ADJ	B
only	O	ADV	O
from	O	ADP	O
7th	O	ADJ	O
to	O	PART	O
8th	O	ADJ	O
grade	O	NOUN	B
.	O	PUNCT	O


Peptide	B-OUT	NOUN	B
T	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
negative	I-OUT	ADJ	B
trial	I-OUT	NOUN	I
result	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


While	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
in	O	ADP	O
the	O	DET	O
number	O	NOUN	O
of	O	ADP	O
lymph	B-OUT	NOUN	B
node	I-OUT	NOUN	I
dissection	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
operative	I-OUT	ADJ	B
time	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
chest	I-OUT	ADJ	O
tube	I-OUT	NOUN	O
drainage	I-OUT	NOUN	O
time	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
surgical	O	ADJ	B
trauma	O	NOUN	I
and	O	CCONJ	O
insulin	B-I	NOUN	B
on	O	ADP	O
whole-body	B-OUT	ADJ	O
protein	I-OUT	NOUN	B
turnover	I-OUT	NOUN	B
in	O	ADP	O
parenterally-fed	B-P	ADJ	B
undernourished	I-P	ADJ	B
patients	I-P	NOUN	B
.	I-P	PUNCT	O


Pre-operatively	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
2	O	NUM	O
h	O	NOUN	O
after	O	ADP	O
commencing	O	VERB	O
their	O	PRON	O
post-operative	O	ADJ	B
feeds	O	NOUN	B
,	O	PUNCT	O
rates	B-OUT	NOUN	B
of	I-OUT	ADP	O
whole-body	I-OUT	ADJ	B
protein	I-OUT	NOUN	O
synthesis	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
breakdown	I-OUT	NOUN	B
were	O	AUX	O
measured	O	VERB	B
over	O	ADP	O
a	O	DET	O
9-h	O	ADJ	O
period	O	NOUN	B
following	O	VERB	O
intravenous	O	ADJ	B
injection	O	NOUN	I
of	O	ADP	O
a	O	DET	O
single	O	ADJ	O
tracer	O	NOUN	B
dose	O	NOUN	B
of	O	ADP	O
15N-glycine	B-I	NOUN	B
by	O	ADP	O
the	O	DET	O
ammonia	O	NOUN	B
and	O	CCONJ	O
urea	O	NOUN	B
end-product	O	NOUN	B
methods	O	NOUN	I
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
glucose	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
plasma	I-OUT	NOUN	B
insulin	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
glucagon	I-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
rose	O	VERB	O
post-operatively	O	ADV	B
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
insulin	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
increment	O	NOUN	B
in	O	ADP	O
insulin	B-OUT	NOUN	B
concentration	I-OUT	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
greater	O	ADJ	O
when	O	SCONJ	O
insulin	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


Apparent	B-OUT	ADJ	B
nitrogen	I-OUT	NOUN	O
balance	I-OUT	NOUN	O
was	O	AUX	O
positive	O	ADJ	B
pre-operatively	O	ADV	B
and	O	CCONJ	O
became	O	VERB	O
less	O	ADV	O
so	O	ADV	O
post-operatively	O	ADV	B
whether	O	SCONJ	O
insulin	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
or	O	CCONJ	O
not	O	PART	O
.	O	PUNCT	O


Similarly	O	ADV	O
,	O	PUNCT	O
post-operative	O	ADJ	B
increments	O	NOUN	B
in	O	ADP	O
urinary	B-OUT	ADJ	B
excretion	I-OUT	NOUN	B
of	I-OUT	ADP	O
ammonia	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
creatinine	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
3-methylhistidine	I-OUT	NOUN	B
were	O	AUX	O
not	O	PART	O
altered	O	VERB	O
by	O	ADP	O
addition	O	NOUN	O
of	O	ADP	O
insulin	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
urea	O	NOUN	B
end-product	O	NOUN	B
method	O	NOUN	I
suggested	O	VERB	O
that	O	SCONJ	O
there	O	PRON	O
was	O	AUX	O
no	O	DET	O
change	O	NOUN	O
in	O	ADP	O
whole-body	B-OUT	ADJ	B
protein	I-OUT	NOUN	B
turnover	I-OUT	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
,	O	PUNCT	O
whether	O	SCONJ	O
or	O	CCONJ	O
not	O	PART	O
insulin	B-I	NOUN	B
was	O	AUX	O
given	O	VERB	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
does	O	AUX	O
not	O	PART	O
support	O	VERB	O
the	O	DET	O
clinical	O	ADJ	B
use	O	NOUN	O
of	O	ADP	O
insulin	B-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
means	O	NOUN	O
of	O	ADP	O
modifying	O	VERB	O
protein	O	NOUN	B
metabolic	O	ADJ	O
losses	O	NOUN	O
after	O	ADP	O
major	B-P	ADJ	O
surgery	I-P	NOUN	B
.	I-P	PUNCT	O


Impact	O	NOUN	B
of	O	ADP	O
work	B-I	NOUN	B
site	I-I	NOUN	I
health	I-I	NOUN	B
promotion	I-I	NOUN	I
on	O	ADP	O
stages	B-P	NOUN	B
of	I-P	ADP	O
dietary	I-P	ADJ	B
change	I-P	NOUN	I
:	I-P	PUNCT	O
the	O	DET	O
Working	O	PROPN	B
Well	O	PROPN	I
Trial	O	PROPN	I
.	O	PUNCT	O


This	O	DET	O
report	O	NOUN	O
examines	O	VERB	O
associations	O	NOUN	B
of	O	ADP	O
stages	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
with	O	ADP	O
diet	O	NOUN	B
prospectively	O	ADV	O
and	O	CCONJ	O
addresses	O	VERB	B
whether	O	SCONJ	O
(	O	PUNCT	O
1	O	X	O
)	O	PUNCT	O
baseline	O	NOUN	B
stage	O	NOUN	O
of	O	ADP	O
change	O	NOUN	O
predicts	O	VERB	O
participation	O	NOUN	B
,	O	PUNCT	O
(	O	PUNCT	O
2	O	X	O
)	O	PUNCT	O
forward	O	NOUN	O
changes	O	NOUN	B
in	O	ADP	O
stage	O	NOUN	B
movement	O	NOUN	B
were	O	AUX	O
greater	O	ADJ	O
in	O	ADP	O
treatment	O	NOUN	B
work	O	NOUN	O
sites	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
(	O	PUNCT	O
3	O	X	O
)	O	PUNCT	O
change	O	NOUN	O
in	O	ADP	O
stage	O	NOUN	B
was	O	AUX	O
associated	O	VERB	B
with	O	ADP	I
adoption	O	NOUN	B
of	O	ADP	O
healthful	O	ADJ	B
diets	O	NOUN	B
,	O	PUNCT	O
using	O	VERB	O
data	O	NOUN	B
from	O	ADP	O
a	B-P	DET	O
cohort	I-P	NOUN	B
of	I-P	ADP	O
11,237	I-P	NUM	O
employees	I-P	NOUN	B
.	I-P	PUNCT	O


Findings	O	NOUN	B
indicate	O	VERB	O
that	O	SCONJ	O
persons	B-P	NOUN	B
in	I-P	ADP	O
later	I-P	ADJ	O
stages	I-P	NOUN	B
of	I-P	ADP	O
change	I-P	NOUN	O
reported	O	VERB	O
higher	O	ADJ	O
participation	O	NOUN	B
levels	O	NOUN	B
.	O	PUNCT	O


Net	B-OUT	ADJ	O
change	I-OUT	NOUN	B
in	O	ADP	O
diet	O	NOUN	B
due	O	ADJ	O
to	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
was	O	AUX	O
modest	O	ADJ	O
.	O	PUNCT	O


Drug	O	NOUN	B
preference	O	NOUN	I
in	O	ADP	O
normal	B-P	ADJ	B
volunteers	I-P	NOUN	I
:	I-P	PUNCT	O
effects	O	NOUN	B
of	O	ADP	I
age	O	NOUN	B
and	O	CCONJ	O
time	O	NOUN	B
of	O	ADP	O
day	O	NOUN	B
.	O	PUNCT	O


Three	B-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
subjects	I-P	NOUN	B
were	I-P	AUX	O
tested	I-P	VERB	B
:	I-P	PUNCT	O
i	I-P	X	O
)	I-P	PUNCT	O
a	I-P	DET	O
group	I-P	NOUN	B
of	I-P	ADP	O
40-55-year-old	I-P	ADJ	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
AGE	I-P	NOUN	B
group	I-P	NOUN	B
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
11	I-P	NUM	O
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
tested	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
morning	I-P	NOUN	B
,	I-P	PUNCT	O
ii	I-P	X	O
)	I-P	PUNCT	O
a	I-P	DET	O
group	I-P	NOUN	B
of	I-P	ADP	O
21-35-year-old	I-P	ADJ	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
CTL	I-P	NOUN	B
group	I-P	NOUN	B
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
12	I-P	NUM	O
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
also	I-P	ADV	O
tested	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
morning	I-P	NOUN	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
iii	I-P	X	O
)	I-P	PUNCT	O
a	I-P	DET	O
group	I-P	NOUN	B
of	I-P	ADP	O
21-35-year-olds	I-P	NUM	O
who	I-P	PRON	O
were	I-P	AUX	O
tested	I-P	VERB	B
in	I-P	ADP	O
the	I-P	DET	O
late	I-P	ADJ	B
afternoon	I-P	NOUN	I
(	I-P	PUNCT	O
AFT	I-P	NOUN	B
group	I-P	NOUN	O
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
13	I-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Disclosure	O	NOUN	B
of	O	ADP	O
HSV-2	O	NOUN	B
serological	O	ADJ	B
test	O	NOUN	I
results	O	NOUN	B
in	O	ADP	O
the	O	DET	O
context	O	NOUN	B
of	O	ADP	O
an	O	DET	O
adolescent	B-P	ADJ	B
HIV	I-P	NOUN	B
prevention	I-P	NOUN	O
trial	I-P	NOUN	O
in	I-P	ADP	O
Kenya	I-P	PROPN	B
.	I-P	PUNCT	O


OBJECTIVES	O	NOUN	O
Herpes	O	NOUN	B
simplex	O	NOUN	I
virus	O	NOUN	I
type	O	NOUN	I
2	O	NUM	I
(	O	PUNCT	O
HSV-2	O	NOUN	B
)	O	PUNCT	O
biomarkers	O	NOUN	B
are	O	AUX	O
often	O	ADV	O
used	O	VERB	O
in	O	ADP	O
adolescent	B-P	ADJ	B
sub-Saharan	I-P	ADJ	O
HIV	I-P	NOUN	B
prevention	I-P	NOUN	O
studies	O	NOUN	O
,	O	PUNCT	O
but	O	CCONJ	O
evaluations	O	NOUN	B
of	O	ADP	O
test	O	NOUN	B
performance	O	NOUN	B
and	O	CCONJ	O
disclosure	O	NOUN	B
outcomes	O	NOUN	I
are	O	AUX	O
rare	O	ADJ	B
in	O	ADP	O
the	O	DET	O
published	O	VERB	B
literature	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
In	O	ADP	O
2011	O	NUM	O
,	O	PUNCT	O
837	B-P	NUM	O
Kenyan	I-P	ADJ	B
orphan	I-P	NOUN	I
youth	I-P	NOUN	B
in	I-P	ADP	O
grades	I-P	NOUN	B
7	I-P	NUM	O
and	I-P	CCONJ	O
8	I-P	NUM	O
enrolled	I-P	VERB	O
in	I-P	ADP	O
an	I-P	DET	O
HIV	I-P	NOUN	B
prevention	I-P	NOUN	O
clinical	I-P	ADJ	B
trial	I-P	NOUN	I
with	I-P	ADP	O
HSV-2	I-P	NOUN	B
biomarker	I-P	NOUN	B
outcomes	I-P	NOUN	B
.	I-P	PUNCT	O


Of	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
22	B-P	NUM	O
positive	I-P	ADJ	B
and	I-P	CCONJ	O
all	I-P	DET	O
indeterminates	I-P	NOUN	B
were	I-P	AUX	O
WB	I-P	NOUN	B
tested	I-P	VERB	B
;	I-P	PUNCT	O
20	I-P	NUM	O
and	I-P	CCONJ	O
5	I-P	NUM	O
,	I-P	PUNCT	O
respectively	I-P	ADV	O
,	O	PUNCT	O
were	O	AUX	O
confirmed	O	VERB	O
positive	O	ADJ	B
.	O	PUNCT	O


Self-reported	B-OUT	ADJ	B
virginity	I-OUT	NOUN	B
was	O	AUX	O
highly	O	ADV	O
inconsistent	O	ADJ	B
with	O	ADP	O
WB-confirmed	B-OUT	ADJ	B
positives	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Determinants	O	NOUN	B
of	O	ADP	O
total	O	NOUN	O
and	O	CCONJ	O
specific	O	ADJ	O
IgE	O	NOUN	B
in	O	ADP	O
infants	B-P	NOUN	B
with	I-P	ADP	O
atopic	I-P	ADJ	B
dermatitis	I-P	NOUN	I
.	I-P	PUNCT	O


In	O	ADP	O
infancy	O	NOUN	B
,	O	PUNCT	O
increased	O	VERB	B
total	B-OUT	ADJ	O
IgE	I-OUT	NOUN	O
is	O	AUX	O
more	O	ADV	O
affected	O	VERB	B
by	O	ADP	O
factors	O	NOUN	B
increasing	O	VERB	B
risk	O	NOUN	B
of	O	ADP	O
intercurrent	O	ADJ	B
infection	O	NOUN	I
and	O	CCONJ	O
non-specific	O	ADJ	B
airway	O	NOUN	B
inflammation	O	NOUN	B
,	O	PUNCT	O
such	O	ADJ	O
as	O	ADP	O
environmental	O	ADJ	B
tobacco	O	NOUN	O
smoke	O	NOUN	O
exposure	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
use	O	NOUN	O
of	O	ADP	O
gas	O	NOUN	B
cookers	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Specific	O	ADJ	O
allergen	B-OUT	NOUN	B
sensitization	I-OUT	NOUN	B
as	O	ADP	O
represented	O	VERB	O
by	O	ADP	O
detectable	O	ADJ	B
IgE	B-OUT	NOUN	B
antibodies	I-OUT	NOUN	I
is	O	AUX	O
influenced	O	VERB	B
primarily	O	ADV	O
by	O	ADP	O
allergen	O	NOUN	B
exposure	O	NOUN	B
.	O	PUNCT	O


[	B-I	PUNCT	O
Median	I-I	ADJ	B
and	I-I	CCONJ	O
mediolateral	I-I	ADJ	B
episiotomy	I-I	NOUN	I
]	I-I	PUNCT	O
.	I-P	PUNCT	O


One	O	NUM	O
intervention	O	NOUN	B
involved	O	VERB	O
a	O	DET	O
peer-mediated	B-I	ADJ	B
approach	I-I	NOUN	I
(	I-I	PUNCT	O
PEER	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
other	O	ADJ	O
involved	O	VERB	O
a	O	DET	O
child-assisted	B-I	ADJ	B
approach	I-I	NOUN	I
(	I-I	PUNCT	O
CHILD	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


Sixty	B-P	NUM	B
children	I-P	NOUN	B
participated	I-P	VERB	O
from	I-P	ADP	O
56	I-P	NUM	O
classrooms	I-P	NOUN	B
in	I-P	ADP	O
30	I-P	NUM	O
schools	I-P	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
data	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
significant	O	ADJ	B
improvements	O	NOUN	B
can	O	AUX	O
be	O	AUX	O
made	B-OUT	VERB	O
in	I-OUT	ADP	O
peer	I-OUT	NOUN	B
social	I-OUT	ADJ	B
connections	I-OUT	NOUN	I
for	O	ADP	O
children	O	NOUN	B
with	B-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
in	O	ADP	O
general	O	ADJ	B
education	O	NOUN	I
classrooms	O	NOUN	I
with	O	ADP	O
a	O	DET	O
brief	O	ADJ	O
intervention	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
that	O	SCONJ	O
these	O	DET	O
gains	O	NOUN	B
persist	O	VERB	O
over	O	ADP	O
time	O	NOUN	B
.	O	PUNCT	O


Lower	O	ADJ	B
relapse	O	NOUN	B
rates	O	NOUN	B
after	O	ADP	O
neighbourhood	O	NOUN	B
injection	O	NOUN	I
of	O	ADP	O
Corynebacterium	B-I	X	B
parvum	I-I	NOUN	I
in	O	ADP	O
operable	O	ADJ	B
cervix	O	NOUN	I
carcinoma	O	NOUN	I
.	O	PUNCT	O


All	B-P	DET	O
patients	I-P	NOUN	B
had	I-P	AUX	O
carcinoma	I-P	NOUN	B
confined	I-P	VERB	O
to	I-P	PART	O
the	I-P	DET	O
cervix	I-P	NOUN	B
,	I-P	PUNCT	O
the	I-P	DET	O
upper	I-P	ADJ	B
part	I-P	NOUN	I
of	I-P	ADP	O
the	I-P	DET	O
vagina	I-P	NOUN	B
or	I-P	CCONJ	O
the	I-P	DET	O
parametrial	I-P	ADJ	B
region	I-P	NOUN	I
.	I-P	PUNCT	O


Only	O	ADV	O
minor	O	ADJ	O
side	B-OUT	NOUN	B
effects	I-OUT	NOUN	I
of	O	ADP	O
CP	O	NOUN	B
were	O	AUX	O
encountered	O	VERB	O
.	O	PUNCT	O


A	O	DET	O
further	O	ADV	O
15	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
more	I-P	ADV	O
advanced	I-P	ADJ	B
malignancies	I-P	NOUN	I
were	I-P	AUX	O
added	I-P	VERB	O
to	I-P	ADP	O
our	I-P	PRON	O
studies	I-P	NOUN	B
.	I-P	PUNCT	O


In	O	ADP	O
these	O	DET	O
,	O	PUNCT	O
CP	B-I	NOUN	B
stimulation	I-I	NOUN	B
had	O	AUX	O
no	O	DET	B
effect	O	NOUN	I
on	O	ADP	O
relapse	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
relapse-free	B-OUT	ADJ	B
intervals	I-OUT	NOUN	I
were	O	AUX	O
longer	O	ADJ	O
after	O	ADP	O
immune	B-I	ADJ	B
stimulation	I-I	NOUN	I
:	I-I	PUNCT	O
control	O	NOUN	B
3.5	O	NUM	O
months	O	NOUN	B
(	O	PUNCT	O
mean	O	NOUN	B
)	O	PUNCT	O
+/-	O	CCONJ	O
1.5	O	NUM	O
(	O	PUNCT	O
s.d	O	ADJ	O
.	O	PUNCT	O


The	O	DET	O
potential	O	ADJ	B
interaction	O	NOUN	B
between	O	ADP	O
racemic	B-I	ADJ	B
warfarin	I-I	NOUN	B
given	O	VERB	O
as	O	ADP	O
a	O	DET	O
25	B-I	NUM	O
mg	I-I	NOUN	O
single	I-I	ADJ	O
oral	I-I	ADJ	B
dose	I-I	NOUN	I
and	I-I	CCONJ	O
chronically	I-I	ADV	B
administered	I-I	VERB	B
ketorolac	I-I	NOUN	B
was	O	AUX	O
studied	O	VERB	O
in	O	ADP	O
12	B-P	NUM	O
young	I-P	ADJ	B
healthy	I-P	ADJ	B
male	I-P	NOUN	B
volunteers	I-P	NOUN	I
.	I-P	PUNCT	O


Ketorolac	B-I	NOUN	B
produced	O	VERB	O
no	B-OUT	DET	O
major	I-OUT	ADJ	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
pharmacokinetics	I-OUT	NOUN	B
of	I-OUT	ADP	O
(	I-OUT	PUNCT	O
R	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
-	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
-warfarin	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


Ketorolac	B-I	NOUN	B
increased	I-OUT	VERB	B
template	I-OUT	NOUN	B
bleeding	I-OUT	NOUN	O
time	I-OUT	NOUN	O
by	O	ADP	O
a	O	DET	O
factor	O	NOUN	B
of	O	ADP	O
1.35	O	NUM	O
as	O	ADP	O
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
.	O	PUNCT	O


Positive	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
crisis	B-I	NOUN	B
resource	I-I	NOUN	B
management	I-I	NOUN	O
training	I-I	NOUN	O
on	O	ADP	O
no-flow	O	ADJ	B
time	O	NOUN	I
and	O	CCONJ	O
team	O	NOUN	B
member	O	NOUN	O
verbalisations	O	NOUN	B
during	O	ADP	O
simulated	B-I	ADJ	O
cardiopulmonary	I-I	NOUN	B
resuscitation	I-I	NOUN	I
:	I-I	PUNCT	O
a	O	DET	O
randomised	O	ADJ	B
controlled	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


RESULTS	B-OUT	VERB	O
NFT	I-OUT	NOUN	B
rates	I-OUT	NOUN	B
were	O	AUX	O
significantly	O	ADV	O
lower	O	ADJ	O
in	O	ADP	O
the	O	DET	O
CRM-training	O	ADJ	B
group	O	NOUN	B
(	O	PUNCT	O
31.46.1	O	NOUN	O
%	O	NOUN	O
vs.	O	CCONJ	O
36.36.6	O	NOUN	O
%	O	NOUN	O
,	O	PUNCT	O
p=0.014	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
exercise	B-I	NOUN	B
training	I-I	NOUN	B
and	I-I	CCONJ	O
dietary	I-I	ADJ	B
macronutrient	I-I	ADJ	B
composition	I-I	NOUN	B
on	O	ADP	O
24	B-OUT	NUM	O
h	I-OUT	NOUN	O
substrate	I-OUT	NOUN	B
oxidation	I-OUT	NOUN	B
in	O	ADP	O
male	B-P	NOUN	B
,	I-P	PUNCT	O
obese	I-P	ADJ	B
subjects	I-P	NOUN	B
.	I-P	PUNCT	O


DESIGN	O	VERB	O
A	O	DET	O
16	O	NUM	O
month	O	NOUN	B
exercise	B-I	NOUN	B
intervention	I-I	NOUN	B
study	O	NOUN	I
was	O	AUX	O
executed	O	VERB	O
,	O	PUNCT	O
including	O	VERB	O
a	O	DET	O
weight	O	NOUN	B
loss	O	NOUN	I
period	O	NOUN	B
with	O	ADP	O
a	O	DET	O
very	B-I	ADV	O
low	I-I	ADJ	O
energy	I-I	NOUN	O
diet	I-I	NOUN	O
(	I-I	PUNCT	O
VLED	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
2	O	NUM	O
months	O	NOUN	B
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
.	O	PUNCT	O


MEASUREMENTS	O	VERB	O
Substrate	B-OUT	NOUN	B
oxidation	I-OUT	NOUN	I
was	O	AUX	O
measured	O	VERB	B
during	O	ADP	O
a	O	DET	O
standardized	O	ADJ	O
36	O	NUM	O
h	O	NOUN	O
stay	O	NOUN	O
in	O	ADP	O
the	O	DET	O
respiration	O	NOUN	B
chamber	O	NOUN	I
at	O	ADP	O
the	O	DET	O
start	O	NOUN	O
of	O	ADP	O
the	O	DET	O
study	O	NOUN	B
(	O	PUNCT	O
0	O	NUM	O
months	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
at	O	ADP	O
4	O	NUM	O
,	O	PUNCT	O
10	O	NUM	O
and	O	CCONJ	O
16	O	NUM	O
months	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
the	O	DET	O
respiration	O	NOUN	B
chamber	O	NOUN	O
subjects	B-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	O	PART	O
a	O	DET	O
high-fat	B-I	NOUN	B
(	I-I	PUNCT	I
Hi.F	I-I	NOUN	I
)	I-I	PUNCT	I
diet	I-I	NOUN	I
(	I-I	PUNCT	O
60	I-I	NUM	O
%	I-I	NOUN	O
of	I-I	ADP	O
energy	I-I	NOUN	B
(	I-I	PUNCT	O
En	I-I	NOUN	O
%	I-I	NOUN	O
)	I-I	PUNCT	O
fat	I-I	NOUN	B
)	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
reduced-fat	I-I	ADJ	B
(	I-I	PUNCT	O
Red.F	I-I	NOUN	O
)	I-I	PUNCT	O
diet	I-I	NOUN	O
(	I-I	PUNCT	O
30	I-I	NUM	O
En	I-I	NOUN	O
%	I-I	NOUN	O
fat	I-I	NOUN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


In	O	ADP	O
the	O	DET	O
well-trained	O	ADJ	B
group	O	NOUN	I
the	O	DET	O
24h	B-OUT	NOUN	O
CHO	I-OUT	NOUN	B
balance	I-OUT	NOUN	B
was	O	AUX	O
even	O	ADV	O
more	O	ADV	O
negative	O	ADJ	B
for	O	ADP	O
both	O	DET	O
types	O	NOUN	O
of	O	ADP	O
diet	O	NOUN	B
(	O	PUNCT	O
-103	O	NUM	O
to	O	PART	O
-185	O	NUM	O
g/d	O	NOUN	O
for	O	ADP	O
the	O	DET	O
Red.F	O	NOUN	B
and	O	CCONJ	O
Hi.F	O	NOUN	B
diet	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
under	O	ADP	O
similar	O	ADJ	O
conditions	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
the	O	DET	O
trained	O	VERB	B
obese	O	ADJ	B
group	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
changes	O	NOUN	B
in	O	ADP	O
24	B-OUT	NUM	O
h	I-OUT	NOUN	O
substrate	I-OUT	NOUN	B
utilization	I-OUT	NOUN	B
in	O	ADP	O
the	O	DET	O
obese	O	ADJ	B
,	O	PUNCT	O
as	O	ADV	O
well	O	ADV	O
as	O	ADP	O
in	O	ADP	O
the	O	DET	O
well-trained	O	ADJ	B
group	O	NOUN	I
,	O	PUNCT	O
suggest	O	VERB	O
that	O	SCONJ	O
endurance	O	NOUN	B
training	O	NOUN	O
increased	O	VERB	B
the	O	DET	O
reliance	O	NOUN	O
on	O	ADP	O
carbohydrate	B-OUT	NOUN	B
oxidation	I-OUT	NOUN	I
and	O	CCONJ	O
therefore	O	ADV	O
did	O	AUX	O
not	O	PART	O
increase	O	VERB	B
24	B-OUT	NUM	O
fat	I-OUT	NOUN	B
oxidation	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


DESIGN	O	VERB	O
Two	O	NUM	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
trials	O	NOUN	I
conducted	O	VERB	O
between	O	ADP	O
June	O	PROPN	O
and	O	CCONJ	O
July	O	PROPN	O
1997	O	NUM	O
.	O	PUNCT	O


SETTING	O	VERB	O
Individual	O	ADJ	B
hotel	O	NOUN	O
rooms	O	NOUN	O
;	O	PUNCT	O
2	B-P	NUM	O
large	I-P	ADJ	O
US	I-P	PROPN	B
university	I-P	NOUN	B
medical	I-P	ADJ	I
schools	I-P	NOUN	I
.	I-P	PUNCT	O


PARTICIPANTS	O	VERB	B
A	B-P	DET	I
total	I-P	NOUN	O
of	I-P	ADP	O
117	I-P	NUM	O
healthy	I-P	ADJ	B
adult	I-P	ADJ	I
volunteers	I-P	NOUN	I
(	I-P	PUNCT	O
aged	I-P	ADJ	B
18-40	I-P	NUM	O
years	I-P	NOUN	B
;	I-P	PUNCT	O
median	I-P	ADJ	B
age	I-P	NOUN	B
,	I-P	PUNCT	O
21	I-P	NUM	O
years	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
susceptible	I-P	ADJ	B
(	I-P	PUNCT	O
hemagglutination-inhibition	I-P	ADJ	B
antibody	I-P	NOUN	I
titer	I-P	NOUN	B
<	I-P	X	O
or	I-P	CCONJ	O
=1:8	I-P	NOUN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


For	O	ADP	O
the	O	DET	O
prophylaxis	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
oral	B-I	ADJ	B
oseltamivir	I-I	NOUN	I
(	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
[	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
[	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
12	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
or	O	CCONJ	O
matching	B-I	VERB	O
placebo	I-I	NOUN	B
[	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
13	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
starting	O	VERB	O
26	O	NUM	O
hours	O	NOUN	B
before	O	ADP	O
virus	O	NOUN	B
inoculation	O	NOUN	B
)	O	PUNCT	O
was	O	AUX	O
administered	O	VERB	B
.	O	PUNCT	O


For	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
study	O	NOUN	I
,	O	PUNCT	O
the	O	DET	O
same	O	ADJ	O
drug	O	NOUN	B
was	O	AUX	O
given	O	VERB	O
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
100	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
or	O	CCONJ	O
200	O	NUM	O
mg	O	NOUN	O
twice	O	ADV	O
daily	O	ADV	B
,	O	PUNCT	O
200	O	NUM	O
mg	O	NOUN	O
once	O	ADV	B
daily	O	ADV	I
,	O	PUNCT	O
or	O	CCONJ	O
matching	O	VERB	O
placebo	B-I	NOUN	B
[	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
16	O	NUM	O
]	O	PUNCT	O
,	O	PUNCT	O
in	O	ADP	O
each	O	DET	O
group	O	NOUN	B
starting	O	VERB	O
28	O	NUM	O
hours	O	NOUN	B
after	O	ADP	O
inoculation	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


MAIN	O	NOUN	O
OUTCOME	O	NOUN	B
MEASURES	O	NOUN	O
Comparing	O	VERB	O
placebo	O	ADJ	B
groups	O	NOUN	B
with	O	ADP	O
pooled	O	ADJ	B
treatment	O	NOUN	B
groups	O	NOUN	I
,	O	PUNCT	O
for	O	ADP	O
prophylaxis	O	NOUN	B
,	O	PUNCT	O
outcomes	O	NOUN	B
included	O	VERB	O
frequency	B-OUT	NOUN	B
of	I-OUT	ADP	O
infection	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
viral	I-OUT	ADJ	B
shedding	I-OUT	NOUN	I
;	I-OUT	PUNCT	O
for	O	ADP	O
treatment	O	NOUN	B
,	O	PUNCT	O
viral	O	ADJ	B
shedding	O	NOUN	I
in	O	ADP	O
titers	O	NOUN	B
.	O	PUNCT	O


Oseltamivir	O	NOUN	B
treatment	O	NOUN	B
also	O	ADV	O
reduced	O	VERB	B
symptom	B-OUT	NOUN	B
scores	I-OUT	NOUN	I
(	O	PUNCT	O
median	O	NOUN	B
[	O	PUNCT	O
IQR	O	NOUN	B
]	O	PUNCT	O
score-hours	O	NOUN	O
,	O	PUNCT	O
225	O	NUM	O
[	O	PUNCT	O
97-349	O	NUM	O
]	O	PUNCT	O
vs	O	CCONJ	O
400	O	NUM	O
[	O	PUNCT	O
189-645	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
.05	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
nasal	B-OUT	ADJ	B
proinflammatory	I-OUT	ADJ	O
cytokine	I-OUT	NOUN	O
levels	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
these	O	DET	O
trials	O	NOUN	B
,	O	PUNCT	O
prophylaxis	O	NOUN	B
and	O	CCONJ	O
early	O	ADJ	B
treatment	O	NOUN	I
with	O	ADP	O
oral	O	ADJ	B
oseltamivir	O	NOUN	I
were	O	AUX	O
both	O	DET	O
associated	O	VERB	B
with	O	ADP	I
significant	O	ADJ	O
antiviral	O	ADJ	B
and	O	CCONJ	O
clinical	O	ADJ	B
effects	O	NOUN	I
in	O	ADP	O
experimental	B-P	ADJ	B
human	I-P	ADJ	B
influenza	I-P	NOUN	B
.	O	PUNCT	O


Antazoline	B-I	NOUN	B
is	O	AUX	O
a	O	DET	O
first	O	ADJ	O
generation	O	NOUN	O
antihistaminic	O	ADJ	B
agent	O	NOUN	I
with	O	ADP	O
chinidin-like	O	ADJ	B
properties	O	NOUN	I
.	O	PUNCT	O


When	O	SCONJ	O
administered	O	VERB	B
intravenously	O	ADV	B
,	O	PUNCT	O
antazoline	B-I	NOUN	B
exerts	O	VERB	O
a	O	DET	O
strong	B-OUT	ADJ	O
antiarrhythmic	I-OUT	ADJ	B
effect	I-OUT	NOUN	I
on	O	ADP	O
supraventricular	B-OUT	ADJ	B
arrhythmia	I-OUT	NOUN	I
,	O	PUNCT	O
especially	O	ADV	O
on	O	ADP	O
AF	B-OUT	PROPN	B
,	O	PUNCT	O
facilitating	O	VERB	O
rapid	B-OUT	ADJ	O
conversion	I-OUT	NOUN	B
to	I-OUT	ADP	O
sinus	I-OUT	NOUN	B
rhythm	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


METHODS/DESIGN	O	NOUN	B
A	O	NOUN	O
randomized	O	ADJ	B
,	O	PUNCT	O
double	O	ADJ	O
blind	O	ADJ	B
,	O	PUNCT	O
placebo-controlled	B-I	ADJ	B
,	O	PUNCT	O
superiority	O	NOUN	O
clinical	O	ADJ	B
trial	O	NOUN	I
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
assess	O	VERB	O
clinical	B-OUT	ADJ	B
efficacy	I-OUT	NOUN	I
of	O	ADP	O
antazoline	B-I	NOUN	B
in	O	ADP	O
rapid	O	ADJ	O
conversion	O	NOUN	B
of	O	ADP	O
AF	O	NOUN	B
to	O	PART	O
sinus	O	NOUN	B
rhythm	O	NOUN	I
.	O	PUNCT	O


Eligible	B-P	ADJ	O
patients	I-P	NOUN	B
will	I-P	AUX	O
present	I-P	VERB	O
AF	I-P	NOUN	B
lasting	I-P	VERB	O
less	I-P	ADJ	O
than	I-P	ADP	O
43	I-P	NUM	O
hours	I-P	NOUN	B
,	I-P	PUNCT	O
will	I-P	AUX	O
be	I-P	AUX	O
in	I-P	ADP	O
stable	I-P	ADJ	B
cardio-pulmonary	I-P	ADJ	B
condition	I-P	NOUN	I
and	I-P	CCONJ	O
will	I-P	AUX	O
have	I-P	AUX	O
no	I-P	DET	O
prior	I-P	ADJ	O
history	I-P	NOUN	O
of	I-P	ADP	O
advanced	I-P	ADJ	B
heart	I-P	NOUN	I
failure	I-P	NOUN	I
or	I-P	CCONJ	O
significant	I-P	ADJ	O
valvular	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


Primary	O	ADJ	B
end	O	NOUN	I
point	O	NOUN	I
will	O	AUX	O
be	O	AUX	O
the	O	DET	O
conversion	B-OUT	NOUN	B
of	I-OUT	ADP	O
AF	I-OUT	NOUN	B
to	I-OUT	PART	O
sinus	I-OUT	NOUN	B
rhythm	I-OUT	NOUN	B
confirmed	I-OUT	VERB	O
in	I-OUT	ADP	O
an	I-OUT	DET	O
electrocardiogram	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
ECG	I-OUT	PROPN	B
)	I-OUT	PUNCT	O
during	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
period	O	NOUN	B
.	O	PUNCT	O


Special	O	ADJ	O
consideration	O	NOUN	O
will	O	AUX	O
be	O	AUX	O
given	O	VERB	O
to	O	ADP	O
the	O	DET	O
observation	O	NOUN	B
of	O	ADP	O
any	O	DET	O
adverse	B-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Effective	O	ADJ	B
strategies	O	NOUN	B
included	O	VERB	O
(	O	PUNCT	O
a	O	X	O
)	O	PUNCT	O
the	B-I	DET	O
use	I-I	NOUN	O
of	I-I	ADP	O
choral	I-I	ADJ	B
responding	I-I	NOUN	O
;	I-I	PUNCT	O
(	O	PUNCT	O
b	O	X	O
)	O	PUNCT	O
the	B-I	DET	O
use	I-I	NOUN	O
of	I-I	ADP	O
student-to-student	I-I	ADJ	B
responding	I-I	NOUN	O
;	I-I	PUNCT	O
(	O	PUNCT	O
c	O	X	O
)	O	PUNCT	O
the	B-I	DET	O
rotation	I-I	NOUN	B
of	I-I	ADP	O
materials	I-I	NOUN	B
every	I-I	DET	O
5	I-I	NUM	O
minutes	I-I	NOUN	B
during	I-I	ADP	O
the	I-I	DET	O
30-minute	I-I	ADJ	O
group	I-I	NOUN	B
while	I-I	SCONJ	O
teaching	I-I	VERB	B
2	I-I	NUM	O
to	I-I	PART	O
3	I-I	NUM	O
concepts	I-I	NOUN	B
;	I-I	PUNCT	O
and	I-I	CCONJ	O
(	O	PUNCT	O
d	O	X	O
)	O	PUNCT	O
the	B-I	DET	O
use	I-I	NOUN	O
of	I-I	ADP	O
random	I-I	ADJ	B
,	I-I	PUNCT	O
unpredictable	I-I	ADJ	B
trials	I-I	NOUN	I
for	I-I	ADP	O
student	I-I	NOUN	B
responding	I-I	VERB	B
.	I-I	PUNCT	O


Migration	B-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
acetabular	I-P	NOUN	B
component	I-P	NOUN	O
:	I-P	PUNCT	O
effect	I-OUT	NOUN	B
of	I-OUT	ADP	O
cement	I-OUT	NOUN	B
pressurization	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
significance	I-OUT	NOUN	B
of	I-OUT	ADP	O
early	I-OUT	ADJ	B
radiolucency	I-OUT	NOUN	B
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
5-year	O	ADJ	O
study	O	NOUN	O
using	O	VERB	O
radiostereometry	B-I	NOUN	B
.	I-I	PUNCT	O


BACKGROUND	O	NOUN	O
Cementing	O	NOUN	B
technique	O	NOUN	I
is	O	AUX	O
a	O	DET	O
crucial	O	ADJ	O
factor	O	NOUN	B
in	O	ADP	O
prosthesis	B-P	NOUN	B
fixation	I-P	NOUN	B
.	I-P	PUNCT	O


Postoperative	O	ADJ	B
radiolucent	B-OUT	ADJ	O
lines	I-OUT	NOUN	O
around	I-OUT	ADP	O
the	I-OUT	DET	O
cup	I-OUT	NOUN	B
were	I-OUT	AUX	O
correlated	I-OUT	VERB	B
to	I-OUT	PART	O
later	I-OUT	ADJ	O
RSA	I-OUT	PROPN	B
results	I-OUT	VERB	B
.	I-OUT	PUNCT	O


Level	O	NOUN	B
of	O	ADP	O
intervention	O	NOUN	B
was	O	AUX	O
controlled	O	VERB	B
by	O	ADP	O
systematically	B-I	ADV	B
varying	I-I	VERB	O
the	I-I	DET	O
manner	I-I	NOUN	O
and	I-I	CCONJ	O
frequency	I-I	NOUN	B
with	I-I	ADP	O
which	I-I	DET	O
objects	I-I	NOUN	B
were	I-I	AUX	O
presented	I-I	VERB	O
,	I-I	PUNCT	O
the	I-I	DET	O
extent	I-I	NOUN	O
to	I-I	PART	O
which	I-I	DET	O
the	I-I	DET	O
experimenter	I-I	NOUN	B
talked	I-I	VERB	O
to	I-I	ADP	O
the	I-I	DET	O
infant	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
physical	I-I	ADJ	B
proximity	I-I	NOUN	I
.	I-I	PUNCT	O


Infant	O	ADJ	B
attention	O	NOUN	B
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
duration	B-OUT	NOUN	B
of	I-OUT	ADP	O
time	I-OUT	NOUN	O
spent	I-OUT	VERB	O
examining	I-OUT	VERB	O
objects	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Aftermath	O	NOUN	B
of	O	ADP	O
a	O	DET	O
clinical	O	ADJ	B
trial	O	NOUN	I
:	O	PUNCT	O
evaluating	O	VERB	B
the	O	DET	O
sustainability	O	NOUN	B
of	O	ADP	O
a	O	DET	O
medical	B-I	ADJ	B
device	I-I	NOUN	I
intervention	I-I	NOUN	B
in	I-P	ADP	O
Ghana	I-P	PROPN	B
.	I-P	PUNCT	O


First-generation	O	ADJ	B
trainees	O	NOUN	I
scored	O	VERB	O
significantly	O	ADV	O
higher	O	ADJ	O
than	O	ADP	O
second-generation	O	ADJ	B
trainees	O	NOUN	I
on	O	ADP	O
both	O	DET	O
skills	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
knowledge	I-OUT	NOUN	B
assessments	I-OUT	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Protocolization	O	NOUN	B
of	O	ADP	O
the	O	DET	O
training	O	NOUN	B
program	O	NOUN	I
,	O	PUNCT	O
in	O	ADP	O
conjunction	O	NOUN	B
with	O	ADP	O
skills	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
knowledge	I-OUT	NOUN	B
assessment	O	NOUN	I
,	O	PUNCT	O
may	O	AUX	O
improve	O	VERB	O
acquisition	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
retention	I-OUT	NOUN	B
among	O	ADP	O
second-	O	ADJ	O
and	O	CCONJ	O
future-generation	O	ADJ	B
trainees	O	NOUN	I
.	O	PUNCT	O


Consecutive	B-I	ADJ	B
procedural	I-I	ADJ	B
angiograms	I-I	NOUN	I
of	I-P	ADP	O
patients	I-P	NOUN	B
randomly	I-P	ADV	O
assigned	I-P	VERB	O
to	I-P	ADP	O
EES	I-I	NOUN	B
(	I-P	PUNCT	O
n=669	I-P	NOUN	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
PES	I-I	NOUN	B
(	I-P	PUNCT	O
n=333	I-P	NUM	O
)	I-P	PUNCT	O
were	I-P	AUX	O
analysed	I-P	VERB	B
by	I-P	ADP	O
an	I-P	DET	O
independent	I-P	ADJ	O
angiographic	I-P	ADJ	B
core	I-P	NOUN	O
laboratory	I-P	NOUN	O
.	I-P	PUNCT	O


Promoting	O	VERB	B
gynecologic	O	ADJ	B
cancer	O	NOUN	I
awareness	B-I	NOUN	B
at	O	ADP	O
a	O	DET	O
critical	O	ADJ	O
juncture	O	NOUN	O
--	O	PUNCT	O
where	O	SCONJ	O
women	O	NOUN	B
and	O	CCONJ	O
providers	O	NOUN	B
meet	O	VERB	B
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
Omeprazole	B-I	NOUN	B
and	O	CCONJ	O
famotidine	B-I	NOUN	B
both	O	DET	O
reduce	O	VERB	B
severity	O	NOUN	B
of	O	ADP	O
exercise-induced	B-OUT	ADJ	B
gastritis	I-OUT	NOUN	I
,	O	PUNCT	O
but	O	CCONJ	O
administering	O	VERB	B
famotidine	O	NOUN	B
is	O	AUX	O
easier	O	ADJ	O
than	O	ADP	O
administering	O	VERB	B
omeprazole	O	NOUN	B
during	O	ADP	O
racing	O	NOUN	B
competition	O	NOUN	I
.	O	PUNCT	O


METHODS	O	NOUN	O
Experiment	O	NOUN	B
1	O	NUM	O
:	O	PUNCT	O
Equal	O	ADJ	B
numbers	O	NOUN	O
of	O	ADP	O
dogs	B-P	NOUN	B
randomly	O	ADV	O
assigned	O	VERB	O
to	O	PART	O
famotidine	B-I	NOUN	B
(	O	PUNCT	O
20	O	NUM	O
mg	O	NOUN	O
q24h	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
no	B-I	DET	O
treatment	I-I	NOUN	B
groups	O	NOUN	I
.	O	PUNCT	O


Mucosal	B-OUT	ADJ	B
appearance	I-OUT	NOUN	B
was	O	AUX	O
blindly	O	ADV	B
scored	O	VERB	B
by	O	ADP	O
previously	O	ADV	O
described	O	VERB	O
scoring	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
AND	O	CCONJ	O
CLINICAL	O	NOUN	O
RELEVANCE	O	NOUN	O
Although	O	SCONJ	O
famotidine	O	NOUN	B
provides	O	VERB	O
some	O	DET	O
benefit	O	NOUN	B
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
exercise-induced	B-OUT	ADJ	B
gastric	I-OUT	ADJ	I
lesions	I-OUT	NOUN	I
,	O	PUNCT	O
omeprazole	O	NOUN	B
is	O	AUX	O
superior	O	ADJ	O
to	O	PART	O
famotidine	O	NOUN	B
in	O	ADP	O
preventing	O	VERB	B
gastritis	B-OUT	NOUN	B
in	O	ADP	O
dogs	B-P	NOUN	B
running	O	VERB	O
300	O	NUM	O
miles	O	NOUN	B
.	O	PUNCT	O


Routine	O	ADJ	B
administration	O	NOUN	B
of	O	ADP	O
omeprazole	B-I	NOUN	B
is	O	AUX	O
recommended	O	VERB	O
to	O	PART	O
prevent	O	VERB	O
stress-associated	B-OUT	ADJ	B
gastric	I-OUT	ADJ	I
disease	I-OUT	NOUN	I
in	O	ADP	O
exercising	B-P	NOUN	B
and	I-P	CCONJ	O
racing	I-P	VERB	B
Alaskan	I-P	ADJ	B
sled	I-P	NOUN	I
dogs	I-P	NOUN	I
.	I-P	PUNCT	O


Esomeprazole	B-I	NOUN	B
resolves	O	VERB	O
chronic	B-OUT	ADJ	B
heartburn	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
without	I-P	ADP	O
erosive	I-P	ADJ	B
oesophagitis	I-P	NOUN	B
.	I-P	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
assess	O	VERB	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
esomeprazole	B-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
frequent	I-OUT	ADJ	B
heartburn	I-OUT	NOUN	B
for	I-P	ADP	O
>	I-P	NOUN	O
or	I-P	CCONJ	O
=	I-P	ADJ	O
6	I-P	NUM	O
months	I-P	NOUN	B
and	I-P	CCONJ	O
no	I-P	DET	O
evidence	I-P	NOUN	O
of	I-P	ADP	O
erosive	I-P	ADJ	B
oesophagitis	I-P	NOUN	I
on	I-P	ADP	O
endoscopy	I-P	NOUN	B
.	I-P	PUNCT	O


Secondary	O	ADJ	B
end-points	O	NOUN	B
included	O	VERB	O
the	O	DET	O
percentage	B-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn-free	I-OUT	ADJ	B
days	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
time	I-OUT	NOUN	O
to	I-OUT	ADP	O
first	I-OUT	ADV	O
and	I-OUT	CCONJ	O
sustained	I-OUT	ADJ	B
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
Patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
either	O	CCONJ	O
dose	O	NOUN	B
of	O	ADP	O
esomeprazole	B-I	NOUN	B
were	O	AUX	O
two	O	NUM	O
to	O	PART	O
three	O	NUM	O
times	O	NOUN	O
more	O	ADV	O
likely	O	ADJ	O
to	O	PART	O
achieve	O	VERB	O
complete	B-OUT	ADJ	O
resolution	I-OUT	NOUN	B
of	I-OUT	ADP	O
heartburn	I-OUT	NOUN	B
than	O	ADP	O
patients	O	NOUN	B
treated	O	VERB	B
with	O	ADP	I
placebo	B-I	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
Esomeprazole	B-I	PROPN	B
,	O	PUNCT	O
at	O	ADP	O
daily	O	ADJ	B
doses	O	NOUN	I
of	O	ADP	O
40	O	NUM	O
mg	O	NOUN	O
or	O	CCONJ	O
20	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
is	O	AUX	O
effective	B-OUT	ADJ	B
and	I-OUT	CCONJ	O
safe	I-OUT	ADJ	O
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
chronic	B-OUT	ADJ	B
heartburn	I-OUT	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
without	I-P	ADP	O
erosive	I-P	ADJ	B
oesophagitis	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
results	O	NOUN	B
are	O	AUX	O
discussed	O	VERB	O
with	O	ADP	O
respect	O	NOUN	O
to	O	PART	O
the	O	DET	O
concept	B-OUT	NOUN	B
of	I-OUT	ADP	O
illness	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
pain	I-OUT	NOUN	B
as	O	ADP	O
a	O	DET	O
setting	O	NOUN	O
event	O	NOUN	B
for	O	ADP	O
problem	O	NOUN	B
behavior	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
need	O	NOUN	O
for	O	ADP	O
research	O	NOUN	B
to	O	PART	O
develop	O	VERB	O
algorithms	O	NOUN	B
that	O	PRON	O
allow	O	VERB	O
one	O	NUM	O
to	O	PART	O
select	O	VERB	O
the	O	DET	O
best	O	ADJ	O
combination	O	NOUN	B
of	O	ADP	O
medical	B-I	ADJ	B
and	I-I	CCONJ	O
behavioral	I-I	ADJ	B
interventions	I-I	NOUN	B
for	O	ADP	O
specific	O	ADJ	O
illnesses	O	NOUN	B
and	O	CCONJ	O
contexts	O	NOUN	B
is	O	AUX	O
noted	O	VERB	O
.	O	PUNCT	O


An	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
chemical	O	ADJ	B
arthrodesis	O	NOUN	I
of	O	ADP	O
the	O	DET	O
proximal	B-P	ADJ	B
interphalangeal	I-P	NOUN	I
joint	I-P	NOUN	I
in	I-P	ADP	O
the	I-P	DET	O
horse	I-P	NOUN	B
by	O	ADP	O
using	O	VERB	O
monoiodoacetate	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
use	O	NOUN	O
of	O	ADP	O
monoiodoacetate	B-I	NOUN	B
(	I-I	PUNCT	O
MIA	I-I	NOUN	B
)	I-I	PUNCT	O
for	O	ADP	O
arthrodesis	O	NOUN	B
of	O	ADP	O
the	O	DET	O
proximal	O	ADJ	B
interphalangeal	O	NOUN	I
joint	O	NOUN	I
(	O	PUNCT	O
PIJ	O	PROPN	B
)	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
exercise	O	NOUN	B
on	O	ADP	O
the	O	DET	O
degree	O	NOUN	B
of	O	ADP	O
fusion	O	NOUN	B
were	O	AUX	O
investigated	O	VERB	B
.	O	PUNCT	O


Eight	B-P	NUM	O
horses	I-P	NOUN	B
received	O	VERB	O
3	O	NUM	O
injections	O	NOUN	B
(	O	PUNCT	O
Weeks	O	PROPN	B
0	O	NUM	O
,	O	PUNCT	O
3	O	NUM	O
,	O	PUNCT	O
6	O	NUM	O
)	O	PUNCT	O
of	O	ADP	O
MIA	B-I	NOUN	B
(	O	PUNCT	O
2	O	NUM	O
mL	O	NOUN	O
;	O	PUNCT	O
60	O	NUM	O
mg/mL	O	NOUN	O
)	O	PUNCT	O
into	O	ADP	O
the	O	DET	O
right	O	ADJ	B
or	O	CCONJ	O
left	O	ADJ	B
front	O	ADJ	I
PIJ	O	PROPN	B
.	O	PUNCT	O


All	B-OUT	DET	O
5	I-OUT	NUM	O
horses	I-OUT	NOUN	B
showed	I-OUT	VERB	O
radiographic	I-OUT	ADJ	B
evidence	I-OUT	NOUN	B
of	I-OUT	ADP	O
bony	I-OUT	NOUN	B
fusion	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
however	I-OUT	ADV	O
,	I-OUT	PUNCT	O
no	I-OUT	DET	O
fusion	I-OUT	NOUN	B
was	I-OUT	AUX	O
present	I-OUT	ADJ	O
when	I-OUT	SCONJ	O
injected	I-OUT	VERB	B
joints	I-OUT	NOUN	I
were	I-OUT	AUX	O
examined	I-OUT	VERB	O
on	I-OUT	ADP	O
postmortem	I-OUT	NOUN	B
examination	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


INTRODUCTION	O	PUNCT	O
Current	O	ADJ	O
evidence	O	NOUN	B
suggests	O	VERB	O
that	O	SCONJ	O
Social	B-I	PROPN	B
Stories	I-I	PROPN	I
can	O	AUX	O
be	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
tackling	O	VERB	O
problem	B-OUT	NOUN	B
behaviours	I-OUT	NOUN	I
exhibited	O	VERB	O
by	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
.	I-P	PUNCT	O


Case	O	NOUN	B
reports	O	VERB	I
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
have	O	AUX	O
suggested	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
stories	O	NOUN	B
can	O	AUX	O
lead	O	VERB	O
to	O	ADP	O
a	O	DET	O
number	O	NOUN	O
of	O	ADP	O
benefits	O	NOUN	B
including	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
social	B-OUT	ADJ	B
interactions	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
choice	I-OUT	NOUN	O
making	I-OUT	VERB	O
in	O	ADP	O
educational	O	ADJ	B
settings	O	NOUN	I
.	O	PUNCT	O


Participants	B-P	NOUN	B
(	I-P	PUNCT	O
n=50	I-P	ADJ	O
)	I-P	PUNCT	O
will	I-P	AUX	O
be	I-P	AUX	O
randomised	I-P	VERB	B
to	I-P	PART	O
either	I-P	CCONJ	O
the	I-P	DET	O
Social	I-I	PROPN	B
Stories	I-I	PROPN	I
intervention	I-I	NOUN	B
or	I-I	CCONJ	O
a	I-I	DET	O
comparator	I-I	NOUN	B
group	I-I	NOUN	I
where	I-P	SCONJ	O
they	I-P	PRON	O
will	I-P	AUX	O
be	I-P	AUX	O
read	I-P	VERB	O
standard	I-P	ADJ	O
stories	I-P	NOUN	B
for	I-P	ADP	O
an	I-P	DET	O
equivalent	I-P	ADJ	O
amount	I-P	NOUN	B
of	I-P	ADP	O
time	I-P	NOUN	B
.	I-P	PUNCT	O


Statistics	O	NOUN	B
will	O	AUX	O
be	O	AUX	O
calculated	O	VERB	B
for	O	ADP	O
recruitment	B-OUT	NOUN	B
rates	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
follow-up	I-OUT	ADJ	B
rates	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
attrition	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Qualitative	O	ADJ	B
analysis	O	NOUN	I
will	O	AUX	O
ascertain	O	VERB	O
information	O	NOUN	B
on	O	ADP	O
perceptions	O	NOUN	B
about	O	ADP	O
the	O	DET	O
feasibility	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
acceptability	I-OUT	NOUN	B
of	O	ADP	O
the	O	DET	O
intervention	O	NOUN	B
.	O	PUNCT	O


Humans	B-P	NOUN	B
have	O	AUX	O
a	O	DET	O
remarkable	O	ADJ	O
ability	O	NOUN	O
to	O	PART	O
understand	O	VERB	O
spoken	O	VERB	B
language	O	NOUN	B
despite	O	SCONJ	O
the	O	DET	O
large	O	ADJ	O
amount	O	NOUN	O
of	O	ADP	O
variability	O	NOUN	B
in	O	ADP	O
speech	O	NOUN	B
.	O	PUNCT	O


Role	O	NOUN	O
of	O	ADP	O
warm	B-I	ADJ	B
saline	I-I	NOUN	I
mouth	I-I	NOUN	I
rinse	I-I	NOUN	B
in	O	ADP	O
prevention	O	NOUN	B
of	O	ADP	O
alveolar	B-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
controlled	O	VERB	I
trial	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
aimed	O	VERB	O
at	O	ADP	O
determining	O	VERB	O
the	O	DET	O
role	O	NOUN	O
warm	B-I	ADJ	B
saline	I-I	NOUN	I
rinse	I-I	NOUN	I
in	O	ADP	O
the	O	DET	O
prevention	B-OUT	NOUN	B
of	I-OUT	ADP	O
alveolar	I-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
following	O	VERB	O
dental	O	NOUN	B
extractions	O	NOUN	I
.	O	PUNCT	O


MATERIALS	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
Apparently	O	ADV	O
patients	B-P	NOUN	B
aged	I-P	ADJ	B
16	I-P	NUM	O
and	I-P	CCONJ	O
above	I-P	ADV	O
who	I-P	PRON	O
were	I-P	AUX	O
referred	I-P	VERB	O
to	I-P	ADP	O
the	I-P	DET	O
Oral	I-P	PROPN	B
Surgery	I-P	PROPN	I
Clinic	I-P	PROPN	B
of	I-P	ADP	O
our	I-P	PRON	O
institution	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
an	I-P	DET	O
indication	I-P	NOUN	B
for	I-P	ADP	O
non-surgical	I-P	ADJ	B
extraction	I-P	NOUN	I
of	I-P	ADP	O
pathologic	I-P	ADJ	B
teeth	I-P	NOUN	I
were	O	AUX	O
prospectively	O	ADV	O
and	O	CCONJ	O
uniformly	O	ADV	O
randomized	O	VERB	B
into	O	ADP	O
warm	B-I	ADJ	B
saline	I-I	NOUN	I
group	I-I	NOUN	I
and	O	CCONJ	O
control	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
experimental	B-P	ADJ	B
group	I-P	NOUN	I
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
80	I-P	NUM	O
)	I-P	PUNCT	O
were	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
gargle	B-I	VERB	B
6	I-I	NUM	O
times	I-I	NOUN	O
daily	I-I	ADV	O
with	I-I	ADP	O
warm	I-I	ADJ	B
saline	I-I	NOUN	I
and	O	CCONJ	O
no	B-I	DET	O
such	I-I	ADJ	O
instructions	I-I	NOUN	B
were	O	AUX	O
given	O	VERB	O
to	O	ADP	O
the	O	DET	O
second	B-P	ADJ	O
group	I-P	NOUN	B
(	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
80	I-P	NUM	O
)	I-P	PUNCT	O
to	O	PART	O
serve	O	VERB	O
as	O	ADP	O
controls	B-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSION	O	NOUN	O
Warm	B-I	ADJ	B
saline	I-I	NOUN	I
mouth	I-I	NOUN	I
rinse	I-I	NOUN	B
instruction	O	NOUN	B
is	O	AUX	O
beneficial	O	ADJ	O
in	O	ADP	O
the	O	DET	O
prevention	O	NOUN	B
of	O	ADP	O
development	O	NOUN	B
of	O	ADP	O
alveolar	B-OUT	ADJ	B
osteitis	I-OUT	NOUN	I
after	O	ADP	O
dental	O	NOUN	B
extractions	O	NOUN	I
.	O	PUNCT	O


Subjects/Study	O	NOUN	B
interventions	O	NOUN	I
:	O	PUNCT	O
Forty-one	B-P	NUM	O
(	I-P	PUNCT	O
41	I-P	NUM	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


CONCLUSIONS	O	NOUN	O
Acupuncture	B-I	NOUN	B
of	I-I	ADP	O
CV24	I-I	PROPN	B
is	O	AUX	O
an	O	DET	O
easy	O	ADJ	O
to	O	PART	O
apply	O	VERB	O
and	O	CCONJ	O
effective	O	ADJ	B
method	O	NOUN	B
to	O	PART	O
reduce	O	VERB	O
gag	B-OUT	NOUN	B
reflex	I-OUT	NOUN	I
during	O	ADP	O
TEE	O	NOUN	B
.	O	PUNCT	O


A	O	DET	O
rigorous	O	ADJ	O
statistical	O	ADJ	B
method	O	NOUN	I
of	O	ADP	O
scale	O	NOUN	O
construction	O	NOUN	B
consisting	O	VERB	O
of	O	ADP	O
a	O	DET	O
modification	O	NOUN	B
of	O	ADP	O
the	O	DET	O
scale	O	NOUN	B
discrimination	O	NOUN	I
technique	O	NOUN	I
was	O	AUX	O
employed	O	VERB	O
,	O	PUNCT	O
resulting	O	VERB	O
in	O	ADP	O
a	O	DET	O
45-item	B-I	ADJ	B
questionnaire	I-I	NOUN	I
representing	O	VERB	O
three	O	NUM	O
orthogonally	O	ADV	O
derived	O	VERB	O
scales	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
Physiological	O	ADJ	B
Tension	O	NOUN	I
Scale	O	NOUN	I
detected	O	VERB	O
significant	O	ADJ	O
increases	O	NOUN	B
in	O	ADP	O
tension	B-OUT	NOUN	B
following	O	VERB	O
tension	O	NOUN	B
inducement	O	NOUN	B
,	O	PUNCT	O
whereas	O	SCONJ	O
the	O	DET	O
Physical	O	PROPN	B
Assessment	O	PROPN	I
Scale	O	PROPN	I
and	O	CCONJ	O
Cognitive	O	ADJ	B
Tension	O	NOUN	I
Scale	O	NOUN	I
detected	O	VERB	B
increases	O	NOUN	B
in	O	ADP	O
relaxation	B-OUT	NOUN	B
following	O	VERB	O
relaxation	B-I	NOUN	B
training	I-I	NOUN	I
.	I-I	PUNCT	O


Randomized	O	ADJ	B
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
secondhand	B-I	NOUN	B
smoke	I-I	NOUN	I
exposure	I-I	NOUN	B
reduction	I-I	NOUN	B
intervention	I-I	NOUN	B
among	O	ADP	O
hospital-based	B-P	ADJ	B
pregnant	I-P	ADJ	I
women	I-P	NOUN	I
.	I-P	PUNCT	O


OBJECTIVE	O	VERB	O
This	O	DET	O
study	O	NOUN	B
sought	O	VERB	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
a	O	DET	O
secondhand	B-I	NOUN	B
tobacco	I-I	NOUN	I
smoke	I-I	NOUN	I
(	I-I	PUNCT	O
SHS	I-I	NOUN	B
)	I-I	PUNCT	O
prevention	I-I	NOUN	B
program	I-I	NOUN	I
based	O	VERB	O
on	O	ADP	O
an	O	DET	O
expanded	O	VERB	O
Health	B-OUT	PROPN	B
Belief	I-OUT	PROPN	I
Model	I-OUT	PROPN	I
(	O	PUNCT	O
HBM	O	PROPN	B
)	O	PUNCT	O
incorporating	O	VERB	O
self-efficacy	O	NOUN	B
among	O	ADP	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
in	I-P	ADP	O
a	I-P	DET	O
hospital	I-P	NOUN	B
setting	I-P	NOUN	I
in	I-P	ADP	O
Taiwan	I-P	PROPN	B
.	I-P	PUNCT	O


METHODOLOGY	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
utilized	O	VERB	O
a	O	DET	O
two-group	B-P	ADJ	B
longitudinal	I-P	ADJ	O
randomized	I-P	ADJ	O
controlled	O	VERB	O
trial	O	NOUN	O
design	O	NOUN	B
.	O	PUNCT	O


Both	B-I	DET	O
groups	I-I	NOUN	B
were	I-I	AUX	O
given	I-I	VERB	O
questionnaires	I-OUT	NOUN	B
as	I-I	ADP	O
a	I-I	DET	O
pre-test	I-I	NOUN	B
,	I-I	PUNCT	O
two	I-I	NUM	O
weeks	I-I	NOUN	B
into	I-I	ADP	O
the	I-I	DET	O
intervention	I-I	NOUN	B
,	I-I	PUNCT	O
and	I-I	CCONJ	O
one	I-I	NUM	O
month	I-I	NOUN	B
following	I-I	VERB	O
the	I-I	DET	O
conclusion	I-I	NOUN	O
of	I-I	ADP	O
the	I-I	DET	O
intervention	I-I	NOUN	B
.	I-I	PUNCT	O


CONCLUSIONS	O	NOUN	O
These	O	DET	O
results	O	NOUN	B
should	O	AUX	O
encourage	O	VERB	O
health	O	NOUN	B
professionals	O	NOUN	I
to	O	PART	O
educate	O	VERB	O
pregnant	B-P	ADJ	B
women	I-P	NOUN	I
regarding	O	VERB	O
the	O	DET	O
harms	O	NOUN	B
of	O	ADP	O
SHS	O	PROPN	B
while	O	SCONJ	O
both	O	DET	O
empowering	O	VERB	B
and	O	CCONJ	O
equipping	O	VERB	B
them	O	PRON	O
with	O	ADP	O
the	O	DET	O
tools	O	NOUN	B
to	O	PART	O
confront	O	VERB	O
their	O	PRON	O
family	O	NOUN	B
members	O	NOUN	I
and	O	CCONJ	O
effectively	O	ADV	O
reduce	O	VERB	O
their	O	PRON	O
SHS	B-OUT	PROPN	B
exposure	I-OUT	NOUN	B
while	O	SCONJ	O
promoting	O	VERB	B
smoke-free	O	ADJ	B
social	O	ADJ	B
norms	O	NOUN	I
.	O	PUNCT	O


BACKGROUND	O	NOUN	O
AND	O	CCONJ	O
OBJECTIVE	O	NOUN	O
This	O	DET	O
study	O	NOUN	B
was	O	AUX	O
designed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
of	O	ADP	O
monthly	O	ADJ	B
alternating	O	VERB	O
ABVD/MOPP	B-I	NOUN	B
compared	I-I	VERB	O
to	I-I	PART	O
ABVD/OPP	I-I	DET	B
regimens	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
advanced	I-P	ADJ	B
stage	I-P	NOUN	I
Hodgkin	I-P	NOUN	B
's	I-P	PART	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
HD	I-P	NOUN	B
)	I-P	PUNCT	O
,	I-P	PUNCT	O
as	I-P	ADV	O
well	I-P	ADV	O
as	I-P	ADP	O
in	I-P	ADP	O
early	I-P	ADJ	B
stage	I-P	NOUN	I
patients	I-P	NOUN	B
with	I-P	ADP	O
systemic	I-P	ADJ	B
symptoms	I-P	NOUN	I
and/or	I-P	CCONJ	O
bulky	I-P	ADJ	B
disease	I-P	NOUN	I
.	I-P	PUNCT	O


DESIGN	O	NOUN	O
AND	O	CCONJ	O
METHODS	O	NOUN	O
218	B-P	NUM	O
patients	I-P	NOUN	B
with	I-P	ADP	O
previously	I-P	ADV	O
untreated	I-P	ADJ	B
HD	I-P	NOUN	B
entered	I-P	VERB	O
this	I-P	DET	O
study	I-P	NOUN	B
:	I-P	PUNCT	O
106	I-P	NUM	O
patients	I-P	NOUN	B
in	I-P	ADP	O
arm	I-P	NOUN	B
A	I-P	NOUN	I
(	I-I	PUNCT	O
ABVD/MOPP	I-I	NOUN	B
)	I-I	PUNCT	O
and	I-P	CCONJ	O
112	I-P	NUM	O
in	I-P	ADP	O
arm	I-P	NOUN	B
B	I-P	NOUN	I
(	I-I	PUNCT	O
ABVD/OPP	I-I	PROPN	B
)	I-I	PUNCT	O
.	I-I	PUNCT	O


RESULTS	O	VERB	O
No	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
observed	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
arms	O	NOUN	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
CR	B-OUT	ADJ	B
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


INTERPRETATION	O	NOUN	B
AND	O	CCONJ	O
CONCLUSIONS	O	NOUN	O
Both	O	DET	O
schemes	O	NOUN	B
of	O	ADP	O
chemotherapy	O	NOUN	B
followed	O	VERB	O
by	O	ADP	O
radiotherapy	O	NOUN	B
produce	O	VERB	O
high	O	ADJ	O
percentages	O	NOUN	B
of	O	ADP	O
CR	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
low	I-OUT	ADJ	B
risk	I-OUT	NOUN	I
of	I-OUT	ADP	O
relapse	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
an	I-OUT	DET	O
acceptable	I-OUT	ADJ	O
toxicity	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


METHODS	O	NOUN	O
AND	O	CCONJ	O
MATERIALS	O	X	O
Toxicity	O	NOUN	B
data	O	NOUN	B
of	O	ADP	O
512	B-P	NUM	O
patients	I-P	NOUN	B
(	I-P	PUNCT	O
conformally	I-P	ADV	B
treated	I-P	VERB	B
to	I-P	PART	O
68	I-P	NUM	O
Gy	I-P	NOUN	O
[	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
284	I-P	NUM	O
]	I-P	PUNCT	O
and	I-P	CCONJ	O
78	I-P	NUM	O
Gy	I-P	NOUN	O
[	I-P	PUNCT	O
n	I-P	NOUN	O
=	I-P	ADJ	O
228	I-P	NUM	O
]	I-P	PUNCT	O
)	I-P	PUNCT	O
with	I-P	ADP	O
complete	I-P	ADJ	O
follow-up	I-P	NOUN	B
at	I-P	ADP	O
3	I-P	NUM	O
years	I-P	NOUN	B
after	I-P	ADP	O
radiotherapy	I-I	NOUN	B
were	I-P	AUX	O
studied	I-P	VERB	O
.	I-P	PUNCT	O


High	B-OUT	ADJ	B
stool	I-OUT	NOUN	B
frequency	I-OUT	NOUN	I
fits	O	VERB	O
only	O	ADV	O
benefitted	O	VERB	O
significantly	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.003-0.006	O	NUM	O
)	O	PUNCT	O
from	O	ADP	O
the	O	DET	O
inclusion	O	NOUN	B
of	O	ADP	O
the	O	DET	O
baseline	O	NOUN	B
toxicity	O	NOUN	B
score	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
primary	O	ADJ	B
outcome	O	NOUN	I
measure	O	NOUN	I
was	O	AUX	O
recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
fits	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
recurrence	B-OUT	NOUN	B
of	I-OUT	ADP	O
fits	I-OUT	NOUN	O
and	O	CCONJ	O
other	B-OUT	ADJ	O
maternal	I-OUT	ADJ	B
complications	I-OUT	NOUN	B
were	O	AUX	O
similar	B-OUT	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
.	O	PUNCT	O


PoC	O	PROPN	B
tests	O	NOUN	I
measured	O	VERB	B
(	O	PUNCT	O
and	O	CCONJ	O
devices	O	NOUN	B
used	O	VERB	O
)	O	PUNCT	O
in	O	ADP	O
the	O	DET	O
trial	O	NOUN	B
were	O	AUX	O
haemoglobin	B-OUT	NOUN	B
A1c	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
urine	I-OUT	NOUN	B
albumin	I-OUT	NOUN	I
:	I-OUT	PUNCT	O
creatinine	I-OUT	NOUN	B
ratio	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
DCA	I-OUT	NOUN	B
2000	I-OUT	NUM	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
lipids	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
Cholestech	I-OUT	NOUN	B
LDX	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
international	I-OUT	ADJ	B
normalized	I-OUT	VERB	O
ratio	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
CoaguChek	I-OUT	NOUN	B
S	I-OUT	PROPN	I
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


Median	B-OUT	ADJ	B
within-practice	I-OUT	NOUN	O
imprecision	I-OUT	NOUN	B
met	O	VERB	O
the	O	DET	O
analytical	O	ADJ	B
goals	O	NOUN	I
for	O	ADP	O
all	O	DET	O
PoC	O	PROPN	B
tests	O	NOUN	I
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
high-density	B-OUT	ADJ	B
lipoprotein-cholesterol	I-OUT	NOUN	I
(	I-OUT	PUNCT	I
HDL-C	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
where	O	SCONJ	O
observed	O	VERB	O
performance	O	NOUN	B
was	O	AUX	O
outside	O	ADP	O
the	O	DET	O
minimum	O	ADJ	B
goal	O	NOUN	B
for	O	ADP	O
one	O	NUM	O
level	O	NOUN	B
and	O	CCONJ	O
one	O	NUM	O
lot	O	NOUN	O
number	O	NOUN	O
of	O	ADP	O
QC	O	PROPN	B
.	O	PUNCT	O


Most	O	ADJ	O
practices	O	NOUN	B
achieved	O	VERB	O
the	O	DET	O
imprecision	B-OUT	NOUN	B
goals	O	NOUN	B
for	O	ADP	O
all	O	DET	O
analytes	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
the	O	DET	O
principal	O	ADJ	B
exception	O	NOUN	O
of	O	ADP	O
HDL-C	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


RESULTS	O	VERB	B
CS	O	ADJ	B
gel	O	NOUN	I
was	O	AUX	O
safe	O	ADJ	O
with	O	ADP	O
no	O	DET	O
reported	O	VERB	O
severe	B-OUT	ADJ	B
or	I-OUT	CCONJ	O
life-threatening	I-OUT	ADJ	B
adverse	I-OUT	ADJ	O
events	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
AE	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
.	I-OUT	PUNCT	O


The	O	DET	O
majority	O	NOUN	O
(	O	PUNCT	O
51	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
of	O	ADP	O
these	O	DET	O
participants	O	NOUN	B
reported	O	VERB	O
only	O	ADV	O
mild	B-OUT	ADJ	B
events	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Fewer	O	ADJ	O
women	O	NOUN	B
(	O	PUNCT	O
62	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
who	O	PRON	O
used	O	VERB	O
CS	O	PROPN	B
experienced	O	VERB	O
urogenital	B-OUT	ADJ	B
AE	I-OUT	NOUN	B
than	O	ADP	O
those	O	DET	O
assigned	O	VERB	O
to	O	PART	O
placebo	B-I	ADJ	B
gel	O	NOUN	I
(	O	PUNCT	O
70	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.59	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	O	DET	O
increase	O	NOUN	B
in	O	ADP	O
AE	B-OUT	NOUN	B
by	O	ADP	O
frequency	O	NOUN	B
of	O	ADP	O
gel	O	NOUN	B
use	O	NOUN	O
or	O	CCONJ	O
sexual	O	ADJ	B
activity	O	NOUN	I
with	O	ADP	O
the	O	DET	O
exception	O	NOUN	O
of	O	ADP	O
abdominal/pelvic	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
which	O	DET	O
was	O	AUX	O
noted	O	VERB	O
more	O	ADV	O
frequently	O	ADV	O
with	O	ADP	O
twice	O	ADV	O
daily	O	ADJ	B
use	O	NOUN	O
among	O	ADP	O
sexually	O	ADV	B
abstinent	O	VERB	I
women	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
Phase	O	NOUN	B
I	O	NUM	I
study	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
CS	B-I	ADJ	B
vaginal	I-I	ADJ	I
gel	I-I	NOUN	I
was	O	AUX	O
safe	B-OUT	ADJ	O
,	I-OUT	PUNCT	O
well	I-OUT	ADV	O
tolerated	I-OUT	VERB	B
and	I-OUT	CCONJ	O
acceptable	I-OUT	ADJ	B
by	O	ADP	O
HIV-infected	B-P	ADJ	B
women	I-P	NOUN	B
and	I-P	CCONJ	O
their	I-P	PRON	O
male	I-P	NOUN	B
partners	I-P	NOUN	B
.	I-P	PUNCT	O


Detection	O	NOUN	B
of	O	ADP	O
traumatic	O	ADJ	B
arthrotomy	O	NOUN	O
of	O	ADP	O
the	O	DET	O
knee	O	NOUN	B
using	O	VERB	O
the	O	DET	O
saline	B-I	NOUN	B
solution	I-I	NOUN	I
load	I-I	NOUN	O
test	I-I	NOUN	O
.	I-I	PUNCT	O


RESULTS	O	VERB	O
The	O	DET	O
study	O	NOUN	B
group	O	NOUN	I
included	O	VERB	O
thirty-one	B-P	NUM	O
female	I-P	ADJ	B
patients	I-P	NOUN	B
and	I-P	CCONJ	O
twenty-five	I-P	ADJ	O
male	I-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
a	I-P	DET	O
combined	I-P	ADJ	O
average	I-P	ADJ	O
age	I-P	NOUN	B
of	I-P	ADP	O
fifty	I-P	NUM	O
years	I-P	NOUN	B
and	I-P	CCONJ	O
an	I-P	DET	O
average	I-OUT	ADJ	B
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
of	I-P	ADP	O
30.9	I-P	NUM	O
.	I-P	PUNCT	O


There	O	PRON	O
was	O	AUX	O
no	B-OUT	DET	O
correlation	I-OUT	NOUN	B
between	I-OUT	ADP	O
necessary	I-OUT	ADJ	O
injection	I-OUT	NOUN	B
volume	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
sex	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
body	I-OUT	NOUN	B
mass	I-OUT	NOUN	I
index	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
or	I-OUT	CCONJ	O
knee	I-OUT	NOUN	B
circumference	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


AIM	O	NOUN	B
To	O	PART	O
investigate	O	VERB	B
the	O	DET	O
sustained	O	ADJ	B
effect	O	NOUN	B
on	O	ADP	O
quality	O	NOUN	B
of	O	ADP	I
life	O	NOUN	I
during	O	ADP	O
the	O	DET	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
the	O	DET	O
SQ-standardized	O	ADJ	B
grass	B-I	NOUN	I
allergy	I-I	NOUN	O
immunotherapy	I-I	NOUN	O
tablet	I-I	NOUN	B
(	I-I	PUNCT	O
AIT	I-I	NOUN	B
)	I-I	PUNCT	O
,	O	PUNCT	O
Graza	O	PROPN	B
(	O	PUNCT	O
Phleum	O	PROPN	B
pratense	O	NOUN	I
75,000	O	NUM	O
SQ-T/2800	O	NOUN	B
BAU	O	NOUN	B
;	O	PUNCT	O
ALK	O	NOUN	B
,	O	PUNCT	O
Denmark	O	PROPN	B
)	O	PUNCT	O
.	O	PUNCT	O


Subjects	B-P	NOUN	B
received	O	VERB	O
3	O	NUM	O
years	O	NOUN	B
of	O	ADP	O
grass	B-I	NOUN	B
AIT	I-I	PROPN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
157	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
placebo	B-I	NOUN	B
(	O	PUNCT	O
n	O	NOUN	O
=	O	ADJ	O
126	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
followed	O	VERB	O
by	O	ADP	O
1	O	NUM	O
year	O	NOUN	B
of	O	ADP	O
follow-up	O	NOUN	B
.	O	PUNCT	O


RESULTS	O	NOUN	B
During	O	ADP	O
follow-up	O	NOUN	B
,	O	PUNCT	O
the	O	DET	O
overall	O	ADJ	B
RQLQ	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
score	I-OUT	NOUN	O
for	O	ADP	O
the	O	DET	O
entire	O	ADJ	O
grass	O	NOUN	B
pollen	O	NOUN	B
season	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
improved	O	VERB	B
in	O	ADP	O
the	O	DET	O
active	O	ADJ	B
group	O	NOUN	I
(	O	PUNCT	O
relative	O	ADJ	O
difference	O	NOUN	O
to	O	PART	O
placebo	B-I	NOUN	B
:	I-I	PUNCT	O
23	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.004	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Improvements	O	NOUN	B
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
all	O	DET	O
seven	O	NUM	O
RQLQ	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
domains	I-OUT	NOUN	O
.	I-OUT	PUNCT	O


The	O	DET	O
RQLQ	B-OUT	NOUN	B
(	I-OUT	PUNCT	O
S	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
as	O	ADP	O
a	O	DET	O
function	O	NOUN	B
of	O	ADP	O
the	O	DET	O
weekly	O	ADJ	B
average	O	ADJ	O
pollen	O	NOUN	B
counts	O	NOUN	I
showed	O	VERB	O
a	O	DET	O
clear	O	ADJ	O
separation	O	NOUN	B
between	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Standard	O	PROPN	B
Trauma	B-I	PROPN	B
Focused	I-I	PROPN	B
Cognitive	I-I	PROPN	I
Behavioral	I-I	PROPN	I
Therapy	I-I	PROPN	I
may	O	AUX	O
be	O	AUX	O
insufficient	O	ADJ	B
for	O	ADP	O
children	O	NOUN	B
traumatized	O	VERB	B
by	O	ADP	O
exposure	O	NOUN	B
to	O	ADP	I
interparental	O	NOUN	B
violence	O	NOUN	I
,	O	PUNCT	O
given	O	VERB	O
the	O	DET	O
pervasive	O	ADJ	B
impact	O	NOUN	B
of	O	ADP	O
interparental	O	ADJ	B
violence	O	NOUN	I
on	O	ADP	O
the	O	DET	O
family	O	NOUN	B
system	O	NOUN	I
.	O	PUNCT	O


HORIZON	O	NOUN	B
is	O	AUX	O
a	O	DET	O
trauma	B-I	NOUN	B
focused	I-I	VERB	O
cognitive	I-I	ADJ	B
behavioral	I-I	ADJ	I
therapy	I-I	NOUN	I
based	O	VERB	O
group	O	NOUN	B
program	O	NOUN	I
with	O	ADP	O
the	O	DET	O
added	O	VERB	O
component	O	NOUN	O
of	O	ADP	O
a	O	DET	O
preparatory	B-I	ADJ	B
parenting	I-I	NOUN	B
program	I-I	NOUN	I
aimed	O	VERB	O
at	O	ADP	O
improving	O	VERB	B
parental	O	ADJ	B
availability	O	NOUN	B
;	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
added	O	VERB	O
component	O	NOUN	O
of	O	ADP	O
parent-child	O	ADJ	B
sessions	O	NOUN	B
to	O	PART	O
improve	O	VERB	B
parent-child	O	ADJ	B
interaction	O	NOUN	B
.	O	PUNCT	O


To	O	PART	O
address	O	VERB	O
this	O	DET	O
secondary	O	ADJ	O
aim	O	NOUN	O
,	O	PUNCT	O
the	O	DET	O
main	O	ADJ	O
parameters	O	NOUN	B
are	O	AUX	O
observational	O	ADJ	B
and	O	CCONJ	O
questionnaire	O	NOUN	B
measures	B-OUT	NOUN	B
of	I-OUT	ADP	O
parental	I-OUT	ADJ	B
availability	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
parent-child	I-OUT	ADJ	B
relationship	I-OUT	NOUN	B
variables	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
children	I-OUT	NOUN	B
's	I-OUT	PART	O
adjustment	I-OUT	NOUN	B
problems	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
children	I-OUT	NOUN	B
's	I-OUT	PART	I
responses	I-OUT	NOUN	B
to	O	PART	O
interparental	O	ADJ	B
violence	O	NOUN	I
.	O	PUNCT	O


Perioperative	B-OUT	ADJ	B
myocardial	I-OUT	ADJ	B
infarctions	I-OUT	NOUN	I
are	O	AUX	O
common	O	ADJ	O
and	O	CCONJ	O
often	O	ADV	O
unrecognized	O	ADJ	B
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
hip	I-P	NOUN	B
fracture	I-P	NOUN	I
surgery	I-P	NOUN	I
.	I-P	PUNCT	O


BACKGROUND	O	NOUN	O
The	O	DET	O
aim	O	NOUN	O
of	O	ADP	O
this	O	DET	O
prospective	O	ADJ	B
cohort	O	NOUN	I
study	O	NOUN	I
was	O	AUX	O
to	O	PART	O
assess	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
characteristics	O	NOUN	B
of	O	ADP	O
acute	O	ADJ	B
myocardial	O	ADJ	I
infarction	O	NOUN	I
in	O	ADP	O
patients	B-P	NOUN	B
undergoing	I-P	VERB	O
surgery	I-P	NOUN	B
for	I-P	ADP	O
acute	I-P	ADJ	B
hip	I-P	NOUN	I
fracture	I-P	NOUN	I
.	I-P	PUNCT	O


TnT	B-OUT	NOUN	B
elevation	I-OUT	NOUN	B
was	O	AUX	O
observed	O	VERB	O
in	O	ADP	O
36	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
51	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
already	O	ADV	O
before	O	ADP	O
surgery	O	NOUN	B
.	O	PUNCT	O


Seven	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
10	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
ST	B-OUT	NOUN	B
elevation	I-OUT	NOUN	O
myocardial	I-OUT	ADJ	O
infarction	I-OUT	NOUN	O
,	O	PUNCT	O
23	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
32	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
new	B-OUT	ADJ	O
ST	I-OUT	ADJ	B
depressions	I-OUT	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
21	O	NUM	O
patients	O	NOUN	B
(	O	PUNCT	O
30	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
had	O	AUX	O
no	O	DET	O
new	O	ADJ	O
ST	O	ADJ	B
segment	O	NOUN	B
changes	O	NOUN	B
in	O	ADP	O
the	O	DET	O
serial	O	ADJ	O
electrocardiographic	O	ADJ	B
recordings	O	NOUN	I
.	O	PUNCT	O


How	O	SCONJ	O
to	O	PART	O
establish	O	VERB	O
equivalence	O	NOUN	B
when	O	SCONJ	O
data	O	NOUN	B
are	O	AUX	O
censored	O	VERB	B
:	O	PUNCT	O
a	O	DET	O
randomized	B-P	ADJ	B
trial	I-P	NOUN	I
of	I-P	ADP	O
treatments	I-P	NOUN	B
for	I-P	ADP	O
B	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
.	I-P	PUNCT	O


An	O	DET	O
equivalence	O	ADJ	O
trial	O	NOUN	O
of	O	ADP	O
maintenance	B-I	NOUN	B
therapy	I-I	NOUN	I
was	O	AUX	O
carried	O	VERB	O
out	O	ADP	O
in	O	ADP	O
children	B-P	NOUN	B
with	I-P	ADP	O
B	I-P	NOUN	B
non-Hodgkin	I-P	ADJ	I
lymphoma	I-P	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
serves	O	VERB	O
as	O	ADP	O
an	O	DET	O
illustration	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
were	O	AUX	O
four	B-I	NUM	O
randomised	I-I	ADJ	B
treatment	I-I	NOUN	I
phases	I-I	NOUN	I
,	O	PUNCT	O
each	O	DET	O
of	O	ADP	O
4	O	NUM	O
weeks	O	NOUN	B
duration	O	NOUN	B
.	O	PUNCT	O


Ambulatory	B-OUT	ADJ	B
BP	I-OUT	NOUN	I
was	O	AUX	O
performed	O	VERB	O
in	O	ADP	O
the	O	DET	O
final	O	ADJ	O
week	O	NOUN	B
of	O	ADP	O
each	O	DET	O
phase	O	NOUN	B
.	O	PUNCT	O


There	O	PRON	O
was	O	AUX	O
a	O	DET	O
dose-dependent	O	ADJ	B
decrease	B-OUT	NOUN	B
in	I-OUT	ADP	O
ambulatory	I-OUT	ADJ	B
daytime	I-OUT	NOUN	I
diastolic	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
mean	I-OUT	VERB	O
arterial	I-OUT	ADJ	B
BP	I-OUT	NOUN	I
with	O	ADP	O
the	O	DET	O
progestogen	O	NOUN	B
treatments	O	NOUN	B
compared	O	VERB	B
with	O	ADP	O
placebo	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
authors	O	NOUN	B
assessed	O	VERB	B
the	O	DET	O
safety	B-OUT	NOUN	B
and	O	CCONJ	O
effectiveness	B-OUT	NOUN	B
of	O	ADP	O
atomoxetine	B-I	NOUN	B
monotherapy	O	NOUN	B
compared	O	VERB	O
with	O	ADP	O
combined	O	ADJ	O
atomoxetine/fluoxetine	B-I	NOUN	B
therapy	I-I	NOUN	I
in	O	ADP	O
a	O	DET	O
population	B-P	NOUN	B
of	I-P	ADP	O
children	I-P	NOUN	B
and	I-P	CCONJ	O
adolescents	I-P	NOUN	B
with	I-P	ADP	O
ADHD	I-P	NOUN	B
and	I-P	CCONJ	O
concurrent	I-P	ADJ	B
symptoms	I-P	NOUN	B
of	I-P	ADP	O
depression	I-P	NOUN	B
or	I-P	CCONJ	O
anxiety	I-P	NOUN	B
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
end	O	NOUN	O
point	O	NOUN	O
,	O	PUNCT	O
reductions	B-OUT	NOUN	B
in	I-OUT	ADP	O
ADHD	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
depressive	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
anxiety	I-OUT	NOUN	B
symptoms	I-OUT	NOUN	B
were	O	AUX	O
marked	O	VERB	O
for	O	ADP	O
both	O	CCONJ	O
treatment	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
.001	O	NUM	O
for	O	ADP	O
the	O	DET	O
relevant	O	ADJ	O
scale	O	NOUN	O
in	O	ADP	O
each	O	DET	O
symptom	O	NOUN	B
cluster	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
In	O	ADP	O
pediatric	B-P	ADJ	B
patients	I-P	NOUN	B
with	I-P	ADP	O
ADHD	I-P	NOUN	B
and	I-P	CCONJ	O
comorbid	I-P	ADJ	B
symptoms	I-P	NOUN	I
of	I-P	ADP	O
depression	I-P	NOUN	B
or	I-P	CCONJ	O
anxiety	I-P	NOUN	B
,	O	PUNCT	O
atomoxetine	B-I	NOUN	B
monotherapy	I-I	NOUN	B
appears	O	VERB	O
to	O	PART	O
be	O	AUX	O
effective	O	ADJ	B
for	O	ADP	O
treating	O	VERB	B
ADHD	O	NOUN	B
.	O	PUNCT	O


Anxiety	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
depressive	I-OUT	ADJ	B
symptoms	I-OUT	NOUN	I
also	O	ADV	O
improved	O	VERB	B
,	O	PUNCT	O
but	O	CCONJ	O
the	O	DET	O
absence	O	NOUN	B
of	O	ADP	O
a	O	DET	O
placebo-only	O	ADJ	O
arm	O	NOUN	O
does	O	AUX	O
not	O	PART	O
allow	O	VERB	O
us	O	PRON	O
to	O	PART	O
conclude	O	VERB	O
that	O	SCONJ	O
these	O	DET	O
effects	O	NOUN	B
are	O	AUX	O
specifically	O	ADV	O
the	O	DET	O
result	O	NOUN	O
of	O	ADP	O
treatment	O	NOUN	B
with	O	ADP	O
atomoxetine	B-I	NOUN	B
.	I-I	PUNCT	O


Double-blind	O	ADJ	B
comparison	O	NOUN	B
of	O	ADP	O
the	O	DET	O
efficacy	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
safety	I-OUT	NOUN	B
of	O	ADP	O
trandolapril	B-I	NOUN	B
2	O	NUM	I
mg	O	NOUN	I
and	O	CCONJ	O
hydrochlorothiazide	B-I	NOUN	B
25	O	NUM	O
mg	O	NOUN	O
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
mild-to-moderate	I-P	ADJ	B
essential	I-P	ADJ	I
hypertension	I-P	NOUN	I
.	I-P	PUNCT	O


This	O	DET	O
multicenter	O	NOUN	B
international	O	ADJ	I
trial	O	NOUN	I
recruited	O	VERB	O
205	B-P	NUM	O
patients	I-P	NOUN	B
from	I-P	ADP	O
16	I-P	NUM	O
investigators	I-P	NOUN	B
.	I-P	PUNCT	O


After	O	ADP	O
a	O	DET	O
4-week	O	NOUN	B
,	O	PUNCT	O
single-blind	B-I	ADJ	B
placebo	I-I	NOUN	B
run-in	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
were	O	AUX	O
randomized	O	VERB	B
to	O	PART	O
receive	O	VERB	O
16	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
trandolapril	B-I	NOUN	B
2	O	NUM	I
mg/day	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
hydrochlorothiazide	B-I	NOUN	B
(	I-I	PUNCT	O
HCTZ	I-I	NOUN	B
)	I-I	PUNCT	O
25	O	NUM	O
mg/day	O	NOUN	B
(	O	PUNCT	O
68	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
or	B-I	CCONJ	O
the	I-I	DET	O
combination	I-I	NOUN	B
(	O	PUNCT	O
69	O	NUM	O
patients	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Intention-to-treat	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
significant	O	ADJ	O
decreases	O	NOUN	B
in	O	ADP	O
all	O	DET	O
three	O	NUM	O
groups	O	NOUN	B
in	O	ADP	O
mean	O	NOUN	O
(	O	PUNCT	O
+/-	O	CCONJ	O
SEM	O	NOUN	B
)	O	PUNCT	O
supine	B-OUT	NOUN	B
DBP	I-OUT	NOUN	B
throughout	O	ADP	O
the	O	DET	O
study	O	NOUN	B
,	O	PUNCT	O
with	O	ADP	O
no	O	DET	B
significant	O	ADJ	I
differences	O	NOUN	O
at	O	ADP	O
week	O	NOUN	B
16	O	NUM	O
between	O	ADP	O
trandolapril	O	NOUN	B
(	O	PUNCT	O
-10.6	O	NUM	O
+/-	O	CCONJ	O
1.3	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
)	O	PUNCT	O
and	O	CCONJ	O
HCTZ	O	NOUN	B
(	O	PUNCT	O
-10.9	O	NUM	O
+/-	O	CCONJ	O
1.3	O	NUM	O
mm	O	NOUN	B
Hg	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


Blood	B-OUT	NOUN	B
pressure	I-OUT	NOUN	I
was	O	AUX	O
normalized	O	VERB	O
in	O	ADP	O
the	O	DET	O
combination	O	NOUN	B
group	O	NOUN	I
in	O	ADP	O
67	O	NUM	O
%	O	NOUN	O
of	O	ADP	O
patients	O	NOUN	B
,	O	PUNCT	O
a	O	DET	O
significantly	O	ADV	O
higher	O	ADJ	O
proportion	O	NOUN	B
than	O	ADP	O
either	O	CCONJ	O
trandolapril	O	NOUN	B
(	O	PUNCT	O
63	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
or	O	CCONJ	O
HCTZ	O	NOUN	B
(	O	PUNCT	O
60	O	NUM	O
%	O	NOUN	O
;	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.04	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	I
diltiazem	B-I	NOUN	B
and	I-I	CCONJ	O
propranolol	I-I	NOUN	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
unstable	I-P	ADJ	B
angina	I-P	NOUN	I
.	I-P	PUNCT	O


A	O	DET	O
coronary	B-I	ADJ	B
arteriography	I-I	NOUN	I
was	O	AUX	O
done	O	VERB	O
on	O	ADP	O
study	O	NOUN	B
entry	O	NOUN	I
.	O	PUNCT	O


RESULTS	O	VERB	B
A	O	DET	O
significative	O	ADJ	O
reduction	B-OUT	NOUN	B
of	I-OUT	ADP	O
angina	I-OUT	ADJ	B
crisis	I-OUT	NOUN	I
number	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
duration	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
intensity	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
sublingual	I-OUT	ADJ	B
nitrates	I-OUT	NOUN	B
doses	I-OUT	NOUN	B
were	O	AUX	O
observed	O	VERB	O
equally	O	ADV	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
SAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
DAP	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
HR	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
RR	I-OUT	NOUN	B
did	O	AUX	O
not	O	PART	O
show	O	VERB	O
statistical	O	ADJ	B
differences	O	NOUN	O
between	O	ADP	O
groups	O	NOUN	B
.	O	PUNCT	O


Individual	O	ADJ	B
groups	O	NOUN	O
analysis	O	NOUN	O
showed	O	VERB	O
significative	O	ADJ	O
reductions	B-OUT	NOUN	B
of	O	ADP	O
SAP	B-OUT	NOUN	B
,	I-OUT	PUNCT	O
DAP	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
HR	I-OUT	NOUN	B
in	O	ADP	O
propranolol	B-I	NOUN	B
group	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
CKMB	B-OUT	NOUN	B
data	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
ECG	I-OUT	PROPN	B
alterations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
coronary	I-OUT	ADJ	B
arteriography	I-OUT	NOUN	I
characteristics	O	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
.	O	PUNCT	O


Moisture-vapour-permeable	B-I	ADJ	B
film	I-I	NOUN	B
as	O	ADP	O
an	O	DET	O
outpatient	B-P	ADJ	B
burn	I-P	NOUN	B
dressing	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
two	B-P	NUM	O
treatment	I-P	NOUN	B
groups	I-P	NOUN	I
were	I-P	AUX	O
closely	I-P	ADV	O
matched	I-P	VERB	B
in	I-P	ADP	O
age	I-P	NOUN	B
,	I-P	PUNCT	O
sex	I-P	NOUN	B
,	I-P	PUNCT	O
per	I-P	ADP	O
cent	I-P	NOUN	O
of	I-P	ADP	O
BSA	I-P	NOUN	B
burned	I-P	VERB	B
,	I-P	PUNCT	O
and	I-P	CCONJ	O
in	I-P	ADP	O
burn	I-P	NOUN	B
severity	I-P	NOUN	B
and	I-P	CCONJ	O
locations	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
clinical	B-OUT	ADJ	B
infection	I-OUT	NOUN	I
rate	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
time	I-OUT	NOUN	B
to	I-OUT	ADP	O
healing	I-OUT	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
both	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


Patients	O	NOUN	B
completed	O	VERB	O
a	O	DET	O
questionnaire	B-I	NOUN	B
before	O	ADP	O
and	O	CCONJ	O
1	O	NUM	O
year	O	NOUN	B
after	O	ADP	O
surgery	O	NOUN	B
to	O	PART	O
evaluate	O	VERB	B
symptoms	O	NOUN	B
,	O	PUNCT	O
function	O	NOUN	B
,	O	PUNCT	O
and	O	CCONJ	O
overall	O	ADJ	B
satisfaction	O	NOUN	I
.	O	PUNCT	O


The	O	DET	O
patients	O	NOUN	B
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
experienced	O	VERB	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain/discomfort	I-OUT	NOUN	O
as	O	ADP	O
scored	O	VERB	B
by	O	ADP	O
pain	B-OUT	NOUN	B
during	I-OUT	ADP	O
bowel	I-OUT	NOUN	B
movement	I-OUT	NOUN	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
total	B-OUT	ADJ	B
analgesic	I-OUT	NOUN	I
requirement	I-OUT	NOUN	I
over	I-OUT	ADP	O
the	I-OUT	DET	O
first	I-OUT	ADJ	O
3	I-OUT	NUM	O
days	I-OUT	NOUN	B
(	O	PUNCT	O
according	O	VERB	O
to	O	ADP	O
the	O	DET	O
World	O	PROPN	B
Health	O	PROPN	I
Organization	O	PROPN	I
[	O	PUNCT	O
WHO	O	PRON	B
]	O	PUNCT	O
class	O	NOUN	B
II	O	NUM	I
analgesics	O	NOUN	I
[	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.002	O	NUM	O
]	O	PUNCT	O
;	O	PUNCT	O
class	O	NOUN	B
III	O	NUM	I
[	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.066	O	NUM	O
]	O	PUNCT	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
per-patient	O	ADJ	B
consumption	O	NOUN	B
frequency	O	NOUN	I
of	O	ADP	O
class	O	NOUN	B
III	O	NUM	I
analgesics	O	NOUN	I
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.089	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


A	O	DET	O
clear	O	ADJ	O
difference	O	NOUN	O
in	O	ADP	O
morphine	B-OUT	NOUN	B
requirement	I-OUT	NOUN	B
became	O	VERB	O
evident	O	ADJ	O
after	O	ADP	O
24	O	NUM	O
hours	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.010	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Hospital	B-OUT	PROPN	B
stay	I-OUT	VERB	I
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	B
in	O	ADP	O
the	O	DET	O
SH	B-I	NOUN	B
group	O	NOUN	B
(	O	PUNCT	O
SH	O	NOUN	B
2.2	O	NUM	O
+/-	O	CCONJ	O
1.2	O	NUM	O
[	O	PUNCT	O
0	O	NUM	O
;	O	PUNCT	O
5.0	O	NUM	O
]	O	PUNCT	O
versus	O	CCONJ	O
MM	B-I	NOUN	B
3.1	O	NUM	O
+/-	O	CCONJ	O
1.7	O	NUM	O
[	O	PUNCT	O
1	O	NUM	O
;	O	PUNCT	O
8.0	O	NUM	O
]	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Stapled	B-I	PROPN	B
hemorrhoidopexy	I-I	NOUN	I
causes	O	VERB	O
significantly	O	ADV	O
less	O	ADV	O
postoperative	B-OUT	ADJ	B
pain	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


The	O	DET	O
technique	O	NOUN	B
is	O	AUX	O
reproducible	O	ADJ	O
and	O	CCONJ	O
can	O	AUX	O
achieve	O	VERB	O
comparable	O	ADJ	O
outcomes	B-OUT	NOUN	B
as	O	ADP	O
those	O	DET	O
of	O	ADP	O
the	O	DET	O
MM	B-I	NOUN	B
technique	O	NOUN	B
as	O	ADV	O
long	O	ADV	O
as	O	ADP	O
the	O	DET	O
well-described	O	ADJ	O
steps	O	NOUN	O
of	O	ADP	O
the	O	DET	O
technique	O	NOUN	B
are	O	AUX	O
followed	O	VERB	O
.	O	PUNCT	O


Its	O	PRON	O
effectiveness	B-OUT	NOUN	B
in	O	ADP	O
relieving	O	VERB	B
symptoms	O	NOUN	B
is	O	AUX	O
equivalent	O	ADJ	O
to	O	PART	O
conventional	O	ADJ	B
surgery	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
the	O	DET	O
number	B-OUT	NOUN	O
of	I-OUT	ADP	O
hemorrhoidal	I-OUT	ADJ	B
prolapse	I-OUT	NOUN	I
recurrences	I-OUT	NOUN	B
at	I-OUT	ADP	O
2	I-OUT	NUM	O
years	I-OUT	NOUN	B
is	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
.	O	PUNCT	O


Hemorroidopexy	B-I	PROPN	B
is	O	AUX	O
applicable	O	ADJ	O
for	O	ADP	O
treating	O	VERB	B
reducible	O	ADJ	B
hemorrhoidal	O	ADJ	I
prolapse	O	NOUN	I
.	O	PUNCT	O


In	O	ADP	O
this	O	DET	O
study	O	NOUN	B
we	O	PRON	O
examined	O	VERB	O
the	O	DET	O
social	O	ADJ	B
behaviors	O	NOUN	I
of	O	ADP	O
4-	B-P	NUM	O
to	I-P	PART	O
12-year-old	I-P	ADJ	O
children	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
;	I-P	PUNCT	O
N	I-P	NOUN	O
=	I-P	ADJ	O
24	I-P	NUM	O
)	I-P	PUNCT	O
during	O	ADP	O
three	O	NUM	O
tradic	O	ADJ	B
interactions	O	NOUN	B
with	O	ADP	O
an	B-I	DET	O
adult	I-I	ADJ	B
confederate	I-I	NOUN	B
and	I-I	CCONJ	O
an	I-I	DET	O
interaction	I-I	NOUN	B
partner	I-I	NOUN	O
,	O	PUNCT	O
where	O	SCONJ	O
the	O	DET	O
interaction	O	NOUN	B
partner	O	NOUN	O
varied	O	VERB	O
randomly	O	ADV	O
among	O	ADP	O
(	B-I	PUNCT	O
1	I-I	X	O
)	I-I	PUNCT	O
another	I-I	DET	O
adult	I-I	ADJ	B
human	I-I	ADJ	B
,	I-I	PUNCT	O
(	I-I	PUNCT	O
2	I-I	X	O
)	I-I	PUNCT	O
a	I-I	DET	O
touchscreen	I-I	NOUN	B
computer	I-I	NOUN	I
game	I-I	NOUN	I
,	I-I	PUNCT	O
and	I-I	CCONJ	O
(	I-I	PUNCT	O
3	I-I	X	O
)	I-I	PUNCT	O
a	I-I	DET	O
social	I-I	ADJ	B
dinosaur	I-I	NOUN	I
robot	I-I	NOUN	I
.	O	PUNCT	O


The	O	DET	O
median	B-OUT	ADJ	B
neutrophil	I-OUT	NOUN	B
count	I-OUT	NOUN	O
at	O	ADP	O
14	O	NUM	O
days	O	NOUN	B
was	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
GM	B-I	PROPN	B
CSF	I-I	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
1.90	O	NUM	O
vs.	O	CCONJ	O
0.46	O	NUM	O
x	O	NOUN	O
10	O	NUM	O
(	O	PUNCT	O
9	O	NUM	O
)	O	PUNCT	O
/l	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Tumor	B-OUT	NOUN	B
budding	I-OUT	NOUN	I
is	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
outcome	O	NOUN	B
in	O	ADP	O
AJCC/UICC	B-P	NOUN	B
stage	I-P	NOUN	I
II	I-P	NUM	I
colorectal	I-P	NOUN	I
cancer	I-P	NOUN	I
.	I-P	PUNCT	O


For	O	ADP	O
multivariable	B-I	ADJ	B
analysis	I-I	NOUN	I
,	O	PUNCT	O
Cox	O	PROPN	B
's	O	PART	I
proportional	O	ADJ	B
hazards	O	NOUN	I
regression	O	NOUN	I
models	O	NOUN	I
were	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Cox	O	PROPN	B
's	O	PART	I
proportional	O	ADJ	B
hazards	O	NOUN	I
regression	O	NOUN	I
models	O	NOUN	I
proved	O	VERB	O
tumor	B-I	NOUN	B
budding	I-I	NOUN	I
to	O	PART	O
be	O	AUX	O
an	O	DET	O
independent	O	ADJ	O
predictor	O	NOUN	B
of	O	ADP	O
disease	B-OUT	NOUN	B
progression	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
3.91	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.3-11.77	O	NOUN	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.02	O	NUM	O
)	O	PUNCT	O
and	B-OUT	CCONJ	O
cancer-related	I-OUT	ADJ	B
death	I-OUT	NOUN	I
(	O	PUNCT	O
hazard	O	NOUN	B
ratio	O	NOUN	I
5.90	O	NUM	O
,	O	PUNCT	O
95	O	NUM	O
%	O	NOUN	O
confidence	O	NOUN	B
interval	O	NOUN	I
1.62-21.51	O	NUM	O
;	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.007	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


Early	O	ADV	B
versus	O	CCONJ	O
late	O	ADJ	B
hCG	B-I	NOUN	B
administration	I-I	NOUN	B
to	O	PART	O
trigger	O	VERB	B
ovulation	O	NOUN	B
in	O	ADP	O
mild	O	ADJ	B
stimulated	O	ADJ	O
IUI	O	NOUN	B
cycles	O	NOUN	B
:	O	PUNCT	O
a	O	DET	O
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
.	O	PUNCT	O


OBJECTIVES	O	NOUN	O
To	O	PART	O
verify	O	VERB	O
non-inferiority	O	NOUN	B
of	O	ADP	O
the	O	DET	O
clinical	O	ADJ	B
pregnancy	O	NOUN	I
rate	O	NOUN	O
of	O	ADP	O
Early	B-I	ADJ	B
hCG	I-I	NOUN	B
administration	I-I	NOUN	B
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
16.0-16.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
compared	O	VERB	O
to	O	PART	O
Late	B-I	ADJ	B
hCG	I-I	NOUN	I
administration	I-I	NOUN	I
(	O	PUNCT	O
leading	O	VERB	O
follicle	O	NOUN	B
sizes	O	NOUN	B
within	O	ADP	O
18.0-18.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
diameter	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Six	B-P	NUM	O
hundred	I-P	NUM	O
and	I-P	CCONJ	O
twelve	I-P	NUM	O
infertile	I-P	ADJ	B
women	I-P	NOUN	B
candidates	I-P	NOUN	O
for	I-P	ADP	O
intrauterine	I-P	NOUN	B
insemination	I-P	NOUN	I
(	I-P	PUNCT	O
IUI	I-P	NOUN	B
)	I-P	PUNCT	O
received	O	VERB	O
HP-hMG	B-I	NOUN	B
75	O	NUM	O
IU/day	O	NOUN	O
SC	O	NOUN	B
from	O	ADP	O
cycle	O	NOUN	B
days	O	NOUN	I
4	O	NUM	O
to	O	PART	O
8	O	NUM	O
and	O	CCONJ	O
then	O	ADV	O
as	O	ADP	O
per	O	ADP	O
ovarian	O	ADJ	B
response	O	NOUN	I
.	O	PUNCT	O


Ovulation	O	NOUN	B
was	O	AUX	O
randomly	O	ADV	O
triggered	O	VERB	O
(	O	PUNCT	O
hCG	O	NOUN	B
5000	O	NUM	O
IU	O	NOUN	B
,	O	PUNCT	O
IM	O	NOUN	B
)	O	PUNCT	O
when	O	SCONJ	O
the	O	DET	O
leading	O	VERB	O
follicle	O	NOUN	B
diameter	O	NOUN	B
ranged	O	VERB	O
between	O	ADP	O
either	O	CCONJ	O
16.0	O	NUM	O
and	O	CCONJ	O
16.9	O	NUM	O
mm	O	PROPN	O
(	O	PUNCT	O
Early	O	ADJ	B
hCG	B-I	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
n=227	O	PROPN	O
)	O	PUNCT	O
or	O	CCONJ	O
18.0	O	NUM	O
and	O	CCONJ	O
18.9	O	NUM	O
mm	O	NOUN	O
(	O	PUNCT	O
Late	O	ADJ	B
hCG	O	NOUN	I
group	O	NOUN	I
,	O	PUNCT	O
n=207	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
IUI	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
approximately	O	ADV	O
36	O	NUM	O
h	O	NOUN	O
later	O	ADV	O
.	O	PUNCT	O


Clinical	O	NOUN	B
(	O	PUNCT	O
11.9	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
12.1	O	NUM	O
%	O	NOUN	O
)	O	PUNCT	O
and	O	CCONJ	O
ongoing	O	ADJ	B
(	O	PUNCT	O
11.0	O	NUM	O
%	O	NOUN	O
versus	O	CCONJ	O
8.6	B-OUT	NUM	O
%	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
pregnancy	I-OUT	NOUN	B
rates	I-OUT	NOUN	I
per	O	ADP	O
randomized	B-P	ADJ	B
women	I-P	NOUN	B
were	O	AUX	O
similar	O	ADJ	O
in	O	ADP	O
the	O	DET	O
two	O	NUM	O
groups	O	NOUN	B
and	O	CCONJ	O
statistical	O	ADJ	B
non-inferiority	O	NOUN	B
of	B-OUT	ADP	O
clinical	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
ongoing	I-OUT	ADJ	O
pregnancy	I-OUT	NOUN	B
rates	O	NOUN	I
was	O	AUX	O
demonstrated	O	VERB	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
These	O	DET	O
results	O	NOUN	B
suggest	O	VERB	O
that	B-I	SCONJ	O
hCG	I-I	NOUN	B
administered	O	VERB	B
when	O	SCONJ	O
the	O	DET	O
largest	O	ADJ	O
follicle	O	NOUN	B
size	O	NOUN	B
reaches	O	VERB	O
16.0-16.9	O	NUM	O
mm	O	NOUN	O
leads	O	VERB	O
to	O	PART	O
similar	O	ADJ	O
clinical	O	ADJ	B
and	O	CCONJ	O
ongoing	O	ADJ	O
pregnancy	O	NOUN	B
rates	O	NOUN	I
as	O	ADP	O
when	O	SCONJ	O
it	O	PRON	O
reaches	O	VERB	O
18.0-18.9	O	NUM	O
mm	O	NOUN	O
in	O	ADP	O
IUI	O	NOUN	B
cycles	O	NOUN	B
.	O	PUNCT	O


Managing	O	VERB	O
repetitive	O	ADJ	B
behaviours	O	NOUN	I
in	O	ADP	O
young	B-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorder	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
:	I-P	PUNCT	O
pilot	O	NOUN	B
randomised	O	VERB	I
controlled	O	ADJ	I
trial	O	NOUN	I
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
parent	B-P	NOUN	B
group	O	NOUN	B
intervention	O	NOUN	B
.	O	PUNCT	O


We	O	PRON	O
report	O	VERB	O
the	O	DET	O
acceptability	O	NOUN	B
,	O	PUNCT	O
feasibility	O	NOUN	B
and	O	CCONJ	O
impact	O	VERB	B
on	O	ADP	O
child	O	NOUN	B
functioning	O	NOUN	B
of	O	ADP	O
a	O	DET	O
new	O	ADJ	O
8	B-I	NUM	O
weeks	I-I	NOUN	B
parent-group	I-I	ADJ	B
intervention	I-I	NOUN	I
to	I-I	PART	O
manage	I-I	VERB	O
restricted	I-I	ADJ	B
and	I-I	CCONJ	O
repetitive	I-I	ADJ	B
behaviours	I-I	NOUN	I
(	I-P	PUNCT	O
RRB	I-P	NOUN	B
)	I-P	PUNCT	O
in	I-P	ADP	O
young	I-P	ADJ	B
children	I-P	NOUN	O
with	I-P	ADP	O
ASD	I-P	VERB	B
aged	I-P	ADJ	B
3-7	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Fidelity	B-OUT	NOUN	B
of	I-OUT	ADP	O
delivery	I-OUT	NOUN	B
was	I-OUT	AUX	O
high	I-OUT	ADJ	B
,	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
attendance	I-OUT	NOUN	B
was	O	AUX	O
90	O	NUM	O
%	O	NOUN	O
.	O	PUNCT	O


BACKGROUND	O	NOUN	B
In	O	ADP	O
1998	O	NUM	O
,	O	PUNCT	O
mandatory	O	ADJ	O
folic	O	ADJ	B
acid	O	NOUN	I
fortification	O	NOUN	B
of	O	ADP	O
white	B-I	ADJ	B
flour	I-I	NOUN	I
and	I-I	CCONJ	O
select	I-I	VERB	O
cereal	I-I	NOUN	B
grain	I-I	NOUN	O
products	I-I	NOUN	B
was	O	AUX	O
implemented	O	VERB	O
in	O	ADP	O
Canada	B-P	PROPN	B
with	O	ADP	O
the	O	DET	O
intention	O	NOUN	B
to	O	PART	O
increase	O	VERB	B
dietary	B-I	ADJ	B
folate	I-I	NOUN	B
intakes	I-I	NOUN	B
of	O	ADP	O
reproducing	B-P	VERB	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
this	O	DET	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
how	O	SCONJ	O
predictive	O	ADJ	B
blood	B-OUT	NOUN	B
folate	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
folate	I-OUT	NOUN	B
intakes	I-OUT	NOUN	O
are	O	AUX	O
of	O	ADP	O
each	O	DET	O
other	O	ADJ	O
in	O	ADP	O
a	O	DET	O
sample	O	NOUN	B
of	O	ADP	O
well-educated	B-P	ADJ	O
lactating	I-P	VERB	B
Canadian	I-P	ADJ	B
women	I-P	NOUN	B
exposed	I-P	VERB	B
to	I-P	PART	I
high	I-P	ADJ	O
levels	I-P	NOUN	B
of	I-P	ADP	O
synthetic	I-P	ADJ	B
folate	I-P	NOUN	I
.	I-P	PUNCT	O


RESULTS	O	VERB	O
Median	O	ADJ	B
blood	B-OUT	NOUN	O
folate	I-OUT	NOUN	O
concentrations	I-OUT	NOUN	B
of	O	ADP	O
all	O	DET	O
participants	O	NOUN	B
were	O	AUX	O
well	O	ADV	O
above	O	ADJ	O
plasma	O	NOUN	B
and	O	CCONJ	O
RBC	O	NOUN	B
folate	O	NOUN	B
cut-off	O	ADJ	O
levels	O	NOUN	O
indicative	O	ADJ	O
of	O	ADP	O
deficiency	O	NOUN	B
(	O	PUNCT	O
6.7	O	NUM	O
and	O	CCONJ	O
317	O	NUM	O
nmol/L	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
and	O	CCONJ	O
all	O	DET	O
,	O	PUNCT	O
except	O	SCONJ	O
for	O	ADP	O
2	O	NUM	O
subjects	O	NOUN	B
,	O	PUNCT	O
were	O	AUX	O
above	O	ADP	O
the	O	DET	O
cut-off	O	NOUN	O
for	O	ADP	O
NTD-risk	O	ADJ	B
reduction	O	NOUN	B
(	O	PUNCT	O
>	O	NOUN	O
906	O	NUM	O
nmol/L	O	NOUN	O
)	O	PUNCT	O
.	O	PUNCT	O


Only	O	ADV	O
modest	O	ADJ	O
associations	O	NOUN	B
existed	O	VERB	O
between	O	ADP	O
total	B-OUT	ADJ	O
folate	I-OUT	NOUN	B
intakes	I-OUT	NOUN	O
and	O	CCONJ	O
plasma	B-OUT	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.46	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.001	O	NUM	O
)	O	PUNCT	O
and	O	CCONJ	O
RBC	O	NOUN	B
(	O	PUNCT	O
r	O	NOUN	O
=	O	ADJ	O
0.36	O	NUM	O
,	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
folate	B-OUT	NOUN	B
concentrations	I-OUT	NOUN	B
at	O	ADP	O
16-wk	O	ADJ	O
postpartum	O	NOUN	B
.	O	PUNCT	O


CONCLUSION	O	NOUN	O
Folate	B-OUT	NOUN	B
intakes	I-OUT	NOUN	B
,	O	PUNCT	O
estimated	O	VERB	O
by	O	ADP	O
food	O	NOUN	B
composition	O	NOUN	I
tables	O	NOUN	I
,	O	PUNCT	O
and	O	CCONJ	O
blood	B-OUT	NOUN	B
folate	I-OUT	NOUN	I
concentrations	I-OUT	NOUN	I
are	O	AUX	O
not	O	PART	O
predictive	O	ADJ	B
of	O	ADP	O
each	O	DET	O
other	O	ADJ	O
in	O	ADP	O
Canadian	O	ADJ	B
lactating	O	VERB	B
women	O	NOUN	B
exposed	O	VERB	B
to	O	PART	I
high	O	ADJ	O
levels	O	NOUN	B
of	O	ADP	O
folate	B-OUT	NOUN	B
.	I-OUT	PUNCT	O


Clinical	O	ADJ	B
and	O	CCONJ	O
radiographic	O	ADJ	B
evaluation	O	NOUN	B
of	O	ADP	O
guided	O	VERB	B
tissue	O	NOUN	I
regeneration	O	NOUN	I
in	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
class	B-P	NOUN	B
II	I-P	NUM	I
furcation	I-P	NOUN	I
defects	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	NOUN	O
To	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
treatment	O	NOUN	B
outcomes	B-OUT	NOUN	B
after	O	ADP	O
guided	B-I	VERB	B
tissue	I-I	NOUN	I
regeneration	I-I	NOUN	I
(	I-I	PUNCT	O
GTR	I-I	NOUN	B
)	I-I	PUNCT	O
with	O	ADP	O
a	O	DET	O
bioabsorbable	O	ADJ	B
membrane	O	NOUN	I
in	O	ADP	O
Class	B-P	NOUN	B
II	I-P	NUM	I
furcation	I-P	NOUN	B
defects	I-P	NOUN	B
in	O	ADP	O
mandibular	O	ADJ	B
molars	O	NOUN	I
.	O	PUNCT	O


METHODS	O	VERB	O
Nine	B-P	NUM	O
patients	I-P	NOUN	B
,	I-P	PUNCT	O
with	I-P	ADP	O
two	I-P	NUM	O
comparable	I-P	ADJ	O
Class	I-P	NOUN	B
II	I-P	NUM	I
furcation	I-P	NOUN	B
defects	I-P	NOUN	B
were	I-P	AUX	O
included	I-P	VERB	O
in	I-P	ADP	O
the	I-P	DET	O
study	I-P	NOUN	B
.	I-P	PUNCT	O


Comparing	O	VERB	B
the	O	DET	O
two	O	NUM	O
treatments	O	NOUN	B
,	O	PUNCT	O
no	O	DET	O
statistically	O	ADV	B
significant	O	ADJ	I
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
in	O	ADP	O
PD	B-OUT	NOUN	B
reduction	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
1.67	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
2.51	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.26	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
CAL-v	B-OUT	NOUN	B
gain	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
0.62	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.16	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P=	O	NOUN	O
0.37	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
and	O	CCONJ	O
GR	B-OUT	NOUN	B
increase	I-OUT	NOUN	B
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
1.04	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.24	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.31	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


GTR	B-I	NOUN	B
provided	O	VERB	O
complete	O	ADJ	O
closure	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
furcation	I-OUT	NOUN	B
defect	I-OUT	NOUN	O
in	O	ADP	O
two	O	NUM	O
sites	O	NOUN	B
and	O	CCONJ	O
superior	B-OUT	ADJ	B
horizontal	I-OUT	ADJ	B
clinical	I-OUT	ADJ	B
attachment	I-OUT	NOUN	O
level	I-OUT	NOUN	O
gain	I-OUT	NOUN	O
(	O	PUNCT	O
GTR	O	NOUN	B
:	O	PUNCT	O
2.27	O	NUM	O
mm	O	NOUN	O
;	O	PUNCT	O
OFD	O	NOUN	B
:	O	PUNCT	O
1.01	O	NUM	O
mm	O	NOUN	O
,	O	PUNCT	O
P	O	NOUN	O
=	O	ADJ	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


In	O	ADP	O
order	O	NOUN	O
to	O	PART	O
identify	O	VERB	O
healthcare	B-OUT	NOUN	B
resource	I-OUT	NOUN	O
use	I-OUT	NOUN	O
patterns	I-OUT	NOUN	O
associated	O	VERB	B
with	O	ADP	I
chronic	B-P	ADJ	B
obstructive	I-P	ADJ	I
pulmonary	I-P	ADJ	I
disease	I-P	NOUN	I
(	I-P	PUNCT	O
COPD	I-P	NOUN	B
)	I-P	PUNCT	O
,	O	PUNCT	O
resource	O	NOUN	B
utilization	O	NOUN	I
(	O	PUNCT	O
RU	O	NOUN	B
)	O	PUNCT	O
data	O	NOUN	B
collection	O	NOUN	I
was	O	AUX	O
integrated	O	VERB	O
into	O	ADP	O
a	O	DET	O
randomized	O	ADJ	B
,	O	PUNCT	O
double-blind	O	ADJ	B
placebo-controlled	B-I	ADJ	B
study	O	NOUN	I
of	O	ADP	O
Viozan	O	NOUN	B
(	O	PUNCT	O
sibenadet	O	NOUN	B
HCl	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Subsequent	O	ADJ	O
data	O	NOUN	B
were	O	AUX	O
collected	O	VERB	O
by	O	ADP	O
means	O	NOUN	O
of	O	ADP	O
an	O	DET	O
Interactive	B-OUT	PROPN	B
Voice	I-OUT	PROPN	I
Response	I-OUT	PROPN	I
System	I-OUT	PROPN	I
(	I-OUT	PUNCT	O
IVRS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
at	O	ADP	O
30-day	O	ADJ	O
intervals	O	NOUN	B
(	O	PUNCT	O
14	O	NUM	O
time	O	NOUN	O
points	O	NOUN	O
)	O	PUNCT	O
during	O	ADP	O
the	O	DET	O
study	O	NOUN	B
and	O	CCONJ	O
in	O	ADP	O
the	O	DET	O
follow-up	O	ADJ	B
period	O	NOUN	B
.	O	PUNCT	O


Physicians	O	NOUN	B
were	O	AUX	O
seen	O	VERB	O
to	O	PART	O
be	O	AUX	O
the	O	DET	O
most	O	ADV	O
common	O	ADJ	O
source	O	NOUN	B
of	O	ADP	O
care	O	NOUN	B
for	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
COPD	O	NOUN	B
and	O	CCONJ	O
more	O	ADJ	O
of	O	ADP	O
the	O	DET	O
patients	B-P	NOUN	B
with	I-P	ADP	O
severe	I-P	ADJ	B
COPD	I-P	NOUN	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
III	I-P	NUM	I
)	I-P	PUNCT	O
than	I-P	ADP	O
mild	I-P	ADJ	B
(	I-P	PUNCT	O
stage	I-P	NOUN	B
I	I-P	NUM	I
)	I-P	PUNCT	O
were	O	AUX	O
seen	O	VERB	O
to	O	PART	O
utilize	O	VERB	O
the	O	DET	O
most	O	ADV	O
expensive	O	ADJ	B
resources	O	NOUN	B
(	O	PUNCT	O
e.g	O	INTJ	O
.	O	PUNCT	O


This	O	DET	O
study	O	NOUN	B
has	O	AUX	O
shown	O	VERB	O
that	O	SCONJ	O
use	O	NOUN	O
of	O	ADP	O
an	O	DET	O
IVRS	O	NOUN	B
,	O	PUNCT	O
even	O	ADV	O
in	O	ADP	O
elderly	B-P	ADJ	B
patients	I-P	NOUN	B
,	O	PUNCT	O
is	O	AUX	O
an	O	DET	O
effective	O	ADJ	B
means	O	NOUN	O
of	O	ADP	O
gathering	O	VERB	B
RU	O	NOUN	B
data	O	NOUN	B
over	O	ADP	O
long	O	ADJ	B
periods	O	NOUN	I
.	O	PUNCT	O


Beliefs	B-I	NOUN	B
underlying	O	VERB	O
the	O	DET	O
intention	O	NOUN	B
to	O	PART	O
donate	O	VERB	O
again	O	ADV	O
among	O	ADP	O
first-time	B-P	ADJ	B
blood	I-P	NOUN	B
donors	I-P	NOUN	I
who	I-P	PRON	O
experience	I-P	VERB	O
a	I-P	DET	O
mild	I-P	ADJ	B
adverse	I-P	ADJ	B
event	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
findings	O	NOUN	B
provide	O	VERB	O
insight	O	NOUN	O
into	O	ADP	O
those	O	DET	O
messages	B-I	NOUN	B
that	O	PRON	O
could	O	AUX	O
be	O	AUX	O
communicated	O	VERB	O
via	O	ADP	O
the	O	DET	O
mass	O	NOUN	B
media	O	NOUN	I
or	O	CCONJ	O
in	O	ADP	O
targeted	O	VERB	B
communications	O	NOUN	I
to	O	PART	O
retain	O	VERB	O
first-time	B-P	ADJ	B
donors	I-P	NOUN	B
who	O	PRON	O
have	O	AUX	O
experienced	O	VERB	O
a	O	DET	O
mild	O	ADJ	B
vasovagal	O	ADJ	B
reaction	O	NOUN	I
.	O	PUNCT	O


[	O	PUNCT	O
Initial	O	ADJ	B
nuclear	B-I	ADJ	B
magnetic	I-I	ADJ	I
resonance	I-I	NOUN	I
tomography	I-I	NOUN	I
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
treatment	B-P	NOUN	B
course	I-P	NOUN	I
of	I-P	ADP	O
avascular	I-P	ADJ	B
femur	I-P	NOUN	I
head	I-P	NOUN	B
necrosis	I-P	NOUN	I
after	I-P	ADP	O
femoral	I-P	ADJ	B
core	I-P	NOUN	I
decompression	I-P	NOUN	I
]	I-P	PUNCT	O
.	I-P	PUNCT	O


The	O	DET	O
vascular	B-P	ADJ	B
femoral	I-P	ADJ	I
head	I-P	NOUN	I
necrosis	I-P	NOUN	I
is	I-P	AUX	O
a	I-P	DET	O
serious	I-P	ADJ	O
illness	I-P	NOUN	B
,	I-P	PUNCT	O
especially	I-P	ADV	O
when	I-P	SCONJ	O
appearing	I-P	VERB	O
in	I-P	ADP	O
patients	I-P	NOUN	B
aged	I-P	ADJ	B
30	I-P	NUM	O
to	I-P	PART	O
50	I-P	NUM	O
years	I-P	NOUN	B
.	I-P	PUNCT	O


Many	O	ADJ	O
etiologic	O	ADJ	B
factors	O	NOUN	I
cause	O	VERB	O
a	O	DET	O
femoral	O	ADJ	B
head	O	NOUN	I
necrosis	O	NOUN	I
such	O	ADJ	O
as	O	ADP	O
,	O	PUNCT	O
for	O	ADP	O
example	O	NOUN	O
,	O	PUNCT	O
high-dose	B-P	ADJ	B
steroids	I-P	NOUN	I
,	I-P	PUNCT	O
abuse	I-P	NOUN	B
of	I-P	ADP	O
alcohol	I-P	NOUN	B
,	I-P	PUNCT	O
defect	I-P	NOUN	B
of	I-P	ADP	O
bone	I-P	NOUN	B
marrow	I-P	NOUN	I
and	I-P	CCONJ	O
trauma	I-P	NOUN	B
of	I-P	ADP	O
the	I-P	DET	O
hip	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
stage	O	NOUN	B
IIc	O	NUM	I
and	O	CCONJ	I
III	O	NUM	I
shows	O	VERB	O
an	O	DET	O
evident	O	ADJ	O
enhancement	O	NOUN	B
in	O	ADP	O
contrast	O	NOUN	B
media	O	NOUN	I
in	O	ADP	O
MRI	B-I	NOUN	B
.	I-I	PUNCT	O


The	O	DET	O
evaluation	O	NOUN	B
of	O	ADP	O
the	O	DET	O
signal	O	NOUN	B
intensity	O	NOUN	I
by	O	ADP	O
the	O	DET	O
dynamic	B-OUT	ADJ	B
screening	I-OUT	NOUN	I
sequence	I-OUT	NOUN	I
is	O	AUX	O
considered	O	VERB	O
as	O	ADP	O
an	O	DET	O
objective	O	ADJ	O
contribution	O	NOUN	B
for	O	ADP	O
the	O	DET	O
staging	B-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
femoral	I-OUT	ADJ	B
head	I-OUT	NOUN	I
necrosis	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


This	O	DET	O
enables	O	VERB	O
one	O	NUM	O
to	O	PART	O
differentiate	O	VERB	B
between	B-P	ADP	O
the	I-P	DET	O
curable	I-OUT	ADJ	B
stage	I-OUT	NOUN	B
IIc	I-OUT	NOUN	B
and	I-P	CCONJ	O
the	I-P	DET	O
stage	I-OUT	NOUN	B
III	I-OUT	NUM	I
,	I-P	PUNCT	O
showing	I-P	VERB	O
the	I-P	DET	O
beginning	I-P	NOUN	O
of	I-P	ADP	O
breakdown	I-OUT	NOUN	B
of	I-OUT	ADP	O
the	I-OUT	DET	O
femoral	I-OUT	ADJ	B
head	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Aminocaproic	B-I	ADJ	B
acid	I-I	NOUN	I
versus	O	CCONJ	O
prednisone	B-I	NOUN	B
for	O	ADP	O
the	O	DET	O
treatment	O	NOUN	B
of	O	ADP	O
traumatic	B-P	ADJ	B
hyphema	I-P	NOUN	I
.	I-P	PUNCT	O


One	B-P	NUM	O
hundred	I-P	NUM	O
twelve	I-P	NUM	O
patients	I-P	NOUN	B
who	I-P	PRON	O
sustained	I-P	VERB	B
hyphema	I-P	NOUN	B
after	I-P	ADP	O
blunt	I-P	NOUN	B
trauma	I-P	NOUN	I
were	I-P	AUX	O
enrolled	I-P	VERB	O
in	O	ADP	O
a	O	DET	O
double-blind	O	ADJ	B
randomized	O	ADJ	B
clinical	O	ADJ	I
trial	O	NOUN	I
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
relative	O	ADJ	O
efficacies	O	NOUN	B
of	O	ADP	O
aminocaproic	B-I	ADJ	B
acid	I-I	NOUN	I
(	I-I	PUNCT	O
Amicar	I-I	NOUN	B
)	I-I	PUNCT	O
and	O	CCONJ	O
systemic	B-I	ADJ	B
prednisone	I-I	NOUN	I
for	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
rate	B-OUT	NOUN	B
of	I-OUT	ADP	O
secondary	I-OUT	ADJ	B
hemorrhage	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


Sun	B-I	PROPN	O
protection	I-I	NOUN	B
behaviors	I-I	NOUN	O
and	O	CCONJ	O
stages	O	NOUN	B
of	O	ADP	O
change	O	NOUN	O
for	O	ADP	O
the	O	DET	O
primary	O	ADJ	B
prevention	O	NOUN	I
of	O	ADP	O
skin	B-P	NOUN	B
cancers	I-P	NOUN	I
among	I-P	ADP	O
beachgoers	I-P	NOUN	B
in	I-P	ADP	O
southeastern	I-P	ADJ	B
New	I-P	PROPN	O
England	I-P	PROPN	O
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Before	O	ADP	O
the	O	DET	O
experiment	O	NOUN	B
,	O	PUNCT	O
72	B-P	NUM	O
rats	I-P	NOUN	B
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
to	I-P	PART	O
receive	I-P	VERB	O
HBO	I-I	NOUN	B
or	I-I	CCONJ	O
air	I-I	NOUN	B
treatment	I-I	NOUN	I
.	I-I	PUNCT	O


SnPP	O	NOUN	B
,	O	PUNCT	O
on	O	ADP	O
the	O	DET	O
contrary	O	NOUN	O
,	O	PUNCT	O
offset	O	VERB	O
the	O	DET	O
effects	O	NOUN	B
of	O	ADP	O
HBO	B-I	NOUN	B
and	O	CCONJ	O
worsened	O	VERB	B
the	O	DET	O
LPS-induced	O	ADJ	B
lung	O	NOUN	B
injury	O	NOUN	I
.	O	PUNCT	O


Furthermore	O	ADV	O
,	O	PUNCT	O
this	O	DET	O
HBO	B-I	NOUN	B
attenuation	O	NOUN	B
of	O	ADP	O
iNOS	O	NOUN	B
expression	O	NOUN	B
involves	O	VERB	O
HO-1	O	NOUN	B
induction	O	NOUN	B
.	O	PUNCT	O


OBJECTIVE	O	NOUN	O
One-third	O	ADJ	O
of	O	ADP	O
the	O	DET	O
total	O	ADJ	B
population	O	NOUN	I
seems	O	VERB	O
to	O	PART	O
develop	O	VERB	O
minor	O	ADJ	O
recurrent	B-P	ADJ	O
aphthous	I-P	ADJ	O
stomatitis	I-P	NOUN	O
(	I-P	PUNCT	O
RAS	I-P	NOUN	B
)	I-P	PUNCT	O
during	O	ADP	O
their	O	PRON	O
lifetime	O	NOUN	B
.	O	PUNCT	O


The	O	DET	O
objective	O	NOUN	B
of	O	ADP	O
the	O	DET	O
present	O	ADJ	O
study	O	NOUN	B
was	O	AUX	O
to	O	PART	O
investigate	O	VERB	B
whether	O	SCONJ	O
the	O	DET	O
prevalence	O	NOUN	B
of	O	ADP	O
RAS	O	NOUN	B
decreased	O	VERB	B
with	O	ADP	O
perilla	B-I	NOUN	B
oil	I-I	NOUN	I
(	O	PUNCT	O
rich	O	ADJ	O
in	O	ADP	O
alpha-linolenic	O	ADJ	B
acid	O	NOUN	I
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
Thirty	B-P	NUM	O
subjects	I-P	NOUN	B
(	I-P	PUNCT	O
8	I-P	NUM	O
men	I-P	NOUN	B
and	I-P	CCONJ	O
22	I-P	NUM	O
women	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
had	I-P	AUX	O
minor	I-P	ADJ	O
RAS	I-P	NOUN	B
at	I-P	ADP	O
least	I-P	ADJ	O
once	I-P	ADV	O
a	I-P	DET	O
month	I-P	NOUN	B
were	O	AUX	O
randomly	O	ADV	O
allocated	O	VERB	O
to	O	ADP	O
a	O	DET	O
soybean	B-I	NOUN	B
oil	I-I	NOUN	I
group	I-I	NOUN	O
or	I-I	CCONJ	O
a	I-I	DET	O
perilla	I-I	NOUN	B
oil	I-I	NOUN	I
group	I-I	NOUN	B
in	I-I	ADP	O
a	I-I	DET	O
double-blind	I-I	ADJ	B
manner	I-I	NOUN	O
(	I-I	PUNCT	O
experimental	I-I	ADJ	B
phase	I-I	NOUN	O
)	I-I	PUNCT	O
after	I-I	ADP	O
a	I-I	DET	O
run-in	I-I	ADJ	B
phase	I-I	NOUN	B
of	I-I	ADP	O
4	I-I	NUM	O
mo	I-I	NOUN	O
during	I-I	ADP	O
which	I-I	DET	O
subjects	I-I	NOUN	B
used	I-I	VERB	O
a	I-I	DET	O
reference	I-I	NOUN	B
oil	I-I	NOUN	I
,	I-I	PUNCT	O
the	I-I	DET	O
most	I-I	ADV	O
popular	I-I	ADJ	O
cooking	I-I	NOUN	B
oil	I-I	NOUN	I
in	I-I	ADP	O
Japan	I-I	PROPN	B
,	I-I	PUNCT	O
or	I-I	CCONJ	O
a	I-I	DET	O
50/50	I-I	NUM	O
mixture	I-I	NOUN	O
of	I-I	ADP	O
soybean	I-I	NOUN	B
oil	I-I	NOUN	I
and	I-I	CCONJ	O
rapeseed	I-I	NOUN	B
oil	I-I	NOUN	I
.	I-I	PUNCT	O


Occurrence	B-OUT	NOUN	B
and	I-OUT	CCONJ	O
needed	I-OUT	VERB	O
days	I-OUT	NOUN	B
for	I-OUT	ADP	O
healing	I-OUT	NOUN	B
of	I-OUT	ADP	O
minor	I-OUT	ADJ	B
RAS	I-OUT	NOUN	B
were	O	AUX	O
recorded	O	VERB	O
during	O	ADP	O
the	O	DET	O
two	O	NUM	O
phases	O	NOUN	B
and	O	CCONJ	O
compared	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-P	NOUN	B
turnover	I-P	NOUN	B
in	I-P	ADP	O
postmenopausal	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


The	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
therapy	O	NOUN	I
on	O	ADP	O
bone	O	NOUN	B
turnover	O	NOUN	B
is	O	AUX	O
unknown	O	ADJ	O
.	O	PUNCT	O


Our	O	PRON	O
aim	O	NOUN	O
was	O	AUX	O
to	O	PART	O
determine	O	VERB	O
the	O	DET	O
effect	O	NOUN	B
of	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
treatment	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
and	O	CCONJ	O
bone	B-OUT	NOUN	B
mineral	I-OUT	ADJ	I
density	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
BMD	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
in	O	ADP	O
postmenopausal	B-P	ADJ	B
,	I-P	PUNCT	O
osteopenic	I-P	ADJ	B
women	I-P	NOUN	B
.	I-P	PUNCT	O


Women	B-P	NOUN	B
aged	I-P	ADJ	B
50	I-P	NUM	O
to	I-P	PART	O
80	I-P	NUM	O
years	I-P	NOUN	B
received	O	VERB	O
raloxifene	B-I	NOUN	B
for	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
and	O	CCONJ	O
were	O	AUX	O
then	O	ADV	O
randomized	O	VERB	B
to	O	PART	O
continue	O	VERB	O
raloxifene	B-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
1	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
or	I-I	CCONJ	O
placebo	I-I	NOUN	B
(	I-P	PUNCT	O
group	I-P	NOUN	B
2	I-P	NUM	O
,	I-P	PUNCT	O
n=20	I-P	ADJ	O
)	I-P	PUNCT	O
for	I-P	ADP	O
a	I-P	DET	O
further	I-P	ADJ	O
96	I-P	NUM	O
weeks	I-P	NOUN	B
.	I-P	PUNCT	O


Continuation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
1	O	NUM	O
)	O	PUNCT	O
maintained	O	VERB	B
these	O	DET	O
changes	O	NOUN	B
.	O	PUNCT	O


Following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
(	O	PUNCT	O
group	O	NOUN	B
2	O	NUM	O
)	O	PUNCT	O
,	O	PUNCT	O
bone	B-OUT	NOUN	B
markers	I-OUT	NOUN	B
returned	O	VERB	O
to	O	PART	O
baseline	O	NOUN	B
levels	O	NOUN	B
(	O	PUNCT	O
by	O	ADP	O
120	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Bone	B-OUT	NOUN	B
loss	I-OUT	NOUN	I
following	O	VERB	O
cessation	O	NOUN	B
of	O	ADP	O
raloxifene	B-I	NOUN	B
therapy	O	NOUN	I
at	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
was	O	AUX	O
greater	O	ADJ	O
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
control	O	NOUN	B
group	O	NOUN	I
,	O	PUNCT	O
suggesting	O	VERB	O
accelerated	B-P	VERB	B
bone	I-P	NOUN	B
loss	I-P	NOUN	I
.	I-P	PUNCT	O


The	O	DET	O
beneficial	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
bone	B-OUT	NOUN	B
turnover	I-OUT	NOUN	B
of	O	ADP	O
96	O	NUM	O
weeks	O	NOUN	B
of	O	ADP	O
raloxifene	O	NOUN	B
was	O	AUX	O
lost	O	VERB	O
6	O	NUM	O
months	O	NOUN	B
after	O	ADP	O
cessation	O	NOUN	B
of	O	ADP	O
treatment	O	NOUN	B
.	O	PUNCT	O


Effects	O	NOUN	B
of	O	ADP	I
hydraulic	O	ADJ	B
circuit	O	NOUN	I
training	O	NOUN	O
on	O	ADP	O
cardiovascular	B-P	ADJ	B
function	I-P	NOUN	I
.	I-P	PUNCT	O


Maximal	B-OUT	ADJ	B
aerobic	I-OUT	ADJ	I
power	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
VO2max	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
with	I-OUT	ADP	O
simultaneous	I-OUT	ADJ	B
measurement	I-OUT	NOUN	B
of	I-OUT	ADP	O
stroke	I-OUT	NOUN	B
volume	I-OUT	NOUN	O
(	I-OUT	PUNCT	O
SV	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
cardiac	I-OUT	ADJ	B
output	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
CO	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
by	I-OUT	ADP	O
impedance	I-OUT	ADJ	B
cardiography	I-OUT	NOUN	I
,	O	PUNCT	O
was	O	AUX	O
assessed	O	VERB	B
pre-	O	ADJ	B
and	O	CCONJ	O
post-training	O	ADJ	B
.	O	PUNCT	O


Following	O	VERB	O
training	O	NOUN	B
VO2max	B-OUT	NOUN	I
(	I-OUT	PUNCT	O
ml.kg-1	I-OUT	NOUN	B
min-1	I-OUT	NOUN	I
)	I-OUT	PUNCT	O
was	O	AUX	O
significantly	O	ADV	O
increased	O	VERB	B
in	O	ADP	O
all	O	DET	O
training	O	NOUN	B
groups	O	NOUN	I
(	O	PUNCT	O
18.0	O	NUM	O
,	O	PUNCT	O
12.5	O	NUM	O
,	O	PUNCT	O
and	O	CCONJ	O
11.3	O	NUM	O
%	O	NOUN	O
for	O	ADP	O
cycle	O	NOUN	B
,	O	PUNCT	O
HCTsub	O	ADV	B
,	O	PUNCT	O
and	O	CCONJ	O
HCTmax	B-OUT	NOUN	B
groups	I-OUT	NOUN	I
,	O	PUNCT	O
respectively	O	ADV	O
;	O	PUNCT	O
P	O	NOUN	O
less	O	ADJ	O
than	O	ADP	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


These	O	DET	O
findings	O	NOUN	B
suggest	O	VERB	O
that	O	SCONJ	O
both	O	CCONJ	O
maximal	O	ADJ	B
and	O	CCONJ	O
submaximal	O	ADJ	B
HCT	O	NOUN	B
programs	O	NOUN	I
can	O	AUX	O
elicit	O	VERB	O
improvements	O	NOUN	B
in	O	ADP	O
cardiovascular	B-OUT	ADJ	B
fitness	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


In	O	ADP	O
all	O	DET	O
3	O	NUM	O
conditions	O	NOUN	B
,	O	PUNCT	O
LF/HF	B-OUT	NOUN	B
ratio	I-OUT	NOUN	I
decreased	O	VERB	B
from	O	ADP	O
Baseline	O	NOUN	B
to	O	ADP	O
Heel	O	PROPN	B
Stick	O	PROPN	I
and	O	CCONJ	O
increased	O	VERB	B
to	O	ADP	O
Recovery	O	PROPN	B
;	O	PUNCT	O
no	O	DET	O
differences	O	NOUN	O
were	O	AUX	O
found	O	VERB	O
between	O	ADP	O
IC	B-I	NOUN	B
and	O	CCONJ	O
two	O	NUM	O
KC	B-I	NOUN	B
conditions	O	NOUN	B
.	O	PUNCT	O


PERSPECTIVE	O	VERB	B
This	O	DET	O
study	O	NOUN	B
showed	O	VERB	O
that	O	SCONJ	O
KC	B-I	NOUN	B
has	O	AUX	O
a	O	DET	O
significant	O	ADJ	O
effect	O	NOUN	B
on	O	ADP	O
reducing	O	VERB	B
autonomic	O	ADJ	B
pain	O	NOUN	I
responses	O	NOUN	I
in	O	ADP	O
preterm	B-P	NOUN	B
infants	I-P	NOUN	I
.	I-P	PUNCT	O


In	B-P	ADP	O
2003	I-P	NUM	O
50	I-P	NUM	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
one	I-I	NUM	O
or	I-I	CCONJ	O
two	I-I	NUM	O
epidural	I-I	ADJ	B
injections	I-I	NOUN	I
have	I-P	AUX	O
been	I-P	AUX	O
selected	I-P	VERB	O
"	I-P	PUNCT	O
ad	I-P	NOUN	B
random	I-P	ADJ	I
"	I-P	PUNCT	O
and	I-P	CCONJ	O
50	I-P	NUM	O
patients	I-P	NOUN	B
treated	I-P	VERB	B
with	I-P	ADP	I
disc	I-I	NOUN	B
coablation	I-I	NOUN	I
.	I-I	PUNCT	O


Finally	O	ADV	O
,	O	PUNCT	O
average	B-OUT	ADJ	B
VAS	I-OUT	NOUN	B
was	O	AUX	O
clearly	O	ADV	O
lower	O	ADJ	O
(	O	PUNCT	O
p	O	NOUN	O
<	O	X	O
0.01	O	NUM	O
)	O	PUNCT	O
after	O	ADP	O
coablation	O	NOUN	B
as	O	ADP	O
compared	O	VERB	O
to	O	PART	O
epidural	B-I	ADJ	B
injections	I-I	NOUN	I
.	O	PUNCT	O


This	O	DET	O
result	O	NOUN	O
revealed	O	VERB	B
that	O	SCONJ	O
acupuncture	B-I	NOUN	B
seemed	O	VERB	O
to	O	PART	O
have	O	AUX	O
more	O	ADV	O
affect	O	VERB	O
on	O	ADP	O
OKT4+	B-OUT	ADJ	B
cells	I-OUT	NOUN	I
than	O	ADP	O
on	O	ADP	O
OKT8+	B-OUT	ADJ	B
cells	I-OUT	NOUN	I
.	I-OUT	PUNCT	O


From	O	ADP	O
our	O	PRON	O
study	O	NOUN	B
we	O	PRON	O
believe	O	VERB	O
that	O	SCONJ	O
acupuncture	B-I	NOUN	B
can	O	AUX	O
be	O	AUX	O
used	O	VERB	O
as	O	ADP	O
one	O	NUM	O
of	O	ADP	O
the	O	DET	O
many	O	ADJ	O
treatments	O	NOUN	B
for	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
cancer	I-P	NOUN	B
.	I-P	PUNCT	O


PURPOSE	O	VERB	O
This	O	DET	O
randomized	O	ADJ	B
group	O	NOUN	I
experiment	O	NOUN	I
compared	O	VERB	O
the	O	DET	O
efficacy	O	NOUN	B
of	O	ADP	O
2	O	NUM	O
communication	B-I	NOUN	B
interventions	I-I	NOUN	B
(	I-I	PUNCT	O
Responsive	I-I	ADJ	B
Education	I-I	PROPN	I
and	I-I	CCONJ	O
Prelinguistic	I-I	PROPN	B
Milieu	I-I	PROPN	I
Teaching	I-I	PROPN	I
[	I-I	PUNCT	O
RPMT	I-I	PROPN	B
]	I-I	PUNCT	O
and	I-I	CCONJ	O
the	I-I	DET	O
Picture	I-I	PROPN	B
Exchange	I-I	PROPN	I
Communication	I-I	PROPN	I
System	I-I	PROPN	I
[	I-I	PUNCT	O
PECS	I-I	PROPN	B
]	I-I	PUNCT	O
)	I-I	PUNCT	O
on	O	ADP	O
spoken	O	VERB	B
communication	O	NOUN	B
in	O	ADP	O
36	B-P	NUM	O
preschoolers	I-P	NOUN	B
with	I-P	ADP	O
autism	I-P	NOUN	B
spectrum	I-P	NOUN	I
disorders	I-P	NOUN	I
(	I-P	PUNCT	O
ASD	I-P	PROPN	B
)	I-P	PUNCT	O
.	I-P	PUNCT	O


RESULTS	O	NOUN	B
PECS	B-OUT	NOUN	B
was	I-OUT	AUX	O
more	I-OUT	ADV	O
successful	I-OUT	ADJ	O
than	I-OUT	ADP	O
RPMT	I-OUT	NOUN	B
in	I-OUT	ADP	O
increasing	I-OUT	VERB	B
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
nonimitative	I-OUT	ADJ	B
spoken	I-OUT	VERB	B
communication	I-OUT	NOUN	B
acts	I-OUT	NOUN	O
and	I-OUT	CCONJ	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
different	I-OUT	ADJ	O
nonimitative	I-OUT	ADJ	B
words	I-OUT	NOUN	B
used	I-OUT	VERB	O
at	I-OUT	ADP	O
the	I-OUT	DET	O
posttreatment	I-OUT	NOUN	B
period	I-OUT	NOUN	B
.	I-OUT	PUNCT	O


Considering	O	VERB	O
growth	O	NOUN	B
over	O	ADP	O
all	O	DET	O
3	O	NUM	O
measurement	O	NOUN	B
periods	O	NOUN	B
,	O	PUNCT	O
an	O	DET	O
exploratory	O	ADJ	B
analysis	O	NOUN	I
showed	O	VERB	O
that	O	SCONJ	O
growth	B-OUT	NOUN	B
rate	I-OUT	NOUN	I
of	I-OUT	ADP	O
the	I-OUT	DET	O
number	I-OUT	NOUN	O
of	I-OUT	ADP	O
different	I-OUT	ADJ	O
nonimitative	I-OUT	ADJ	B
words	I-OUT	NOUN	B
was	I-OUT	AUX	O
faster	I-OUT	ADJ	O
in	I-OUT	ADP	O
the	I-OUT	DET	O
PECS	I-OUT	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
RPMT	O	NOUN	B
group	O	NOUN	B
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
relatively	O	ADV	O
high	O	ADJ	O
object	O	NOUN	B
exploration	O	NOUN	B
.	O	PUNCT	O


In	O	ADP	O
contrast	O	NOUN	O
,	O	PUNCT	O
analogous	B-OUT	ADJ	O
slopes	I-OUT	NOUN	B
were	O	AUX	O
steeper	O	ADJ	O
in	O	ADP	O
the	O	DET	O
RPMT	O	NOUN	B
group	O	NOUN	B
than	O	ADP	O
in	O	ADP	O
the	O	DET	O
PECS	O	NOUN	B
group	O	NOUN	B
for	O	ADP	O
children	O	NOUN	B
who	O	PRON	O
began	O	VERB	O
treatment	O	NOUN	B
with	O	ADP	O
relatively	O	ADV	O
low	O	ADJ	B
object	O	NOUN	B
exploration	O	NOUN	B
.	O	PUNCT	O


All	O	DET	O
cavities	B-P	NOUN	B
received	O	VERB	O
the	O	DET	O
same	O	ADJ	O
adhesive	O	ADJ	B
system	O	NOUN	I
and	O	CCONJ	O
were	O	AUX	O
restored	O	VERB	B
with	O	ADP	O
flowable	O	ADJ	B
composite	O	NOUN	I
according	O	VERB	O
to	O	ADP	O
manufacturer	O	NOUN	B
's	O	PART	I
instructions	O	NOUN	I
.	O	PUNCT	O


Teeth	O	NOUN	B
were	O	AUX	O
submitted	O	VERB	O
to	O	PART	O
thermal	B-I	ADJ	B
cycling	I-I	NOUN	O
and	O	CCONJ	O
immersed	O	VERB	B
in	O	ADP	O
50	O	NUM	O
%	O	NOUN	O
silver	B-I	ADJ	B
nitrate	I-I	NOUN	B
solutions	I-I	NOUN	I
for	O	ADP	O
8	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
total	O	ADJ	O
darkness	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
It	O	PRON	O
can	O	AUX	O
be	O	AUX	O
concluded	O	VERB	O
that	O	SCONJ	O
no	O	DET	B
significant	O	ADJ	I
difference	O	NOUN	O
was	O	AUX	O
noted	O	VERB	O
between	O	ADP	O
the	O	DET	O
two	O	NUM	O
types	O	NOUN	O
of	O	ADP	O
enamel	B-I	NOUN	B
preparation	I-I	NOUN	O
when	O	SCONJ	O
etching	O	NOUN	B
was	O	AUX	O
performed	O	VERB	O
.	O	PUNCT	O


Dexmedetomidine	B-I	NOUN	B
pretreatment	O	NOUN	B
alleviates	O	VERB	O
propofol	B-P	NOUN	B
injection	I-P	NOUN	B
pain	I-P	NOUN	I
.	I-P	PUNCT	O


METHODS	O	NOUN	O
Patients	B-P	NOUN	B
undergoing	I-P	VERB	O
elective	I-P	ADJ	B
surgical	I-P	ADJ	I
procedures	I-P	NOUN	I
were	I-P	AUX	O
randomly	I-P	ADV	O
allocated	I-P	VERB	O
into	I-P	ADP	O
seven	I-P	NUM	O
groups	I-P	NOUN	B
of	I-P	ADP	O
30	I-P	NUM	O
patients	I-P	NOUN	B
each	I-P	DET	O
.	I-P	PUNCT	O


Patients	O	NOUN	B
in	O	ADP	O
groups	O	NOUN	B
V	O	NOUN	I
,	O	PUNCT	O
VI	O	PROPN	B
,	O	PUNCT	O
and	O	CCONJ	O
VII	O	NOUN	B
received	B-I	VERB	O
DEX	I-I	NOUN	B
as	I-I	ADP	O
above	I-I	ADV	O
,	I-I	PUNCT	O
but	I-I	CCONJ	O
5	I-I	NUM	O
minutes	I-I	NOUN	B
before	I-I	ADP	O
propofol	I-I	NOUN	B
injection	I-I	NOUN	B
.	I-I	PUNCT	O


There	O	PRON	O
were	O	AUX	O
no	O	DET	O
differences	O	NOUN	O
in	O	ADP	O
either	B-OUT	CCONJ	O
mean	I-OUT	ADJ	O
arterial	I-OUT	ADJ	B
pressure	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
heart	I-OUT	NOUN	B
rate	I-OUT	NOUN	I
at	O	ADP	O
any	O	DET	O
time	O	NOUN	B
point	O	NOUN	I
after	B-I	ADP	O
DEX	O	NOUN	B
injection	O	NOUN	B
among	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


CONCLUSIONS	O	VERB	O
Pretreatment	O	NOUN	B
with	O	ADP	O
intravenous	B-I	ADJ	B
DEX	O	NOUN	O
1	O	NUM	O
g/kg	O	NOUN	O
5	O	NUM	O
min	O	NOUN	O
prior	O	ADJ	O
to	O	PART	O
injection	O	NOUN	B
of	O	ADP	O
long-chain	O	ADJ	B
triglyceride	O	NOUN	I
propofol	O	NOUN	B
is	O	AUX	O
effective	O	ADJ	B
and	O	CCONJ	O
safe	O	ADJ	O
in	O	ADP	O
reducing	O	VERB	B
the	O	DET	O
incidence	O	NOUN	B
and	O	CCONJ	O
severity	O	NOUN	B
of	O	ADP	O
pain	O	NOUN	B
due	O	ADJ	O
to	O	PART	O
propofol	O	NOUN	B
injection	O	NOUN	B
.	O	PUNCT	O


Shock	O	NOUN	B
success	O	NOUN	I
was	O	AUX	O
defined	O	VERB	O
as	O	ADP	O
return	B-OUT	NOUN	B
of	I-OUT	ADP	I
sinus	I-OUT	NOUN	B
rhythm	I-OUT	NOUN	O
for	O	ADP	O
>	O	X	O
/=30	O	PUNCT	O
seconds	O	NOUN	O
.	O	PUNCT	O


CONCLUSION	O	VERB	O
The	O	DET	O
low-tilt	B-I	ADJ	B
biphasic	I-I	ADJ	B
waveform	I-I	NOUN	I
was	O	AUX	O
more	O	ADV	O
successful	O	ADJ	O
for	O	ADP	O
the	O	DET	O
internal	O	ADJ	B
cardioversion	O	NOUN	I
of	O	ADP	O
both	O	CCONJ	O
persistent	O	ADJ	B
and	O	CCONJ	O
induced	O	VERB	B
AF	B-P	NOUN	B
in	I-P	ADP	O
patients	I-P	NOUN	B
(	O	PUNCT	O
in	O	ADP	O
terms	O	NOUN	O
of	O	ADP	O
leading	O	VERB	B
edge	O	NOUN	I
voltage	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


AIM	O	NOUN	B
In	O	ADP	O
our	O	PRON	O
randomized	O	ADJ	B
prospective	O	ADJ	I
study	O	NOUN	I
,	O	PUNCT	O
we	O	PRON	O
aimed	O	VERB	O
to	O	PART	O
evaluate	O	VERB	B
the	O	DET	O
efficiency	O	NOUN	B
of	O	ADP	O
plasmakinetic	B-I	ADJ	B
resection	I-I	NOUN	I
of	I-I	ADP	I
prostate	I-I	NOUN	I
(	I-I	PUNCT	O
PKRP	I-I	PROPN	B
)	I-I	PUNCT	O
by	O	ADP	O
comparing	O	VERB	B
the	O	DET	O
preoperative	O	ADJ	B
and	O	CCONJ	O
postoperative	O	ADJ	B
results	O	NOUN	B
of	O	ADP	O
the	O	DET	O
transurethral	B-I	ADJ	B
resection	I-I	NOUN	I
of	I-I	ADP	I
prostate	I-I	NOUN	I
(	O	PUNCT	O
TURP	O	NOUN	B
)	O	PUNCT	O
and	O	CCONJ	O
PKRP	O	PROPN	B
techniques	O	NOUN	I
which	O	DET	O
we	O	PRON	O
administered	O	VERB	B
in	O	ADP	O
patients	B-P	NOUN	B
with	I-P	ADP	O
benign	I-P	ADJ	B
prostate	I-P	NOUN	I
hyperplasia	I-P	NOUN	I
(	I-P	PUNCT	O
BPH	I-P	NOUN	B
)	I-P	PUNCT	O
in	I-P	ADP	O
our	I-P	PRON	O
clinic	I-P	NOUN	B
.	I-P	PUNCT	O


International	B-OUT	ADJ	B
prostate	I-OUT	NOUN	I
symptom	I-OUT	NOUN	I
scores	I-OUT	NOUN	I
(	I-OUT	PUNCT	O
I-PSS	I-OUT	NOUN	B
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
uroflowmetry	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
measurement	I-OUT	NOUN	B
of	I-OUT	ADP	O
residual	I-OUT	ADJ	B
urine	I-OUT	NOUN	B
amount	I-OUT	NOUN	I
and	I-OUT	CCONJ	O
ultrasonography	I-OUT	NOUN	B
were	O	AUX	O
performed	O	VERB	O
for	O	ADP	O
each	O	DET	O
patient	O	NOUN	B
both	O	CCONJ	O
preoperatively	O	ADV	B
and	O	CCONJ	O
postoperatively	O	ADV	B
(	O	PUNCT	O
first	O	ADJ	O
month	O	NOUN	B
and	O	CCONJ	O
first	O	ADJ	O
year	O	NOUN	B
)	O	PUNCT	O
.	O	PUNCT	O


Operation	B-OUT	NOUN	B
times	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
urethral	I-OUT	ADJ	B
catheterization	I-OUT	NOUN	I
times	I-OUT	NOUN	O
,	I-OUT	PUNCT	O
preoperative	I-OUT	ADJ	B
and	I-OUT	CCONJ	O
postoperative	I-OUT	ADJ	B
Hb	I-OUT	NOUN	B
,	I-OUT	PUNCT	O
Htc	I-OUT	NOUN	B
and	I-OUT	CCONJ	O
serum	I-OUT	NOUN	B
Na	I-OUT	NOUN	O
values	I-OUT	NOUN	O
of	O	ADP	O
the	O	DET	O
patients	O	NOUN	B
were	O	AUX	O
compared	O	VERB	B
and	O	CCONJ	O
the	O	DET	O
complications	O	NOUN	B
of	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
were	O	AUX	O
also	O	ADV	O
compared	O	VERB	B
.	O	PUNCT	O


The	O	DET	O
decrease	O	NOUN	B
in	O	ADP	O
serum	B-OUT	NOUN	B
Na	I-OUT	NOUN	B
level	I-OUT	NOUN	B
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
significantly	O	ADV	O
higher	O	ADJ	O
in	O	ADP	O
the	O	DET	O
TURP	O	PROPN	B
group	O	NOUN	B
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0.05	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


The	O	DET	O
operation	B-OUT	NOUN	B
times	I-OUT	NOUN	O
were	O	AUX	O
not	O	PART	O
significantly	O	ADV	O
different	O	ADJ	O
between	O	ADP	O
the	O	DET	O
groups	O	NOUN	B
.	O	PUNCT	O


While	O	SCONJ	O
the	O	DET	O
postoperative	B-OUT	ADJ	B
catheterization	I-OUT	NOUN	B
time	I-OUT	NOUN	O
was	O	AUX	O
75.7	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
TURP	O	NOUN	B
group	O	NOUN	B
,	O	PUNCT	O
it	O	PRON	O
was	O	AUX	O
found	O	VERB	O
to	O	PART	O
be	O	AUX	O
42	O	NUM	O
h	O	NOUN	O
in	O	ADP	O
PKRP	O	PROPN	B
group	O	NOUN	B
and	O	CCONJ	O
it	O	PRON	O
was	O	AUX	O
clear	O	ADJ	O
that	O	SCONJ	O
catheterization	B-OUT	NOUN	B
time	I-OUT	NOUN	O
was	O	AUX	O
significantly	O	ADV	O
shorter	O	ADJ	O
(	O	PUNCT	O
P	O	NOUN	O
<	O	X	O
0001	O	NUM	O
)	O	PUNCT	O
.	O	PUNCT	O


METHODS	O	NOUN	O
The	O	DET	O
relationship	O	NOUN	B
between	O	ADP	O
ACE	O	NOUN	B
genotype	O	NOUN	B
and	O	CCONJ	O
the	O	DET	O
response	O	NOUN	B
to	O	ADP	O
11weeks	B-I	NOUN	O
of	I-I	ADP	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
training	I-I	NOUN	O
was	O	AUX	O
determined	O	VERB	O
in	O	ADP	O
37	B-P	NUM	O
CHF	I-P	NOUN	B
patients	I-P	NOUN	B
(	I-P	PUNCT	O
New	I-P	PROPN	B
York	I-P	PROPN	I
Heart	I-P	PROPN	I
Association	I-P	PROPN	I
Functional	I-P	ADJ	O
Class=2.30.5	I-P	NOUN	O
;	I-P	PUNCT	O
left	I-P	VERB	B
ventricular	I-P	ADJ	I
ejection	I-P	NOUN	I
fraction	I-P	NOUN	I
287	I-P	NUM	O
%	I-P	NOUN	O
;	I-P	PUNCT	O
age	I-P	NOUN	B
6412years	I-P	NOUN	O
;	I-P	PUNCT	O
32:5	I-P	NOUN	O
male	I-P	NOUN	B
:	I-P	PUNCT	O
female	I-P	NOUN	B
)	I-P	PUNCT	O
who	I-P	PRON	O
were	I-P	AUX	O
randomised	I-P	VERB	B
to	O	PART	O
either	B-I	CCONJ	O
resistance	I-I	NOUN	B
exercise	I-I	NOUN	B
(	O	PUNCT	O
n=19	O	ADJ	O
)	O	PUNCT	O
or	B-I	CCONJ	O
inactive	I-I	ADJ	B
control	I-I	NOUN	O
group	I-I	NOUN	O
(	O	PUNCT	O
n=18	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


RESULTS	O	NOUN	B
At	O	ADP	O
baseline	O	NOUN	B
,	O	PUNCT	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
I	O	NOUN	B
allele	O	NOUN	B
had	O	AUX	O
higher	B-OUT	ADJ	O
VO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2peak	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
(	I-OUT	PUNCT	O
p=0.02	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
and	I-OUT	CCONJ	O
peak	I-OUT	VERB	B
power	I-OUT	NOUN	I
(	O	PUNCT	O
p=0.003	O	NOUN	O
)	O	PUNCT	O
compared	O	VERB	O
to	O	ADP	O
patients	O	NOUN	B
who	O	PRON	O
were	O	AUX	O
homozygous	O	ADJ	B
for	O	ADP	O
the	O	DET	O
D	O	NOUN	B
allele	O	NOUN	I
.	O	PUNCT	O


No	O	DET	B
significant	O	ADJ	I
genotype-dependent	O	ADJ	B
changes	O	NOUN	B
were	O	AUX	O
observed	B-OUT	VERB	O
in	I-OUT	ADP	O
VO	I-OUT	NOUN	B
(	I-OUT	PUNCT	O
2peak	I-OUT	NOUN	O
)	I-OUT	PUNCT	O
,	I-OUT	PUNCT	O
muscle	I-OUT	NOUN	B
strength	I-OUT	NOUN	I
,	I-OUT	PUNCT	O
muscle	I-OUT	NOUN	B
endurance	I-OUT	NOUN	I
or	I-OUT	CCONJ	O
lactate	I-OUT	NOUN	B
threshold	I-OUT	NOUN	I
.	O	PUNCT	O


The	O	DET	O
acute	O	ADJ	B
effects	O	NOUN	B
of	O	ADP	O
fluid	O	ADJ	B
intake	O	NOUN	B
on	O	ADP	O
urine	O	NOUN	B
specific	O	ADJ	O
gravity	O	NOUN	B
and	O	CCONJ	O
fluid	O	ADJ	B
retention	O	NOUN	B
in	O	ADP	O
a	B-P	DET	O
mildly	I-P	ADV	B
dehydrated	I-P	ADJ	O
state	I-P	NOUN	O
.	I-P	PUNCT	O


Many	O	ADJ	O
athletes	B-P	NOUN	B
arrive	O	VERB	O
at	O	ADP	O
training	O	NOUN	B
sessions	O	NOUN	B
and	O	CCONJ	O
competitions	O	NOUN	B
in	O	ADP	O
a	O	DET	O
mildly	B-P	ADV	B
hypohydrated	I-P	VERB	O
(	I-P	PUNCT	O
HYPO	I-P	NOUN	B
)	I-P	PUNCT	O
state	I-P	NOUN	O
and	O	CCONJ	O
are	O	AUX	O
instructed	O	VERB	O
to	O	PART	O
drink	O	VERB	B
fluids	O	NOUN	I
before	O	ADP	O
exercise	O	NOUN	B
to	O	PART	O
reach	O	VERB	O
a	O	DET	O
euhydrated	O	ADJ	B
(	O	PUNCT	O
HYD	O	NOUN	B
)	O	PUNCT	O
state	O	NOUN	O
.	O	PUNCT	O


Following	O	VERB	O
baseline	O	NOUN	B
(	O	PUNCT	O
6	O	NUM	O
weeks	O	NOUN	B
)	O	PUNCT	O
,	O	PUNCT	O
patients	O	NOUN	B
entered	O	VERB	O
a	O	DET	O
19-week	O	ADJ	O
double-blind	O	ADJ	B
phase	B-I	NOUN	O
:	I-I	PUNCT	O
6-week	I-I	ADJ	B
titration	I-I	NOUN	B
(	I-I	PUNCT	O
2	I-I	NUM	O
mg/week	I-I	NOUN	B
increments	I-I	NOUN	B
to	I-I	PART	O
target	I-I	VERB	B
dose	I-I	NOUN	B
)	I-I	PUNCT	O
followed	I-I	VERB	O
by	I-I	ADP	O
a	I-I	DET	O
13-week	I-I	NOUN	O
maintenance	I-I	NOUN	B
period	I-I	NOUN	B
.	O	PUNCT	O


Using	O	VERB	O
this	O	DET	O
intent-to-treat	O	ADJ	B
population	O	NOUN	I
over	O	ADP	O
the	O	DET	O
double-blind	O	ADJ	B
phase	O	NOUN	B
,	O	PUNCT	O
the	B-OUT	DET	O
median	I-OUT	ADJ	B
percent	I-OUT	NOUN	O
change	I-OUT	NOUN	O
in	I-OUT	ADP	O
seizure	I-OUT	NOUN	B
frequency	I-OUT	NOUN	B
was	O	AUX	O
-21.0	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
-26.3	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
-34.5	O	NUM	O
%	O	NOUN	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
and	I-I	CCONJ	O
perampanel	I-I	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0261	O	NUM	O
and	O	CCONJ	O
p	O	NOUN	O
=	O	ADJ	O
0.0158	O	NUM	O
for	O	ADP	O
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
vs	O	CCONJ	O
placebo	O	NOUN	B
,	O	PUNCT	O
respectively	O	ADV	O
)	O	PUNCT	O
.	O	PUNCT	O


Fifty	O	NUM	O
percent	O	ADJ	O
responder	O	NOUN	B
rates	O	NOUN	B
during	O	ADP	O
the	O	DET	O
maintenance	O	NOUN	B
period	O	NOUN	B
were	O	AUX	O
26.4	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
37.6	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
and	O	CCONJ	O
36.1	O	NUM	O
%	O	NOUN	O
,	O	PUNCT	O
respectively	O	ADV	O
,	O	PUNCT	O
for	B-I	ADP	O
placebo	I-I	NOUN	B
,	I-I	PUNCT	O
perampanel	I-I	NOUN	B
8	O	NUM	O
mg	O	NOUN	O
,	O	PUNCT	O
and	B-I	CCONJ	O
perampanel	I-I	NOUN	B
12	O	NUM	O
mg	O	NOUN	O
;	O	PUNCT	O
these	O	DET	O
differences	O	NOUN	B
were	O	AUX	O
not	O	PART	O
statistically	O	ADV	B
significant	O	ADJ	I
for	O	ADP	O
8	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0760	O	NUM	O
)	O	PUNCT	O
or	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
(	O	PUNCT	O
p	O	NOUN	O
=	O	ADJ	O
0.0914	B-P	NUM	O
)	I-P	PUNCT	O
.	I-P	PUNCT	O


Sixty-eight	B-P	NUM	O
(	I-P	PUNCT	O
17.5	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
patients	I-P	NOUN	B
discontinued	I-P	VERB	B
,	I-P	PUNCT	O
including	I-P	VERB	O
40	I-P	NUM	O
(	I-P	PUNCT	O
10.3	I-P	NUM	O
%	I-P	NOUN	O
)	I-P	PUNCT	O
for	I-P	ADP	O
adverse	I-P	ADJ	B
events	I-P	NOUN	I
.	O	PUNCT	O


CONCLUSIONS	O	NOUN	O
This	O	DET	O
trial	O	NOUN	B
demonstrated	O	VERB	O
that	O	SCONJ	O
once-daily	O	NOUN	B
,	O	PUNCT	O
adjunctive	B-I	ADJ	B
perampanel	I-I	NOUN	B
at	O	ADP	O
doses	O	NOUN	B
of	O	ADP	O
8	O	NUM	O
or	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
improved	B-OUT	VERB	B
seizure	I-OUT	NOUN	B
control	I-OUT	NOUN	O
in	I-P	ADP	O
patients	I-P	NOUN	B
with	I-P	ADP	O
uncontrolled	I-P	ADJ	B
partial-onset	I-P	ADJ	B
seizures	I-P	NOUN	I
.	O	PUNCT	O


CLASSIFICATION	O	NOUN	B
OF	O	ADP	O
EVIDENCE	O	NOUN	B
This	O	DET	O
study	O	NOUN	B
provides	O	VERB	O
Class	O	NOUN	B
I	O	NUM	I
evidence	O	NOUN	B
that	O	SCONJ	O
once-daily	O	NOUN	B
8	O	NUM	O
and	O	CCONJ	O
12	O	NUM	O
mg	O	NOUN	O
doses	O	NOUN	B
of	O	ADP	O
adjunctive	B-I	ADJ	B
perampanel	I-I	NOUN	B
are	O	AUX	O
effective	O	ADJ	B
in	O	ADP	O
patients	O	NOUN	B
with	O	ADP	O
uncontrolled	O	ADJ	B
partial-onset	O	ADJ	B
seizures	O	NOUN	I
.	O	PUNCT	O
